{"cfbf6e27ce04786b06f0866fff1dfc918c95ed4a": [["Coronavirus SARS-CoV-2 as the cause of COVID-19 (Corona Virus Disease 2019) has affected over 8 million people worldwide.", [["Corona Virus Disease", "DISEASE", 49, 69], ["Coronavirus SARS-CoV-2", "ORGANISM", 0, 22], ["COVID-19", "ORGANISM", 39, 47], ["Corona Virus", "ORGANISM", 49, 61], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["Coronavirus SARS", "TEST", 0, 16], ["CoV", "TEST", 17, 20], ["COVID", "TEST", 39, 44], ["Corona Virus Disease", "PROBLEM", 49, 69]]], ["One of the consensus observations emerging among COVID-19 patients is the systemic inflammation associated with disease severity [1] .", [["inflammation", "DISEASE", 83, 95], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["COVID", "TEST", 49, 54], ["the systemic inflammation", "PROBLEM", 70, 95], ["disease severity", "PROBLEM", 112, 128], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["inflammation", "OBSERVATION", 83, 95]]], ["There is mounting evidence showing that some COVID-19 patients are presenting with a cytokine storm syndrome similar to secondary hemophagocytic lymphohistiocytosis (sHLH) and is associated with the degree of disease severity [2] .", [["hemophagocytic lymphohistiocytosis", "DISEASE", 130, 164], ["sHLH", "DISEASE", 166, 170], ["patients", "ORGANISM", 54, 62], ["sHLH", "CANCER", 166, 170], ["cytokine", "PROTEIN", 85, 93], ["patients", "SPECIES", 54, 62], ["a cytokine storm syndrome", "PROBLEM", 83, 108], ["secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 120, 164], ["disease severity", "PROBLEM", 209, 225], ["cytokine storm", "OBSERVATION", 85, 99], ["secondary", "OBSERVATION_MODIFIER", 120, 129], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 130, 164], ["disease", "OBSERVATION", 209, 216]]], ["Studies comparing overlapping clinical features and pathogenesis of COVID-19 and sHLH have shown overlapping markers of inflammation [3] .", [["inflammation", "DISEASE", 120, 132], ["COVID-19", "GENE_OR_GENE_PRODUCT", 68, 76], ["sHLH", "CANCER", 81, 85], ["Studies", "TEST", 0, 7], ["overlapping clinical features", "PROBLEM", 18, 47], ["COVID", "TEST", 68, 73], ["inflammation", "PROBLEM", 120, 132], ["overlapping", "OBSERVATION_MODIFIER", 97, 108], ["markers", "OBSERVATION", 109, 116], ["inflammation", "OBSERVATION", 120, 132]]], ["Therefore, treatment with antiviral drugs alone may not be sufficient to combat COVID-19 related cytokine storm syndrome.", [["cytokine", "PROTEIN", 97, 105], ["antiviral drugs", "TREATMENT", 26, 41], ["COVID", "TREATMENT", 80, 85], ["cytokine storm syndrome", "PROBLEM", 97, 120], ["cytokine storm syndrome", "OBSERVATION", 97, 120]]], ["Several anti-inflammatory agents have been considered to reduce inflammation in COVID-19 patients [4] .", [["inflammation", "DISEASE", 64, 76], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Several anti-inflammatory agents", "TREATMENT", 0, 32], ["inflammation", "PROBLEM", 64, 76], ["COVID", "TEST", 80, 85]]], ["Those infected with SARS-CoV-2 show a significant increase in cytokine profiles such as IL-2, IL-17, and TGF\u03b1 [5, 6] .", [["SARS-CoV-2", "ORGANISM", 20, 30], ["IL-2", "GENE_OR_GENE_PRODUCT", 88, 92], ["IL-17", "GENE_OR_GENE_PRODUCT", 94, 99], ["TGF\u03b1", "GENE_OR_GENE_PRODUCT", 105, 109], ["cytokine", "PROTEIN", 62, 70], ["IL-17", "PROTEIN", 94, 99], ["TGF\u03b1", "PROTEIN", 105, 109], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV", "TEST", 20, 28], ["a significant increase in cytokine profiles", "PROBLEM", 36, 79], ["IL", "TEST", 88, 90], ["IL", "TEST", 94, 96], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["cytokine profiles", "OBSERVATION", 62, 79]]], ["In the early stages of infection, CD4 + and CD8 + T cells are critical for defense against SARS-CoV-2.", [["CD4 +", "ANATOMY", 34, 39], ["CD8 + T cells", "ANATOMY", 44, 57], ["infection", "DISEASE", 23, 32], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["SARS-CoV-2", "ORGANISM", 91, 101], ["CD4 + and CD8 + T cells", "CELL_TYPE", 34, 57], ["SARS-CoV", "SPECIES", 91, 99], ["infection", "PROBLEM", 23, 32], ["CD4", "TEST", 34, 37], ["CD8", "TEST", 44, 47], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["early stages", "OBSERVATION_MODIFIER", 7, 19], ["infection", "OBSERVATION", 23, 32]]], ["CD4 + T cells induce virus-specific antibodies by stimulating B cells.", [["CD4 + T cells", "ANATOMY", 0, 13], ["B cells", "ANATOMY", 62, 69], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["B cells", "CELL", 62, 69], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["virus-specific antibodies", "PROTEIN", 21, 46], ["B cells", "CELL_TYPE", 62, 69], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["virus", "PROBLEM", 21, 26], ["specific antibodies", "TEST", 27, 46]]], ["On the other hand, CD8 + T cells attack and kill the viral infected cells.", [["CD8 + T cells", "ANATOMY", 19, 32], ["cells", "ANATOMY", 68, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 19, 22], ["cells", "CELL", 68, 73], ["CD8 + T cells", "CELL_TYPE", 19, 32], ["viral infected cells", "CELL_TYPE", 53, 73], ["T cells attack", "PROBLEM", 25, 39], ["the viral infected cells", "PROBLEM", 49, 73], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infected cells", "OBSERVATION", 59, 73]]], ["To support the immune system, proinflammatory cytokines are produced by helper T cells.", [["immune system", "ANATOMY", 15, 28], ["helper T cells", "ANATOMY", 72, 86], ["helper T cells", "CELL", 72, 86], ["proinflammatory cytokines", "PROTEIN", 30, 55], ["helper T cells", "CELL_TYPE", 72, 86], ["proinflammatory cytokines", "TEST", 30, 55]]], ["However, the increasing viral load can induce apoptosis of T cells, leading to an increased immune response in the patient [7] .", [["T cells", "ANATOMY", 59, 66], ["T cells", "CELL", 59, 66], ["patient", "ORGANISM", 115, 122], ["T cells", "CELL_TYPE", 59, 66], ["patient", "SPECIES", 115, 122], ["the increasing viral load", "PROBLEM", 9, 34], ["apoptosis of T cells", "PROBLEM", 46, 66], ["an increased immune response", "PROBLEM", 79, 107], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["viral load", "OBSERVATION", 24, 34], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["immune response", "OBSERVATION", 92, 107]]], ["The overreaction of inflammatory cytokines, or hyper-inflammatory syndrome, can cause severe and irreversible damages to the lungs and other organs leading to cell death and multi-organ system failure.", [["lungs", "ANATOMY", 125, 130], ["organs", "ANATOMY", 141, 147], ["cell", "ANATOMY", 159, 163], ["multi-organ system", "ANATOMY", 174, 192], ["hyper-inflammatory syndrome", "DISEASE", 47, 74], ["death", "DISEASE", 164, 169], ["multi-organ system failure", "DISEASE", 174, 200], ["lungs", "ORGAN", 125, 130], ["organs", "ORGAN", 141, 147], ["cell", "CELL", 159, 163], ["inflammatory cytokines", "PROTEIN", 20, 42], ["inflammatory cytokines", "PROBLEM", 20, 42], ["hyper-inflammatory syndrome", "PROBLEM", 47, 74], ["severe and irreversible damages to the lungs and other organs", "PROBLEM", 86, 147], ["cell death", "PROBLEM", 159, 169], ["multi-organ system failure", "PROBLEM", 174, 200], ["inflammatory cytokines", "OBSERVATION", 20, 42], ["hyper", "OBSERVATION_MODIFIER", 47, 52], ["inflammatory syndrome", "OBSERVATION", 53, 74], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["irreversible", "OBSERVATION_MODIFIER", 97, 109], ["damages", "OBSERVATION", 110, 117], ["lungs", "ANATOMY", 125, 130], ["cell death", "OBSERVATION", 159, 169], ["multi-organ system failure", "OBSERVATION", 174, 200]]]], "3b06eb3b1e5f43e9effb7515bca6b1c3542c7f08": [["IntroductionSARS-CoV-2, the pathogenic virus for COVID-19, has caused a global pandemic since its first report in early December 2019 in Wuhan China (1), posing a gravely crisis for health and economic and social order.", [["COVID-19", "CHEMICAL", 49, 57], ["IntroductionSARS-CoV-2", "ORGANISM", 0, 22], ["IntroductionSARS", "TEST", 0, 16], ["CoV", "TEST", 17, 20], ["the pathogenic virus", "PROBLEM", 24, 44], ["COVID", "TEST", 49, 54], ["a global pandemic", "PROBLEM", 70, 87], ["global", "OBSERVATION_MODIFIER", 72, 78], ["pandemic", "OBSERVATION", 79, 87]]], ["SARS-CoV-2 is heavily decorated by its surface Spike (S) (2, 3) , a single-pass membrane protein that is key for the host-virus interactions.", [["surface", "ANATOMY", 39, 46], ["membrane", "ANATOMY", 80, 88], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["membrane", "CELLULAR_COMPONENT", 80, 88], ["single-pass membrane protein", "PROTEIN", 68, 96], ["SARS", "TEST", 0, 4], ["heavily decorated", "PROBLEM", 14, 31], ["a single-pass membrane protein", "TREATMENT", 66, 96]]], ["During the infection, S is cleaved by host proteases (4, 5) , yielding the Nterminal S1 and the C-terminal S2 subunit.", [["infection", "DISEASE", 11, 20], ["C", "CHEMICAL", 96, 97], ["Nterminal S1", "GENE_OR_GENE_PRODUCT", 75, 87], ["C-terminal S2", "GENE_OR_GENE_PRODUCT", 96, 109], ["host proteases", "PROTEIN", 38, 52], ["Nterminal S1", "PROTEIN", 75, 87], ["C-terminal S2 subunit", "PROTEIN", 96, 117], ["the infection", "PROBLEM", 7, 20], ["infection", "OBSERVATION", 11, 20], ["Nterminal S1", "ANATOMY", 75, 87], ["terminal", "ANATOMY_MODIFIER", 98, 106], ["S2", "ANATOMY", 107, 109]]], ["S1 binds to angiotensin-converting enzyme 45 2 (ACE2) (6-10) on the host cell membrane via its receptor-binding domain (RBD), causing conformational changes that trigger a secondary cleavage needed for the S2mediated membrane fusion at the plasma membrane or in the endosome.", [["cell membrane", "ANATOMY", 73, 86], ["membrane", "ANATOMY", 217, 225], ["plasma membrane", "ANATOMY", 240, 255], ["endosome", "ANATOMY", 266, 274], ["angiotensin", "CHEMICAL", 12, 23], ["angiotensin-converting enzyme 45 2", "GENE_OR_GENE_PRODUCT", 12, 46], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["cell membrane", "CELLULAR_COMPONENT", 73, 86], ["membrane", "CELLULAR_COMPONENT", 217, 225], ["plasma membrane", "CELLULAR_COMPONENT", 240, 255], ["endosome", "CELLULAR_COMPONENT", 266, 274], ["S1", "PROTEIN", 0, 2], ["angiotensin-converting enzyme 45 2 (ACE2) (6-10", "PROTEIN", 12, 59], ["receptor-binding domain", "PROTEIN", 95, 118], ["RBD", "PROTEIN", 120, 123], ["angiotensin", "TEST", 12, 23], ["converting enzyme", "TEST", 24, 41], ["ACE2", "TEST", 48, 52], ["conformational changes", "PROBLEM", 134, 156], ["a secondary cleavage", "PROBLEM", 170, 190], ["the S2mediated membrane fusion", "TREATMENT", 202, 232], ["host cell membrane", "OBSERVATION", 68, 86]]], ["Because of this essential role, RBD has been a hot spot for the development of therapeutic monoclonal antibodies (mAbs) and vaccine (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) .", [["RBD", "GENE_OR_GENE_PRODUCT", 32, 35], ["11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26)", "SIMPLE_CHEMICAL", 133, 211], ["RBD", "PROTEIN", 32, 35], ["therapeutic monoclonal antibodies", "PROTEIN", 79, 112], ["mAbs", "PROTEIN", 114, 118], ["RBD", "PROBLEM", 32, 35], ["a hot spot", "PROBLEM", 45, 55], ["therapeutic monoclonal antibodies", "TREATMENT", 79, 112], ["vaccine", "TEST", 124, 131]]], ["50 Llama-derived heavy chain-only antibodies (nanobodies) are attractive biotherapeutics (29) .", [["Llama-derived heavy chain", "PROTEIN", 3, 28], ["antibodies", "PROTEIN", 34, 44], ["heavy chain", "OBSERVATION_MODIFIER", 17, 28]]], ["These small (~14 kDa) proteins are robust, straightforward to produce, and amenable to engineering such as mutation and fusion.", [["mutation and fusion", "TREATMENT", 107, 126], ["small", "OBSERVATION_MODIFIER", 6, 11]]], ["Owing to their ultra-stability, nanobodies have been reported to survive nebulization, a feature that has been explored 55 for the development of inhaled nanobodies to treat respiratory viral diseases (30, 31) which categorizes COVID-19.", [["respiratory viral diseases", "DISEASE", 174, 200], ["inhaled nanobodies", "TREATMENT", 146, 164], ["respiratory viral diseases", "PROBLEM", 174, 200], ["respiratory", "ANATOMY", 174, 185], ["viral diseases", "OBSERVATION", 186, 200]]], ["Owing to their high sequence similarities with human type 3 VH domains (VH3), nanobodies are known to cause little immunogenicity (29) .IntroductionFor the same reason, they can be humanized with relative ease to reduce immunogenicity when needed.", [["human", "ORGANISM", 47, 52], ["human type 3 VH domains", "DNA", 47, 70], ["VH3", "DNA", 72, 75], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human type 3 VH domains (VH3)", "PROBLEM", 47, 76]]], ["Therefore, nanobodies as biotherapeutics are being 60 increasingly recognized.", [["nanobodies", "TREATMENT", 11, 21], ["biotherapeutics", "TREATMENT", 25, 40]]], ["Examples of nanobody drugs include caplacizumab (32) for the treatment of acquired thrombotic thrombocytopenic purpura, and ozoralizumab and vobarilizumab that are in the clinical trials for rheumatoid arthritis (29, 33) .", [["nanobody", "ANATOMY", 12, 20], ["caplacizumab", "CHEMICAL", 35, 47], ["thrombotic thrombocytopenic purpura", "DISEASE", 83, 118], ["ozoralizumab", "CHEMICAL", 124, 136], ["vobarilizumab", "CHEMICAL", 141, 154], ["rheumatoid arthritis", "DISEASE", 191, 211], ["caplacizumab", "CHEMICAL", 35, 47], ["ozoralizumab", "CHEMICAL", 124, 136], ["vobarilizumab", "CHEMICAL", 141, 154], ["caplacizumab", "SIMPLE_CHEMICAL", 35, 47], ["ozoralizumab", "SIMPLE_CHEMICAL", 124, 136], ["vobarilizumab", "SIMPLE_CHEMICAL", 141, 154], ["nanobody drugs", "TREATMENT", 12, 26], ["caplacizumab", "TREATMENT", 35, 47], ["acquired thrombotic thrombocytopenic purpura", "PROBLEM", 74, 118], ["ozoralizumab", "TREATMENT", 124, 136], ["vobarilizumab", "TREATMENT", 141, 154], ["rheumatoid arthritis", "PROBLEM", 191, 211], ["thrombotic", "OBSERVATION_MODIFIER", 83, 93], ["thrombocytopenic purpura", "OBSERVATION", 94, 118], ["rheumatoid arthritis", "OBSERVATION", 191, 211]]], ["Recently, several groups have independently reported neutralizing nanobodies (22, (34) (35) (36) (37) (38) (39) or single-chain VH antibodies (40) against SARS-CoV-2 with variable potencies.", [["SARS-CoV-2", "ORGANISM", 155, 165], ["VH antibodies", "PROTEIN", 128, 141], ["SARS-CoV", "SPECIES", 155, 163], ["neutralizing nanobodies", "TEST", 53, 76], ["single-chain VH antibodies", "TEST", 115, 141], ["SARS", "PROBLEM", 155, 159], ["variable potencies", "PROBLEM", 171, 189]]], ["65 We have recently reported several synthetic nanobodies (sybodies) which bind RBD with various affinity and neutralizing activity (35) .", [["RBD", "GENE_OR_GENE_PRODUCT", 80, 83], ["RBD", "PROTEIN", 80, 83], ["several synthetic nanobodies (sybodies)", "PROBLEM", 29, 68], ["various affinity", "PROBLEM", 89, 105], ["neutralizing activity", "OBSERVATION", 110, 131]]], ["Affinity and neutralizing activity are very important characteristics for therapeutic antibodies, and they can be improved by a number of ways such as random mutagenesis (22, 36) and structure-70 based design.", [["therapeutic antibodies", "PROTEIN", 74, 96], ["Affinity and neutralizing activity", "PROBLEM", 0, 34], ["therapeutic antibodies", "PROBLEM", 74, 96], ["random mutagenesis", "TEST", 151, 169], ["neutralizing activity", "OBSERVATION", 13, 34]]], ["Previously, in the case of one modestly-neutralizing sybody MR17, we have determined its structure and designed a single mutant that improves its potency by over 23 folds (35) .", [["MR17", "SIMPLE_CHEMICAL", 60, 64], ["MR17", "PROTEIN", 60, 64], ["a single mutant", "PROBLEM", 112, 127]]], ["The rational design approach, while very effective, inevitably requires high-resolution structural information which are non-trivial to obtain.IntroductionGenerally applicable tools will be welcome.IntroductionHere, we report a strategy to increase sybody potency by biparatopic fusion with SR31, a sybody that binds RBD tightly with a KD of 5.6 nM.", [["SR31", "CHEMICAL", 291, 295], ["SR31", "SIMPLE_CHEMICAL", 291, 295], ["RBD", "GENE_OR_GENE_PRODUCT", 317, 320], ["SR31", "PROTEIN", 291, 295], ["sybody", "PROTEIN", 299, 305], ["RBD", "PROTEIN", 317, 320], ["biparatopic fusion", "TREATMENT", 267, 285], ["a KD", "TEST", 334, 338]]], ["As revealed by crystal structure, SR31 engages the RBD at a conserved site that is distal to the RBM.", [["SR31", "SIMPLE_CHEMICAL", 34, 38], ["SR31", "PROTEIN", 34, 38], ["RBD", "PROTEIN", 51, 54], ["RBM", "DNA", 97, 100], ["the RBD", "PROBLEM", 47, 54], ["crystal structure", "OBSERVATION", 15, 32], ["RBD", "OBSERVATION", 51, 54], ["distal", "OBSERVATION_MODIFIER", 83, 89], ["RBM", "OBSERVATION", 97, 100]]], ["As such, it does not neutralize SARS-CoV-2 but forms non-competing pairs with several other RBM-binders and increases their neutralization potency when conjugated.", [["SARS", "DISEASE", 32, 36], ["CoV-2", "ORGANISM", 37, 42], ["RBM", "PROTEIN", 92, 95], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["non-competing pairs", "PROBLEM", 53, 72], ["several other RBM-binders", "TREATMENT", 78, 103]]], ["SR31 may 80 be used as a general affinity-enhancer for both detection and therapeutic applications.Results and DiscussionA high-affinity RBD binder without neutralizing activity 85 Previously, we generated 99 sybodies from three highly diverse synthetic libraries by ribosome and phage display with in vitro selections against the SARS-CoV-2 RBD.Results and DiscussionMost of the sybody binders showed neutralizing activity.", [["SR31", "CHEMICAL", 0, 4], ["RBD", "DISEASE", 342, 345], ["SR31", "GENE_OR_GENE_PRODUCT", 0, 4], ["ribosome", "CELLULAR_COMPONENT", 267, 275], ["SARS-CoV-2", "ORGANISM", 331, 341], ["SR31", "PROTEIN", 0, 4], ["RBD", "PROTEIN", 137, 140], ["SARS-CoV-2 RBD", "PROTEIN", 331, 345], ["SARS-CoV", "SPECIES", 331, 339], ["a general affinity-enhancer", "TREATMENT", 23, 50], ["both detection", "TEST", 55, 69], ["therapeutic applications", "TREATMENT", 74, 98], ["DiscussionA high-affinity RBD binder", "TREATMENT", 111, 147], ["ribosome and phage", "TREATMENT", 267, 285], ["the SARS", "PROBLEM", 327, 335], ["CoV", "TEST", 336, 339], ["RBD", "PROBLEM", 342, 345], ["the sybody binders", "TREATMENT", 376, 394], ["neutralizing activity", "PROBLEM", 402, 423], ["neutralizing activity", "OBSERVATION", 402, 423]]], ["Interestingly, about 10 sybodies bind RBD but showed no neutralizing activities (35) even at 1 \uf06dM concentration.90One such sybodies, named SR31, was characterized in this study.", [["RBD", "GENE_OR_GENE_PRODUCT", 38, 41], ["RBD", "PROTEIN", 38, 41], ["SR31", "DNA", 139, 143], ["10 sybodies bind RBD", "PROBLEM", 21, 41], ["neutralizing activities", "PROBLEM", 56, 79], ["this study", "TEST", 166, 176], ["no", "UNCERTAINTY", 53, 55], ["neutralizing", "OBSERVATION", 56, 68]]], ["In analytic fluorescence-detection size exclusion chromatography (FSEC), SR31 caused earlier retention of RBD (Fig. 1A) which was included at a low concentration (0.5 \uf06dM), suggesting nanomolar affinity for SR31-RBD binding.", [["SR31", "CHEMICAL", 73, 77], ["RBD", "DISEASE", 106, 109], ["SR31", "SIMPLE_CHEMICAL", 73, 77], ["SR31-RBD", "SIMPLE_CHEMICAL", 206, 214], ["RBD", "PROTEIN", 106, 109], ["SR31", "PROTEIN", 206, 210], ["RBD", "PROTEIN", 211, 214], ["analytic fluorescence", "TEST", 3, 24], ["earlier retention of RBD", "PROBLEM", 85, 109], ["nanomolar affinity", "TEST", 183, 201], ["SR31", "PROBLEM", 206, 210], ["RBD binding", "PROBLEM", 211, 222], ["RBD", "OBSERVATION", 106, 109], ["RBD", "OBSERVATION", 211, 214]]], ["This was confirmed by bio-layer 95 interferometry analysis (Fig. 1B) which showed a KD of 5.6 nM and an off-rate of 1 \u00d7 10 -3 s -1 .", [["interferometry analysis", "TEST", 35, 58], ["a KD", "TEST", 82, 86], ["rate", "TEST", 108, 112]]], ["Consistent with its inability to neutralize SARS-CoV-2 pseudovirus, SR31 did not affect RBD-ACE2 binding (Fig. 1C) .Structure of SR31 in complex with RBDTo characterize the SR31-RBD interactions in detail, we purified the complex (Fig. 1D ), and obtained crystals (Fig. 1D ) that diffracted to 1.97 \u00c5 resolution ( Table 1) .", [["SARS-CoV-2 pseudovirus", "ORGANISM", 44, 66], ["SR31", "ORGANISM", 68, 72], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 88, 96], ["SR31", "GENE_OR_GENE_PRODUCT", 129, 133], ["RBDTo", "GENE_OR_GENE_PRODUCT", 150, 155], ["SR31", "GENE_OR_GENE_PRODUCT", 173, 177], ["SR31", "PROTEIN", 68, 72], ["RBD", "PROTEIN", 88, 91], ["ACE2", "PROTEIN", 92, 96], ["SR31", "PROTEIN", 129, 133], ["RBDTo", "PROTEIN", 150, 155], ["SR31", "PROTEIN", 173, 177], ["RBD", "PROTEIN", 178, 181], ["SARS-CoV-2 pseudovirus", "SPECIES", 44, 66], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["pseudovirus", "TEST", 55, 66], ["RBD", "TEST", 88, 91]]], ["The structure was solved by molecular replacement using the published RBD and sybody 110 structures (PDB IDs 6M0J and 5M13) (6, 41) as search models.", [["RBD", "PROTEIN", 70, 73], ["sybody 110 structures", "PROTEIN", 78, 99], ["molecular replacement", "TREATMENT", 28, 49], ["PDB IDs", "TEST", 101, 108], ["search models", "TEST", 135, 148], ["molecular replacement", "OBSERVATION", 28, 49]]], ["The asymmetric unit contained one molecule each for the RBD and SR31, indicating an expected 1:1 stoichiometry.", [["SR31", "SIMPLE_CHEMICAL", 64, 68], ["RBD", "PROTEIN", 56, 59], ["SR31", "PROTEIN", 64, 68], ["the RBD and SR31", "TEST", 52, 68], ["asymmetric", "OBSERVATION_MODIFIER", 4, 14], ["one molecule", "OBSERVATION", 30, 42], ["RBD", "ANATOMY", 56, 59], ["1:1 stoichiometry", "OBSERVATION", 93, 110]]], ["SR31 binds to the RBD sideways at a buried surface area of 1,386.3 \u00c5 2 ( Fig. 2A) , which is significantly larger than that for the previously reported sybodies SR4 (727.4 \u00c5 2 ) and MR17 (853.944 \u00c5 2 ) (35) .", [["SR31", "CHEMICAL", 0, 4], ["SR31", "GENE_OR_GENE_PRODUCT", 0, 4], ["SR31", "PROTEIN", 0, 4], ["RBD", "PROTEIN", 18, 21], ["SR4", "PROTEIN", 161, 164], ["a buried surface area", "TEST", 34, 55], ["MR17", "TEST", 182, 186], ["buried", "OBSERVATION_MODIFIER", 36, 42], ["surface", "OBSERVATION_MODIFIER", 43, 50], ["significantly", "OBSERVATION_MODIFIER", 93, 106], ["larger", "OBSERVATION_MODIFIER", 107, 113]]], ["The binding surface is near a heavily decorated glycosylation site, Asn343 ( Fig. 2A-2C) , which, although at an apparent strategic 130 position to possibly divide the accessible surfaces for immune surveillance, does not show clashes with SR31.", [["surface", "ANATOMY", 12, 19], ["Asn343", "SIMPLE_CHEMICAL", 68, 74], ["SR31", "GENE_OR_GENE_PRODUCT", 240, 244], ["SR31", "PROTEIN", 240, 244], ["a heavily decorated glycosylation site", "PROBLEM", 28, 66], ["immune surveillance", "TEST", 192, 211], ["surface", "OBSERVATION_MODIFIER", 12, 19]]], ["All three CDRs participated in the interaction by providing five (CDR1), three (CDR2), and nine H-bonds (CDR3) (Fig. 2E-2G) .", [["H", "CHEMICAL", 96, 97], ["CDR1", "GENE_OR_GENE_PRODUCT", 66, 70], ["CDR2", "GENE_OR_GENE_PRODUCT", 80, 84], ["CDRs", "PROTEIN", 10, 14], ["CDR1", "PROTEIN", 66, 70], ["CDR2", "PROTEIN", 80, 84], ["CDR3", "PROTEIN", 105, 109]]], ["Peculiarly, the CDR3, which contains a cluster of hydrophobic side chains that include Met99, Val100, Phe102, Trp103, and Tyr104, inserted into a greasy pocket (Fig. 2B ) in the RBD that 135 was lined with twelve hydrophobic/aromatic residues (Fig. 2F) .", [["Met99", "CHEMICAL", 87, 92], ["Val", "CHEMICAL", 94, 97], ["Phe102", "CHEMICAL", 102, 108], ["Trp", "CHEMICAL", 110, 113], ["Tyr104", "CHEMICAL", 122, 128], ["CDR3", "GENE_OR_GENE_PRODUCT", 16, 20], ["Met99", "GENE_OR_GENE_PRODUCT", 87, 92], ["Phe102", "GENE_OR_GENE_PRODUCT", 102, 108], ["Trp", "AMINO_ACID", 110, 113], ["103", "AMINO_ACID", 113, 116], ["Tyr104", "GENE_OR_GENE_PRODUCT", 122, 128], ["CDR3", "PROTEIN", 16, 20], ["hydrophobic side chains", "PROTEIN", 50, 73], ["Met99", "PROTEIN", 87, 92], ["Tyr104", "PROTEIN", 122, 128], ["greasy pocket", "PROTEIN", 146, 159], ["Fig. 2B", "PROTEIN", 161, 168], ["RBD", "PROTEIN", 178, 181], ["hydrophobic side chains", "PROBLEM", 50, 73], ["Met99", "TEST", 87, 92], ["Val", "TEST", 94, 97], ["Phe102", "TEST", 102, 108], ["Trp", "TEST", 110, 113], ["a greasy pocket", "PROBLEM", 144, 159], ["twelve hydrophobic/aromatic residues", "TREATMENT", 206, 242], ["CDR3", "ANATOMY", 16, 20], ["cluster", "OBSERVATION_MODIFIER", 39, 46], ["aromatic residues", "OBSERVATION", 225, 242]]], ["Unlike salt bridges, hydrophobic interactions are more tolerant to environment such as change of pH and ionic strength.", [["salt bridges", "SIMPLE_CHEMICAL", 7, 19], ["salt bridges", "OBSERVATION", 7, 19]]], ["This binding mode thus makes SR31 an attractive candidate for detection purposes.140Most RBD-targeting neutralizing antibodies, including neutralizing nanobodies characterized so far (8, 13-15, 19, 20, 22-24, 26-28, 34, 35, 37) , engage the RBD at the receptor-binding motif (RBM) (Fig. 3A) , thus competing off ACE2 and preventing viral entry.", [["RBD", "DISEASE", 89, 92], ["RBD", "DISEASE", 241, 244], ["SR31", "SIMPLE_CHEMICAL", 29, 33], ["RBD", "GENE_OR_GENE_PRODUCT", 241, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 312, 316], ["RBD", "PROTEIN", 89, 92], ["neutralizing antibodies", "PROTEIN", 103, 126], ["neutralizing nanobodies", "PROTEIN", 138, 161], ["RBD", "PROTEIN", 241, 244], ["receptor-binding motif", "PROTEIN", 252, 274], ["RBM", "PROTEIN", 276, 279], ["ACE2", "PROTEIN", 312, 316], ["detection purposes", "TEST", 62, 80], ["Most RBD", "TEST", 84, 92], ["neutralizing antibodies", "TEST", 103, 126], ["neutralizing nanobodies", "TEST", 138, 161], ["the RBD", "PROBLEM", 237, 244], ["ACE2", "TREATMENT", 312, 316], ["neutralizing antibodies", "OBSERVATION", 103, 126], ["viral entry", "OBSERVATION", 332, 343]]], ["Aligning the ACE2 structure to the SR31-RBD structure showed that the SR31-145 binding epitope is distant from the RBM (Fig. 3A) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["SR31", "GENE_OR_GENE_PRODUCT", 35, 39], ["SR31-145", "GENE_OR_GENE_PRODUCT", 70, 78], ["ACE2", "PROTEIN", 13, 17], ["SR31", "PROTEIN", 35, 39], ["RBD", "PROTEIN", 40, 43], ["SR31-145 binding epitope", "PROTEIN", 70, 94], ["RBM", "PROTEIN", 115, 118], ["the SR31", "TEST", 66, 74]]], ["Comparing the epitopes of existing monoclonal antibodies showed that the SR31 epitope partly overlaps with CR3022 (12) and the recently identified EY6A (22) (Fig. 3B, 3C ).", [["SR31", "GENE_OR_GENE_PRODUCT", 73, 77], ["epitopes", "PROTEIN", 14, 22], ["monoclonal antibodies", "PROTEIN", 35, 56], ["SR31 epitope", "PROTEIN", 73, 85], ["existing monoclonal antibodies", "TEST", 26, 56], ["the SR31 epitope", "PROBLEM", 69, 85], ["CR3022", "TEST", 107, 113], ["EY6A", "TEST", 147, 151], ["monoclonal antibodies", "OBSERVATION", 35, 56]]], ["It has been established that the binding of the bulky CR3022 and EY6A at the interface between RBD and the N- .", [["CR3022", "CHEMICAL", 54, 60], ["EY6A", "CHEMICAL", 65, 69], ["CR3022", "GENE_OR_GENE_PRODUCT", 54, 60], ["EY6A", "GENE_OR_GENE_PRODUCT", 65, 69], ["CR3022", "PROTEIN", 54, 60], ["EY6A", "PROTEIN", 65, 69], ["RBD", "PROTEIN", 95, 98], ["N", "PROTEIN", 107, 108], ["the bulky CR3022", "TEST", 44, 60], ["bulky", "OBSERVATION_MODIFIER", 48, 53]]], ["Taken together, the structural data rationalize the high-affinity binding between SR31 and RBD, and its inability to neutralize SARS-CoV-2.140Because nanobodies are relatively easy to produce, the availability of nanobodies that recognize a wide spectrum of epitopes can be a useful toolkit to probe binding 160 mode of uncharacterized antibodies using competitive binding assays.", [["SARS-CoV-2.140", "CHEMICAL", 128, 142], ["SR31", "GENE_OR_GENE_PRODUCT", 82, 86], ["RBD", "GENE_OR_GENE_PRODUCT", 91, 94], ["SR31", "PROTEIN", 82, 86], ["RBD", "PROTEIN", 91, 94], ["epitopes", "PROTEIN", 258, 266], ["uncharacterized antibodies", "PROTEIN", 320, 346], ["the structural data", "TEST", 16, 35], ["RBD", "PROBLEM", 91, 94], ["CoV", "TEST", 133, 136], ["competitive binding assays", "PROBLEM", 353, 379]]], ["They may also be used to select binders with new epitopes by including them as pre-formed sybody-RBD complexes during in vitro selection (and thus excluding binders at the same site). other RBD-targeting nanobodies (22, 35, 36, 39) and mAbs (13-15, 19, 20, 23, 24, 26-28) .", [["epitopes", "PROTEIN", 49, 57], ["sybody", "PROTEIN", 90, 96], ["RBD complexes", "PROTEIN", 97, 110], ["RBD", "PROTEIN", 190, 193], ["mAbs", "PROTEIN", 236, 240], ["pre-formed sybody-RBD complexes", "PROBLEM", 79, 110], ["binders", "TREATMENT", 157, 164], ["other RBD", "TEST", 184, 193], ["mAbs", "TEST", 236, 240], ["RBD", "OBSERVATION", 190, 193]]], ["Red, the collective epitope of RBM-binders; blue, the SR31 epitope; magenta, the collective epitope of CR3022 and EY6A; orange, the overlap between theSR31-RBD structure suggests high RBD domain stabilityStructure alignment of SR31-RBD with ACE2-RBD revealed that the two RBD structures were overall very similar with a C\uf061 RMSD of 0.452 \u00c5 (Fig. 4A) .SR31-RBD structure suggests high RBD domain stabilityNevertheless, significant structural rearrangements at the binding interface were observed (Fig. 4A, 4B) .", [["RBM", "GENE_OR_GENE_PRODUCT", 31, 34], ["CR3022", "GENE_OR_GENE_PRODUCT", 103, 109], ["SR31", "GENE_OR_GENE_PRODUCT", 151, 155], ["SR31-RBD", "GENE_OR_GENE_PRODUCT", 227, 235], ["ACE2-RBD", "GENE_OR_GENE_PRODUCT", 241, 249], ["SR31", "GENE_OR_GENE_PRODUCT", 350, 354], ["RBM", "PROTEIN", 31, 34], ["SR31 epitope", "PROTEIN", 54, 66], ["CR3022", "PROTEIN", 103, 109], ["EY6A", "PROTEIN", 114, 118], ["SR31", "PROTEIN", 151, 155], ["RBD structure", "PROTEIN", 156, 169], ["RBD domain", "PROTEIN", 184, 194], ["SR31", "PROTEIN", 227, 231], ["RBD", "PROTEIN", 232, 235], ["ACE2", "PROTEIN", 241, 245], ["RBD", "PROTEIN", 246, 249], ["RBD", "PROTEIN", 272, 275], ["SR31", "PROTEIN", 350, 354], ["RBD", "PROTEIN", 355, 358], ["RBD", "PROTEIN", 383, 386], ["binders", "TREATMENT", 35, 42], ["blue", "TREATMENT", 44, 48], ["the SR31 epitope", "TREATMENT", 50, 66], ["magenta", "TREATMENT", 68, 75], ["theSR31", "TEST", 148, 155], ["high RBD domain stability", "PROBLEM", 179, 204], ["SR31", "TEST", 227, 231], ["ACE2", "TEST", 241, 245], ["a C\uf061 RMSD", "TEST", 318, 327], ["high RBD domain stability", "PROBLEM", 378, 403], ["significant structural rearrangements at the binding interface", "PROBLEM", 417, 479], ["high RBD", "OBSERVATION", 179, 187], ["stability", "OBSERVATION_MODIFIER", 195, 204], ["very", "OBSERVATION_MODIFIER", 300, 304], ["similar", "OBSERVATION", 305, 312], ["RBD", "OBSERVATION", 355, 358], ["high RBD", "OBSERVATION", 378, 386], ["significant", "OBSERVATION_MODIFIER", 417, 428], ["structural rearrangements", "OBSERVATION", 429, 454], ["binding interface", "OBSERVATION", 462, 479]]], ["Specifically, the small \uf061-helix \uf061364-370 (numbers mark start-end) 185 moves towards the direction of RBM by a dramatic ~8.0 \u00c5 and transforms to a short \uf062sheet (\uf062367-370) which in turn forms a parallel \uf062-sheet pair with \uf062102-104 in the CDR3 region.", [["\uf062367-370", "CHEMICAL", 160, 168], ["small \uf061-helix \uf061364-370", "DNA", 18, 40], ["RBM", "PROTEIN", 101, 104], ["CDR3 region", "PROTEIN", 235, 246], ["a parallel \uf062-sheet pair", "TREATMENT", 190, 213], ["small", "OBSERVATION_MODIFIER", 18, 23], ["CDR3", "ANATOMY", 235, 239], ["region", "ANATOMY_MODIFIER", 240, 246]]], ["In addition, nudged by the CDR1, the short helix \uf061383-388 swings towards the RBD core by ~4.0 \u00c5.", [["CDR1", "GENE_OR_GENE_PRODUCT", 27, 31], ["CDR1", "DNA", 27, 31], ["RBD core", "DNA", 77, 85], ["the short helix", "TEST", 33, 48], ["the RBD core", "TEST", 73, 85]]], ["Remarkable, the dramatic rearrangements did not cause noticeable conformational change of RBM (Fig. 4A) nor did it affect ACE2 binding (Fig. 1C) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["RBM", "PROTEIN", 90, 93], ["ACE2", "PROTEIN", 122, 126], ["noticeable conformational change of RBM", "PROBLEM", 54, 93]]], ["Given that RBD is 210 a relatively small entity, and that the two surfaces are relatively close (~25 \u00c5), this was somewhat unexpected.", [["RBD", "DISEASE", 11, 14], ["RBD", "PROTEIN", 11, 14], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["small", "OBSERVATION_MODIFIER", 35, 40], ["entity", "OBSERVATION", 41, 47], ["surfaces", "OBSERVATION_MODIFIER", 66, 74]]], ["A probable explanation is that RBD is very rigid and hence stable.", [["RBD", "DISEASE", 31, 34], ["RBD", "PROTEIN", 31, 34], ["RBD", "PROBLEM", 31, 34], ["very rigid", "PROBLEM", 38, 48], ["probable explanation is", "UNCERTAINTY", 2, 25], ["RBD", "OBSERVATION", 31, 34], ["very", "OBSERVATION_MODIFIER", 38, 42], ["rigid", "OBSERVATION", 43, 48], ["stable", "OBSERVATION_MODIFIER", 59, 65]]], ["Indeed, as shown in Fig. 4C , RBD showed ultra-stability, with an apparent melting temperature of greater than 95 \u00ba C (20-min heating).215Intriguingly, the rearrangement happens at a region that is rich in disulfide bonds.215Specifically, \uf062367-370 is tethered between the disulfide pairs Cys379-Cys432 and Cys336-Cys361, and \uf061383-388 bridges Cys379-Cys432 and Cys-391-Cys525 (Fig. 4D) .215Thus, the three disulfide bonds segregate the two local motifs from the rest of RBD, preventing these conformational changes from propagating through the domain.SR31 as a non-competing sybody for RBM bindersThe neutral feature of SR31 so far suggests it could bind to RBD in addition to RBM binders such as MR17 and SR4 (35) .", [["RBD", "DISEASE", 657, 660], ["disulfide", "CHEMICAL", 206, 215], ["disulfide", "CHEMICAL", 272, 281], ["Cys379", "CHEMICAL", 288, 294], ["Cys432", "CHEMICAL", 295, 301], ["Cys336-", "CHEMICAL", 306, 313], ["Cys361", "CHEMICAL", 313, 319], ["\uf061383-388", "CHEMICAL", 325, 333], ["Cys379-", "CHEMICAL", 342, 349], ["Cys-391-Cys525", "CHEMICAL", 360, 374], ["disulfide", "CHEMICAL", 405, 414], ["Cys379-Cys432", "SIMPLE_CHEMICAL", 288, 301], ["Cys336-", "AMINO_ACID", 306, 313], ["Cys361", "AMINO_ACID", 313, 319], ["\uf061383-388", "AMINO_ACID", 325, 333], ["Cys379-", "AMINO_ACID", 342, 349], ["Cys432", "AMINO_ACID", 349, 355], ["SR31", "GENE_OR_GENE_PRODUCT", 550, 554], ["SR31", "GENE_OR_GENE_PRODUCT", 619, 623], ["RBD", "GENE_OR_GENE_PRODUCT", 657, 660], ["MR17", "GENE_OR_GENE_PRODUCT", 696, 700], ["RBD", "PROTEIN", 30, 33], ["disulfide pairs", "PROTEIN", 272, 287], ["RBD", "PROTEIN", 469, 472], ["SR31", "PROTEIN", 550, 554], ["SR31", "PROTEIN", 619, 623], ["RBD", "PROTEIN", 657, 660], ["ultra-stability", "PROBLEM", 41, 56], ["an apparent melting temperature", "PROBLEM", 63, 94], ["the three disulfide bonds", "TREATMENT", 395, 420], ["RBD", "PROBLEM", 469, 472], ["these conformational changes", "PROBLEM", 485, 513], ["a non-competing sybody for RBM binders", "TREATMENT", 558, 596], ["RBD", "PROBLEM", 657, 660], ["RBM binders", "TREATMENT", 676, 687], ["ultra-stability", "OBSERVATION", 41, 56], ["melting", "OBSERVATION_MODIFIER", 75, 82], ["temperature", "OBSERVATION_MODIFIER", 83, 94], ["disulfide bonds", "OBSERVATION", 206, 221], ["RBD", "OBSERVATION", 469, 472], ["neutral feature", "OBSERVATION_MODIFIER", 600, 615]]], ["Indeed, BLI assays showed no competition 225 between SR31 and MR17 (Fig. 5A) , indicating a 'sandwich complex' where the RBD is bound with both sybodies.", [["RBD", "DISEASE", 121, 124], ["BLI", "PROTEIN", 8, 11], ["RBD", "PROTEIN", 121, 124], ["BLI assays", "TEST", 8, 18], ["SR31", "TEST", 53, 57], ["a 'sandwich complex'", "PROBLEM", 90, 110], ["RBD", "OBSERVATION", 121, 124]]], ["This non-competing feature was also observed in the case of MR6 (Fig. 5B) which has also been shown to have neutralizing activities (35) .", [["neutralizing", "OBSERVATION_MODIFIER", 108, 120]]], ["As a further proof for the simultaneous binding, we determined the structure of the sandwich complex SR31-RBD-MR17 (Fig. 5C, Table 1 ) to 2.10 \u00c5 resolution.", [["sandwich complex", "PROTEIN", 84, 100], ["SR31", "PROTEIN", 101, 105], ["RBD", "PROTEIN", 106, 109], ["MR17", "PROTEIN", 110, 114], ["Fig. 5C, Table 1", "PROTEIN", 116, 132]]], ["The sandwich 230 complex was similar to the individual MR17-and SR31-RBD complexes, with an overall C\uf061 RMSD of 0.667 and 0.375 \u00c5, respectively.", [["MR17", "GENE_OR_GENE_PRODUCT", 55, 59], ["SR31-RBD", "GENE_OR_GENE_PRODUCT", 64, 72], ["sandwich 230 complex", "PROTEIN", 4, 24], ["MR17", "PROTEIN", 55, 59], ["SR31", "PROTEIN", 64, 68], ["RBD complexes", "PROTEIN", 69, 82], ["the individual MR17", "TEST", 40, 59], ["RBD complexes", "ANATOMY", 69, 82], ["overall", "OBSERVATION_MODIFIER", 92, 99]]], ["Aligning the sandwich complex with the MR17-RBD structure revealed no noticeable changes at the MR17-binding surface (Fig. 5C) , reinforcing the idea that SR31-binding does not allosterically change the RBM surface nor affect RBM binders. to the two-component complex structure (RBD (green) and MR17, PDB ID 7c8w) (35) .SR31 fusion increases affinity and neutralization activity of MR17 and MR6Although SR31 does not neutralize SARS-CoV-2 pseudovirus itself, its highaffinity may help increase the affinity of other neutralizing nanobodies through avidity 250 effect by fusion.", [["RBM surface", "ANATOMY", 203, 214], ["SR31", "CHEMICAL", 155, 159], ["surface", "CELLULAR_COMPONENT", 109, 116], ["SR31", "SIMPLE_CHEMICAL", 155, 159], ["SR31", "GENE_OR_GENE_PRODUCT", 320, 324], ["MR17", "SIMPLE_CHEMICAL", 382, 386], ["SARS-CoV-2 pseudovirus", "ORGANISM", 428, 450], ["sandwich complex", "PROTEIN", 13, 29], ["MR17", "PROTEIN", 39, 43], ["RBD", "PROTEIN", 44, 47], ["MR17", "PROTEIN", 96, 100], ["SR31", "PROTEIN", 155, 159], ["-component complex structure", "PROTEIN", 249, 277], ["RBD", "PROTEIN", 279, 282], ["MR17", "PROTEIN", 295, 299], ["SR31", "PROTEIN", 320, 324], ["SR31", "PROTEIN", 403, 407], ["the MR17-RBD structure", "TEST", 35, 57], ["noticeable changes", "PROBLEM", 70, 88], ["RBM binders", "TREATMENT", 226, 237], ["SR31 fusion increases affinity", "PROBLEM", 320, 350], ["neutralization activity", "TEST", 355, 378], ["MR17", "TEST", 382, 386], ["MR6Although SR31", "TEST", 391, 407], ["SARS", "PROBLEM", 428, 432], ["CoV", "TEST", 433, 436], ["other neutralizing nanobodies", "TREATMENT", 510, 539], ["no", "UNCERTAINTY", 67, 69], ["noticeable", "OBSERVATION_MODIFIER", 70, 80], ["changes", "OBSERVATION", 81, 88]]], ["Indeed, the biparatopic fusion SR31-MR17 displayed remarkable increase in binding affinity compared to SR31 or MR17 alone.", [["SR31-MR17", "CHEMICAL", 31, 40], ["MR17", "CHEMICAL", 111, 115], ["SR31", "CHEMICAL", 103, 107], ["MR17", "CHEMICAL", 111, 115], ["SR31", "GENE_OR_GENE_PRODUCT", 31, 35], ["SR31", "SIMPLE_CHEMICAL", 103, 107], ["MR17", "SIMPLE_CHEMICAL", 111, 115], ["SR31", "PROTEIN", 31, 35], ["MR17", "PROTEIN", 36, 40], ["SR31", "PROTEIN", 103, 107], ["MR17", "PROTEIN", 111, 115], ["the biparatopic fusion SR31", "TEST", 8, 35], ["remarkable increase in binding affinity", "PROBLEM", 51, 90], ["remarkable", "OBSERVATION_MODIFIER", 51, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["binding affinity", "OBSERVATION", 74, 90]]], ["Its KD of 0.3 nM (Fig. 6A ) was lower than MR17 (KD = 83.7 nM) (35) by 230 folds and lower than SR31 (KD = 5.6 nM) by 17 folds.", [["Its KD", "TEST", 0, 6], ["nM (Fig. 6A", "TEST", 14, 25], ["MR17", "TEST", 43, 47], ["KD", "TEST", 49, 51], ["folds", "TEST", 75, 80], ["KD", "TEST", 102, 104]]], ["Consistently, SR31-MR17 neutralized SARS-CoV-2 pseudovirus 13 times more effectively (in molarity) than MR17 alone (Fig. 6B) .", [["SR31-MR17", "GENE_OR_GENE_PRODUCT", 14, 23], ["SARS-CoV-2 pseudovirus", "ORGANISM", 36, 58], ["MR17", "SIMPLE_CHEMICAL", 104, 108], ["SR31", "PROTEIN", 14, 18], ["CoV-2 pseudovirus", "SPECIES", 41, 58], ["SARS-CoV-2 pseudovirus", "SPECIES", 36, 58], ["SR31", "TEST", 14, 18], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44]]], ["255 That SR31 can enhance potency of its fusion partner was also demonstrated in the case for MR6.", [["SR31", "CHEMICAL", 9, 13], ["MR6", "PROTEIN", 94, 97], ["fusion", "OBSERVATION", 41, 47]]], ["At its free form, MR6 bound to RBD with a KD of 23.2 nM (Fig. 6C) , and showed modest neutralizing activity with an IC50 of 1.32 \uf06dg mL -1 (77.5 nM).", [["MR6", "SIMPLE_CHEMICAL", 18, 21], ["MR6", "PROTEIN", 18, 21], ["RBD", "PROTEIN", 31, 34], ["RBD", "TEST", 31, 34], ["a KD", "TEST", 40, 44], ["nM (Fig. 6C", "TEST", 53, 64], ["modest neutralizing activity", "PROBLEM", 79, 107], ["an IC50", "TEST", 113, 120], ["modest", "OBSERVATION_MODIFIER", 79, 85], ["neutralizing activity", "OBSERVATION", 86, 107]]], ["Fusing it to SR31 increased its affinity by over 40 folds, displaying a KD of 0.5 nM (Fig. 6D) .", [["SR31", "CHEMICAL", 13, 17], ["SR31", "GENE_OR_GENE_PRODUCT", 13, 17], ["SR31", "PROTEIN", 13, 17]]], ["260 In line with this, SR31-MR6 showed a 27-fold higher neutralization activity compared to MR6, with an IC50 of 2.7 nM (0.08 \uf06dg mL -1 ) (Fig. 6E) .", [["SR31-MR6", "SIMPLE_CHEMICAL", 23, 31], ["MR6", "SIMPLE_CHEMICAL", 92, 95], ["SR31", "PROTEIN", 23, 27], ["MR6", "DNA", 28, 31], ["SR31", "TEST", 23, 27], ["a 27-fold higher neutralization activity", "PROBLEM", 39, 79], ["an IC50", "TEST", 102, 109], ["neutralization activity", "OBSERVATION", 56, 79]]], ["Interestingly, when fused to MR3, a neutralizing antibody that had higher affinity (KD = 1.0 nM) than SR31, the neutralizing activity decreased by 2 folds (Fig. 6F) .", [["MR3", "GENE_OR_GENE_PRODUCT", 29, 32], ["MR3", "PROTEIN", 29, 32], ["neutralizing antibody", "PROTEIN", 36, 57], ["MR3", "TEST", 29, 32], ["a neutralizing antibody", "TEST", 34, 57], ["higher affinity", "PROBLEM", 67, 82], ["KD", "TEST", 84, 86], ["the neutralizing activity", "PROBLEM", 108, 133], ["neutralizing activity", "OBSERVATION", 112, 133]]], ["Possible reasons include steric incompatibility caused by improper link length, and allosteric effects.", [["steric incompatibility", "PROBLEM", 25, 47], ["improper link length", "PROBLEM", 58, 78], ["steric incompatibility", "OBSERVATION", 25, 47], ["length", "OBSERVATION_MODIFIER", 72, 78], ["allosteric effects", "OBSERVATION", 84, 102]]], ["Such hypothesis 265 warrants future structural investigation.", [["future structural investigation", "TEST", 29, 60]]], ["Binding affinity and neutralizing activity are important characteristics of therapeutic antibodies.", [["therapeutic antibodies", "PROTEIN", 76, 98], ["Binding affinity", "PROBLEM", 0, 16], ["neutralizing activity", "PROBLEM", 21, 42], ["therapeutic antibodies", "PROBLEM", 76, 98], ["neutralizing activity", "OBSERVATION", 21, 42]]], ["For modestly neutralizing nanobodies, the potency can be increased in a number of ways, including random mutagenesis (22) , structure-based 280 design (35) , and fusion (35, 36, 42) .", [["modestly neutralizing nanobodies", "PROBLEM", 4, 36], ["random mutagenesis", "TEST", 98, 116], ["fusion", "TEST", 162, 168], ["neutralizing nanobodies", "OBSERVATION", 13, 36], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["Compared with the other two approaches, the fusion technique is more rapid, less involving and does not rely on prior structural information.SR31 fusion increases affinity and neutralization activity of MR17 and MR6Depending on whether the two fusion partners are the same, divalent nanobodies 285 can be categorized into two types: monoparatopic and biparatopic.", [["SR31", "GENE_OR_GENE_PRODUCT", 141, 145], ["MR17", "GENE_OR_GENE_PRODUCT", 203, 207], ["SR31", "PROTEIN", 141, 145], ["MR17", "PROTEIN", 203, 207], ["MR6Depending", "PROTEIN", 212, 224], ["the fusion technique", "TREATMENT", 40, 60], ["SR31 fusion increases affinity", "PROBLEM", 141, 171], ["neutralization activity", "TEST", 176, 199], ["MR17", "TEST", 203, 207], ["the two fusion partners", "PROBLEM", 236, 259], ["monoparatopic and biparatopic", "TREATMENT", 333, 362], ["fusion", "OBSERVATION", 44, 50], ["rapid", "OBSERVATION_MODIFIER", 69, 74]]], ["Biparatopic fusions recognize two distinct epitopes on the same target.", [["epitopes", "PROTEIN", 43, 51], ["Biparatopic fusions", "TREATMENT", 0, 19], ["fusions", "OBSERVATION", 12, 19], ["two", "OBSERVATION_MODIFIER", 30, 33], ["distinct", "OBSERVATION_MODIFIER", 34, 42], ["epitopes", "OBSERVATION", 43, 51]]], ["Therefore, they are more likely to be resistant to escape mutants because simultaneous mutations at two epitopes should occur at a much lower rate than at a single epitope.290Because of the minute size, SR31 could be used as an 'add-on' to monoclonal antibodies, scFv fragments, and other nanobodies to enhance their affinity and potency, especially for those with modest neutralizing activities.", [["SR31", "CHEMICAL", 203, 207], ["SR31", "SIMPLE_CHEMICAL", 203, 207], ["epitopes", "PROTEIN", 104, 112], ["SR31", "PROTEIN", 203, 207], ["monoclonal antibodies", "PROTEIN", 240, 261], ["scFv fragments", "PROTEIN", 263, 277], ["escape mutants", "PROBLEM", 51, 65], ["simultaneous mutations at two epitopes", "PROBLEM", 74, 112], ["monoclonal antibodies", "TEST", 240, 261], ["scFv fragments", "PROBLEM", 263, 277], ["more likely", "UNCERTAINTY", 20, 31], ["size", "OBSERVATION_MODIFIER", 197, 201]]], ["In addition, due to its small size and high stability, SR31 may be chemically modified as a vector to deliver smallmolecule inhibitors specifically targeting SARS-CoV-2.295In summary, we have structurally characterized SR31, a high-affinity nanobody against SARS-CoV-2 RBD.", [["SR31", "CHEMICAL", 55, 59], ["SR31", "SIMPLE_CHEMICAL", 55, 59], ["SR31", "SIMPLE_CHEMICAL", 219, 223], ["SR31", "PROTEIN", 55, 59], ["SARS-CoV", "PROTEIN", 158, 166], ["SR31", "PROTEIN", 219, 223], ["SARS-CoV-2 RBD", "PROTEIN", 258, 272], ["SARS-CoV", "SPECIES", 258, 266], ["its small size", "PROBLEM", 20, 34], ["a vector", "TREATMENT", 90, 98], ["smallmolecule inhibitors", "TREATMENT", 110, 134], ["SARS-CoV", "TEST", 158, 166], ["SR31", "TEST", 219, 223], ["SARS", "PROBLEM", 258, 262], ["CoV", "TEST", 263, 266], ["RBD", "PROBLEM", 269, 272], ["small", "OBSERVATION_MODIFIER", 24, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["high stability", "OBSERVATION_MODIFIER", 39, 53]]], ["Although lacking neutralizing activity alone, SR31 is an attractive biparatopic partner for RBM-binders owing to its distinct epitope from RBM.295Our work presents a generally useful strategy and offers a simple and fast approach to 300 enhance potency of modestly active antibodies against SARS-CoV2.CONFLICT OF INTERESTThe authors claim no conflict of interest.Protein purificationSARS-CoV-2 RBD was expressed essentially as described (35) .", [["SR31", "CHEMICAL", 46, 50], ["SARS", "DISEASE", 291, 295], ["SR31", "SIMPLE_CHEMICAL", 46, 50], ["RBM", "CANCER", 139, 142], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 291, 300], ["SR31", "PROTEIN", 46, 50], ["RBM", "PROTEIN", 92, 95], ["RBM", "PROTEIN", 139, 142], ["Protein purificationSARS-CoV-2 RBD", "PROTEIN", 363, 397], ["RBM", "PROBLEM", 92, 95], ["binders", "TREATMENT", 96, 103], ["a simple and fast approach", "TREATMENT", 203, 229], ["SARS", "PROBLEM", 291, 295], ["Protein purificationSARS", "TEST", 363, 387], ["CoV", "TEST", 388, 391], ["neutralizing activity", "OBSERVATION", 17, 38], ["distinct", "OBSERVATION_MODIFIER", 117, 125], ["epitope", "OBSERVATION", 126, 133]]], ["Briefly, a DNA 330 fragment encoding, from N-to C-terminus, residues 330-541 of SARS-CoV2 S, a Gly-Thr linker, the 3C protease site (LEVLFQGP), a Gly-Ser linker, the Avi tag (GLNDIFEAQKIEWHE), a Ser-Gly linker, and a deca-His tag were cloned into the pFastBac-based vector.", [["Gly-Thr", "CHEMICAL", 95, 102], ["N", "CHEMICAL", 43, 44], ["C", "CHEMICAL", 48, 49], ["Gly", "CHEMICAL", 95, 98], ["Thr", "CHEMICAL", 99, 102], ["Gly", "CHEMICAL", 146, 149], ["Ser", "CHEMICAL", 150, 153], ["Ser", "CHEMICAL", 195, 198], ["Gly", "CHEMICAL", 199, 202], ["deca-His", "CHEMICAL", 217, 225], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["Avi tag", "GENE_OR_GENE_PRODUCT", 166, 173], ["pFastBac", "GENE_OR_GENE_PRODUCT", 251, 259], ["DNA 330 fragment", "DNA", 11, 27], ["N-to C-terminus", "PROTEIN", 43, 58], ["SARS-CoV2", "PROTEIN", 80, 89], ["Gly-Thr linker", "PROTEIN", 95, 109], ["3C protease site", "PROTEIN", 115, 131], ["LEVLFQGP", "PROTEIN", 133, 141], ["Gly-Ser linker", "PROTEIN", 146, 160], ["Avi tag", "PROTEIN", 166, 173], ["GLNDIFEAQKIEWHE", "PROTEIN", 175, 190], ["Ser-Gly linker", "PROTEIN", 195, 209], ["deca", "PROTEIN", 217, 221], ["pFastBac-based vector", "DNA", 251, 272], ["a DNA 330 fragment", "PROBLEM", 9, 27], ["a Gly-Thr linker", "TREATMENT", 93, 109], ["the 3C protease site", "TREATMENT", 111, 131], ["a Gly-Ser linker", "TREATMENT", 144, 160], ["a Ser-Gly linker", "TREATMENT", 193, 209], ["a deca", "TREATMENT", 215, 221], ["His tag", "TREATMENT", 222, 229], ["based", "ANATOMY_MODIFIER", 260, 265], ["vector", "ANATOMY", 266, 272]]], ["Baculovirus was generated in Sf9 cells following the Invitrogen Bac-to-Bac transfection protocol.", [["Sf9 cells", "ANATOMY", 29, 38], ["Baculovirus", "ORGANISM", 0, 11], ["Sf9 cells", "CELL", 29, 38], ["Sf9 cells", "CELL_LINE", 29, 38], ["Baculovirus", "SPECIES", 0, 11], ["Sf9", "SPECIES", 29, 32], ["Baculovirus", "TREATMENT", 0, 11], ["the Invitrogen Bac", "TREATMENT", 49, 67], ["Bac transfection protocol", "TREATMENT", 71, 96]]], ["High Five insect cells were infected with P3 virus.", [["cells", "ANATOMY", 17, 22], ["cells", "CELL", 17, 22], ["P3 virus", "ORGANISM", 42, 50], ["P3 virus", "SPECIES", 42, 50], ["High Five insect cells", "PROBLEM", 0, 22], ["P3 virus", "PROBLEM", 42, 50], ["insect cells", "OBSERVATION", 10, 22], ["P3 virus", "OBSERVATION", 42, 50]]], ["For crystallization, SR31 or SR31-MR17 was mixed with RBD at a 1:1.5molar ratio.", [["SR31", "CHEMICAL", 21, 25], ["SR31-MR17", "CHEMICAL", 29, 38], ["RBD", "DISEASE", 54, 57], ["SR31", "CHEMICAL", 21, 25], ["SR31-MR17", "CHEMICAL", 29, 38], ["SR31", "SIMPLE_CHEMICAL", 21, 25], ["SR31-MR17", "SIMPLE_CHEMICAL", 29, 38], ["SR31", "PROTEIN", 29, 33], ["MR17", "PROTEIN", 34, 38], ["RBD", "PROTEIN", 54, 57], ["crystallization", "TEST", 4, 19], ["SR31", "TEST", 21, 25], ["SR31", "TEST", 29, 33], ["RBD", "PROBLEM", 54, 57]]], ["The mixture was then loaded onto a Superdex 200 column for gel filtration.365Fractions containing the complex were pooled and concentrated to 10 mg mL -1 .Fluorescence-detection size-exclusion chromatography (FSEC)To screen RBD binders by size exclusion chromatography (SEC) using unpurified sybodies, RBD was fluorescently labelled as follows.", [["RBD", "PROTEIN", 302, 305], ["a Superdex 200 column", "TREATMENT", 33, 54], ["gel filtration", "TREATMENT", 59, 73], ["Fluorescence", "TEST", 155, 167], ["exclusion chromatography", "TEST", 183, 207], ["RBD binders", "TEST", 224, 235], ["size exclusion chromatography", "TEST", 239, 268], ["RBD", "PROBLEM", 302, 305], ["complex", "OBSERVATION_MODIFIER", 102, 109], ["size", "OBSERVATION_MODIFIER", 178, 182]]], ["First the avi-tagged RBD was for 200-300 s, before moving into sybody-free buffer for dissociation.", [["RBD", "DISEASE", 21, 24], ["avi-tagged RBD", "PROTEIN", 10, 24], ["dissociation", "PROBLEM", 86, 98]]], ["BLI signal was monitored during the whole process.", [["BLI signal", "TEST", 0, 10]]], ["Data were fitted with a 1:1 stoichiometry using the build-in software Analysis 10.0 for kinetic parameters.", [["a 1:1 stoichiometry", "TREATMENT", 22, 41], ["software Analysis", "TEST", 61, 78], ["kinetic parameters", "TEST", 88, 106]]], ["For competitive assay of the 390 RBD between SR31 and ACE2, the RBD-coated sensor was saturated in 200 nM of SR31, before soaked in 25 nM SR31 with or without 25 nM of ACE2.", [["SR31", "CHEMICAL", 109, 113], ["SR31", "CHEMICAL", 138, 142], ["SR31", "CHEMICAL", 138, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["SR31", "SIMPLE_CHEMICAL", 109, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 168, 172], ["390 RBD", "PROTEIN", 29, 36], ["SR31", "PROTEIN", 45, 49], ["ACE2", "PROTEIN", 54, 58], ["RBD", "PROTEIN", 64, 67], ["ACE2", "PROTEIN", 168, 172], ["competitive assay", "TEST", 4, 21], ["ACE2", "TEST", 54, 58]]], ["As a control, BLI assays were also carried out by soaking the RBD-coated sensor in ACE2 without SR31.", [["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["SR31", "GENE_OR_GENE_PRODUCT", 96, 100], ["RBD", "PROTEIN", 62, 65], ["ACE2", "PROTEIN", 83, 87], ["SR31", "PROTEIN", 96, 100], ["BLI assays", "TEST", 14, 24]]], ["For competitive RBD-binding assays for different sybodies, the assays were carried out the same manner as described above.", [["RBD", "PROTEIN", 16, 19], ["competitive RBD-binding assays", "PROBLEM", 4, 34], ["different sybodies", "PROBLEM", 39, 57], ["the assays", "TEST", 59, 69]]], ["Desired crystals were cryo-protected, harvested using a MiTeGen loop under a microscope, and flash-cooled in liquid nitrogen before diffraction.Data collection and structure determinationX-ray diffraction data were collected at beamline BL19U1 (44) at Shanghai Synchrotron Radiation Facility with a 50 x 50 \u03bcm beam on a Pilatus 6M detector, with 440 oscillation of 0.5\u00b0 and a wavelength of 0.97853 \u00c5.", [["nitrogen", "CHEMICAL", 116, 124], ["Desired crystals", "PROBLEM", 0, 16], ["a MiTeGen loop", "TREATMENT", 54, 68], ["a microscope", "TREATMENT", 75, 87], ["flash", "PROBLEM", 93, 98], ["liquid nitrogen", "TREATMENT", 109, 124], ["Data collection", "TEST", 144, 159], ["structure determinationX", "TEST", 164, 188], ["ray diffraction data", "TEST", 189, 209], ["a Pilatus 6M detector", "TREATMENT", 318, 339], ["a wavelength", "TEST", 374, 386], ["crystals", "OBSERVATION_MODIFIER", 8, 16]]], ["Data were integrated using the software XDS (45) , and scaled and merged using Aimless (46) .", [["the software XDS", "TEST", 27, 43]]], ["The SR31-RBD structure was solved by molecular replacement using Phaser (47) with PDB IDs 6M0J and 5M13 (41) as the search model.", [["SR31", "PROTEIN", 4, 8], ["RBD", "PROTEIN", 9, 12], ["The SR31", "TEST", 0, 8], ["molecular replacement", "TREATMENT", 37, 58], ["PDB IDs", "TEST", 82, 89], ["RBD", "OBSERVATION", 9, 12], ["molecular replacement", "OBSERVATION", 37, 58]]], ["The SR31-MR17-RBD structure was solved using the SR31-RBD and MR17 structure (35) as search models.", [["SR31", "GENE_OR_GENE_PRODUCT", 4, 8], ["SR31", "PROTEIN", 4, 8], ["MR17", "PROTEIN", 9, 13], ["RBD", "PROTEIN", 14, 17], ["SR31", "PROTEIN", 49, 53], ["RBD", "PROTEIN", 54, 57], ["The SR31", "TEST", 0, 8], ["the SR31", "TEST", 45, 53], ["search models", "TEST", 85, 98], ["RBD", "ANATOMY", 54, 57]]], ["The models were manually 445 adjusted as guided by the 2Fo-Fc maps in Coot (48) , and refined using Phenix (49) .Data collection and structure determinationStructures were visualized using PyMol (50).Data availabilityThe structure factors and coordinates were deposited in the protein data bank (PDB) under accession codes 7D2Z (SR31+RBD) and 7D30 (SR31-MR17+RBD).", [["PyMol", "CHEMICAL", 189, 194], ["2Fo-Fc maps", "DNA", 55, 66], ["structure factors", "PROTEIN", 221, 238], ["SR31", "PROTEIN", 329, 333], ["RBD", "PROTEIN", 334, 337], ["7D30", "PROTEIN", 343, 347], ["SR31", "PROTEIN", 349, 353], ["MR17", "PROTEIN", 354, 358], ["RBD", "PROTEIN", 359, 362], ["Phenix", "TEST", 100, 106], ["Data collection", "TEST", 113, 128], ["structure determinationStructures", "TEST", 133, 166], ["SR31", "TEST", 349, 353], ["PDB", "ANATOMY", 296, 299]]]], "46c9bd4aa92ac01a99efa2f82e2e6c105fcdd078": [["Methods:The physical therapy gymnasium was the area designated to test the ability to create a negative-pressure isolation environment in a large space.", [["large", "OBSERVATION_MODIFIER", 140, 145]]], ["The conversion was planned in advance of an unscheduled drill to convert the space.", [["The conversion", "TREATMENT", 0, 14], ["an unscheduled drill", "TREATMENT", 41, 61]]], ["Four highefficiency particulate air (HEPA) filtered forced air machines were used to generate negative pressure.", [["Four highefficiency particulate air (HEPA)", "PROBLEM", 0, 42], ["forced air machines", "TREATMENT", 52, 71], ["highefficiency", "OBSERVATION_MODIFIER", 5, 19], ["particulate", "OBSERVATION_MODIFIER", 20, 31], ["air", "OBSERVATION", 32, 35], ["negative pressure", "OBSERVATION", 94, 111]]], ["The units were vented to the outside air by a 25-foot length of 10inch-diameter reusable duct.", [["duct", "ANATOMY", 89, 93], ["foot", "ORGANISM_SUBDIVISION", 49, 53], ["duct", "MULTI-TISSUE_STRUCTURE", 89, 93], ["The units", "TREATMENT", 0, 9], ["vented", "TREATMENT", 15, 21], ["a 25-foot length of 10inch-diameter reusable duct", "TREATMENT", 44, 93], ["duct", "ANATOMY", 89, 93]]], ["We evaluated the time needed for equipment setup and room conversion and noted any subjective difficulty with either setup or operation of the equipment.", [["equipment setup", "TREATMENT", 33, 48], ["operation of the equipment", "TREATMENT", 126, 152]]], ["We measured the ability of the equipment to generate a negative air pressure relative to adjacent areas and determined the noise levels created during the use of different combinations of machines at various power settings.Methods:Results: After drill activation and the request for equipment setup, 1 hour was required to convert the physical therapy gymnasium into an operational negative-pressure environment.", [["the equipment", "TREATMENT", 27, 40], ["the noise levels", "PROBLEM", 119, 135], ["machines", "TREATMENT", 188, 196], ["equipment setup", "TREATMENT", 283, 298], ["air pressure", "OBSERVATION", 64, 76]]], ["The room pressure readings ''high'' power ranged from \u00ff1.5 to \u00ff13 Pa (\u00ff0.006 to \u00ff0.052 inches of water), and noise levels ranged from 70 to 76 dB.", [["The room pressure readings", "TEST", 0, 26], ["noise levels", "TEST", 109, 121]]], ["Calculated air changes per hour using 1, 2, 3, or 4 units running simultaneously at ''high'' power were 4.1, 8.2, 12.3, and 16.4, respectively.", [["Calculated air changes", "PROBLEM", 0, 22], ["air changes", "OBSERVATION", 11, 22]]], ["Using 4 units at once running at ''low'' power setting yielded 8.2 air changes per hour and generated a room pressure reading of \u00ff8.0 Pa, or \u00ff0.032 inches of water.Methods:Conclusion: Portable HEPA filtered forced air units are an effective means of creating large patient care areas with the negative-pressure environment required for respiratory isolation.", [["respiratory", "ANATOMY", 336, 347], ["patient", "ORGANISM", 265, 272], ["patient", "SPECIES", 265, 272], ["a room pressure", "TEST", 102, 117], ["Portable HEPA filtered forced air units", "TREATMENT", 184, 223], ["creating large patient care areas", "TREATMENT", 250, 283], ["the negative-pressure environment", "TREATMENT", 289, 322], ["respiratory isolation", "TREATMENT", 336, 357], ["8.2 air", "OBSERVATION", 63, 70], ["large", "OBSERVATION_MODIFIER", 259, 264], ["respiratory isolation", "OBSERVATION", 336, 357]]], ["This type of unit would allow treatment of many more patients than current hospital capability would permit and would be an important asset in meeting the needs created by bioterrorism or a naturally occurring epidemic.I N T R O D U C T I O NPatients with communicable diseases, such as influenza and tuberculosis, often require respiratory isolation precautions to reduce the chance of transmission.", [["respiratory", "ANATOMY", 329, 340], ["communicable diseases", "DISEASE", 256, 277], ["influenza", "DISEASE", 287, 296], ["tuberculosis", "DISEASE", 301, 313], ["patients", "ORGANISM", 53, 61], ["I", "PROTEIN", 219, 220], ["patients", "SPECIES", 53, 61], ["treatment", "TREATMENT", 30, 39], ["communicable diseases", "PROBLEM", 256, 277], ["influenza", "PROBLEM", 287, 296], ["tuberculosis", "PROBLEM", 301, 313], ["respiratory isolation precautions", "TREATMENT", 329, 362], ["tuberculosis", "OBSERVATION", 301, 313]]], ["Isolation has been effectively accomplished using a single patient room with negative air pressure and a ventilation system separated from the rest of the hospital.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["Isolation", "TREATMENT", 0, 9], ["negative air pressure", "TREATMENT", 77, 98], ["a ventilation system", "TREATMENT", 103, 123], ["air pressure", "OBSERVATION", 86, 98]]], ["1 Airborne infection isolation refers to the isolation of patients infected with organisms spread by airborne droplet nuclei less than 5 mm in diameter.", [["nuclei", "ANATOMY", 118, 124], ["infection", "DISEASE", 11, 20], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Airborne infection isolation", "TREATMENT", 2, 30], ["the isolation", "TREATMENT", 41, 54], ["organisms spread", "PROBLEM", 81, 97], ["Airborne", "OBSERVATION_MODIFIER", 2, 10], ["infection", "OBSERVATION", 11, 20]]], ["This isolation area receives 6 to 12 air changes per hour and is under negative pressure so that the direction of airflow is from the outside adjacent space (eg, corridor) into the room.", [["This isolation area", "TREATMENT", 0, 19], ["negative pressure", "OBSERVATION", 71, 88], ["airflow", "OBSERVATION", 114, 121]]], ["The air in an airborne infection isolation room is preferably exhausted to the outside, but may be recirculated, provided that the return air is filtered through a highefficiency particulate air (HEPA) filter.", [["infection", "DISEASE", 23, 32], ["The air in an airborne infection isolation", "PROBLEM", 0, 42], ["the return air", "PROBLEM", 127, 141], ["a highefficiency particulate air (HEPA) filter", "TREATMENT", 162, 208], ["air", "OBSERVATION", 4, 7], ["airborne", "OBSERVATION_MODIFIER", 14, 22], ["infection", "OBSERVATION", 23, 32], ["air", "OBSERVATION", 138, 141]]], ["The use of personal respiratory protection is indicated for persons entering these rooms.", [["respiratory", "ANATOMY", 20, 31], ["persons", "ORGANISM", 60, 67], ["persons", "SPECIES", 60, 67], ["personal respiratory protection", "TREATMENT", 11, 42]]], ["3 Recent naturally occurring outbreaks of influenza or severe acute respiratory syndrome (SARS) have underscored the need to develop a flexible capacity for isolation to contain an outbreak.", [["influenza", "DISEASE", 42, 51], ["acute respiratory syndrome", "DISEASE", 62, 88], ["SARS", "DISEASE", 90, 94], ["influenza", "PROBLEM", 42, 51], ["severe acute respiratory syndrome", "PROBLEM", 55, 88], ["a flexible capacity", "PROBLEM", 133, 152], ["isolation", "TREATMENT", 157, 166], ["an outbreak", "PROBLEM", 178, 189], ["influenza", "OBSERVATION", 42, 51], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory syndrome", "OBSERVATION", 68, 88], ["outbreak", "OBSERVATION", 181, 189]]], ["4 The risk of bioterrorism with a transmissible pathogen such as smallpox or plague has necessitated planning for the contingency of having to isolate large numbers of patients.", [["smallpox", "DISEASE", 65, 73], ["plague", "DISEASE", 77, 83], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["bioterrorism", "PROBLEM", 14, 26], ["a transmissible pathogen", "PROBLEM", 32, 56], ["smallpox", "PROBLEM", 65, 73]]], ["Such planning calls for airborne infection isolation that is well beyond the scope of current isolation practices at most hospitals and requires either retrofitting existing facilities or constructing new ones.I N T R O D U C T I O NGiven the expense of either approach, we sought a means for mass isolation that would be inexpensive and feasible at most facilities.", [["infection", "DISEASE", 33, 42], ["O", "CHEMICAL", 230, 231], ["I", "PROTEIN", 210, 211], ["airborne infection isolation", "TREATMENT", 24, 52], ["current isolation practices", "TREATMENT", 86, 113], ["mass isolation", "PROBLEM", 293, 307], ["infection", "OBSERVATION", 33, 42]]], ["This article describes a project designed to transform existing space within a hospital into an airborne infection isolation unit with the capacity to isolate large numbers of patients in a negative-pressure environment.", [["infection", "DISEASE", 105, 114], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["an airborne infection isolation unit", "TREATMENT", 93, 129], ["the capacity", "PROBLEM", 135, 147], ["infection", "OBSERVATION", 105, 114], ["large", "OBSERVATION_MODIFIER", 159, 164], ["numbers", "OBSERVATION_MODIFIER", 165, 172]]], ["This exercise was designed to assess whether the negative-pressure environment needed to isolate multiple patients can be achieved quickly and effectively using existing hospital space.M A T E R I A L S A N D M E T H O D SIn designing the project's specification, we used the Centers for Disease Control and Prevention (CDC) Healthcare Infection Control Practices Advisory Committee Guidelines for Environmental Infection Control in Healthcare Facilities from 2003.", [["Infection", "DISEASE", 336, 345], ["Infection", "DISEASE", 412, 421], ["H O D", "CHEMICAL", 215, 220], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["the project's specification", "TREATMENT", 235, 262], ["Disease Control", "TREATMENT", 288, 303]]], ["Our clinical engineering department performed all work in-house.M A T E R I A L S A N D M E T H O D SThe physical therapy gymnasium at our facility was used on April 28, 2003, to test the ability to create a negative air pressure environment in a large space not previously designed for such a use ( Figure 1 ).", [["O D", "CHEMICAL", 96, 99], ["physical therapy gymnasium", "TREATMENT", 105, 131], ["a negative air pressure environment", "PROBLEM", 206, 241], ["negative", "OBSERVATION", 208, 216], ["air pressure", "OBSERVATION", 217, 229], ["large", "OBSERVATION_MODIFIER", 247, 252]]], ["This area required several minor modifications to allow use of the equipment and to effectively isolate the air in the gymnasium from that of the rest of the hospital.", [["several minor modifications", "TREATMENT", 19, 46], ["the equipment", "TREATMENT", 63, 76], ["several", "OBSERVATION_MODIFIER", 19, 26], ["minor", "OBSERVATION_MODIFIER", 27, 32], ["air", "OBSERVATION", 108, 111]]], ["The gymnasium area is shown in Figure 1 as ''large gymnasium'' and encompasses 2,930 square feet, with a 10-foot ceiling, for a total air volume of 29,300 cubic feet.M A T E R I A L S A N D M E T H O D SThe waiting area for the physical therapy gymnasium (labeled ''waiting'' on Figure 1 ) would be used as an anteroom for health care workers entering the negativepressure area.", [["O D", "CHEMICAL", 198, 201], ["a total air volume", "TEST", 126, 144], ["the physical therapy gymnasium", "TREATMENT", 224, 254]]], ["This waiting area is separated from the main hospital by a fixed door, over which an airtight seal was applied using plastic barriers that can be zippered open and closed.", [["an airtight seal", "TREATMENT", 82, 98], ["plastic barriers", "TREATMENT", 117, 133], ["airtight seal", "OBSERVATION", 85, 98]]], ["The anteroom contains cabinets for supplies, a sink for hand washing, and ample space for donning and doffing personal protective garments and equipment.", [["hand", "ANATOMY", 56, 60], ["hand", "ORGANISM_SUBDIVISION", 56, 60], ["hand washing", "TREATMENT", 56, 68], ["ample space", "TREATMENT", 74, 85], ["personal protective garments", "TREATMENT", 110, 138]]], ["The anteroom serves as an added barrier to fomite transmission to the outside.M A T E R I A L S A N D M E T H O D SA work area within the physical therapy department was used because it could be closed off from the rest of the gymnasium by a door and a glass wall (labeled ''therapists'' in Figure 1 ), which allowed workers to be separated from patients while still being able to monitor activity within the physical therapy gymnasium.", [["H O D", "CHEMICAL", 108, 113], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 346, 354], ["an added barrier", "TREATMENT", 23, 39], ["A N D M E T H O D SA work area", "TEST", 96, 126], ["a glass wall", "TREATMENT", 251, 263], ["closed", "OBSERVATION", 195, 201]]], ["This workroom was equipped with previously installed computers, telephones, a fax machine, and other telecommunications equipment that would be essential for patient care.M A T E R I A L S A N D M E T H O D SFour Aramsco FA 2000 EC model HEPA-filtered forced air machines (Aramsco, Inc., Thorofare, NJ) were used for this test.", [["O D", "CHEMICAL", 203, 206], ["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165], ["other telecommunications equipment", "TREATMENT", 95, 129], ["A N D M E T H", "TEST", 189, 202], ["SFour Aramsco FA", "TEST", 207, 223], ["EC model HEPA", "TEST", 229, 242], ["Aramsco", "TEST", 273, 280], ["Thorofare, NJ", "TREATMENT", 288, 301], ["this test", "TEST", 317, 326], ["HEPA", "ANATOMY", 238, 242], ["forced air", "OBSERVATION", 252, 262]]], ["Each unit is capable of moving 1,000 to 2,000 cubic feet of air per minute, depending on whether a ''low'' or ''high'' setting is used.", [["a ''low'' or ''high'' setting", "PROBLEM", 97, 126]]], ["Each unit weighs 160 pounds and is 26.5 inches high by 32.5 inches wide by 37.5 inches deep.", [["26.5 inches", "OBSERVATION_MODIFIER", 35, 46]]], ["Each air handler runs on 115 V, 60 Hz, and 13 A of electricity.", [["air handler", "OBSERVATION", 5, 16]]], ["Four dedicated 120-V, 20-A emergency power circuits wereM A T E R I A L S A N D M E T H O D Sinstalled before the drill at a location convenient for placement of the airflow units and near the external door.M A T E R I A L S A N D M E T H O D SThe units were vented to the outside air by a reusable duct 10 inches in diameter and 25 feet long (Aramsco model FA 600, Aramsco, Inc.).", [["H O D", "CHEMICAL", 86, 91], ["H O D", "CHEMICAL", 237, 242], ["duct", "MULTI-TISSUE_STRUCTURE", 299, 303], ["A emergency power circuits", "TREATMENT", 25, 51], ["Sinstalled", "TREATMENT", 92, 102], ["the drill", "TREATMENT", 110, 119], ["placement of the airflow units", "TREATMENT", 149, 179], ["A N D M E T H", "TEST", 225, 238], ["SThe units", "TREATMENT", 243, 253], ["vented", "TREATMENT", 259, 265], ["Aramsco model FA", "TEST", 344, 360], ["Aramsco", "TEST", 366, 373], ["airflow units", "OBSERVATION", 166, 179], ["external door", "OBSERVATION", 193, 206], ["duct", "ANATOMY", 299, 303]]], ["A prefabricated plywood insert, with 4 holes cut to a 12-inch diameter, was secured and sealed to enclose the gymnasium's exterior doorframe.", [["A prefabricated plywood insert", "TREATMENT", 0, 30], ["4 holes", "TREATMENT", 37, 44], ["a 12-inch diameter", "TREATMENT", 52, 70], ["prefabricated", "OBSERVATION_MODIFIER", 2, 15], ["plywood insert", "OBSERVATION", 16, 30]]], ["The ducts were attached to the insert and individually secured with round collars to create an airtight seal ( Figure 2 ).", [["ducts", "ANATOMY", 4, 9], ["ducts", "MULTI-TISSUE_STRUCTURE", 4, 9], ["the insert", "TREATMENT", 27, 37], ["round collars", "TREATMENT", 68, 81], ["an airtight seal", "TREATMENT", 92, 108], ["ducts", "ANATOMY", 4, 9], ["insert", "OBSERVATION_MODIFIER", 31, 37], ["round collars", "OBSERVATION", 68, 81], ["airtight seal", "OBSERVATION", 95, 108]]], ["Sheet-metal blanks were fabricated to provide an airtight cover for existing air returns.", [["Sheet-metal blanks", "TREATMENT", 0, 18], ["an airtight cover", "TREATMENT", 46, 63], ["metal blanks", "OBSERVATION", 6, 18], ["air", "OBSERVATION", 77, 80]]], ["These blanks facilitate rapid conversion to an isolation area by preventing contaminated air from flowing back into the main heating, ventilating, and air conditioning (HVAC) system once negative pressure has been created.", [["rapid conversion", "TREATMENT", 24, 40], ["an isolation area", "TREATMENT", 44, 61], ["contaminated air", "PROBLEM", 76, 92], ["ventilating", "TREATMENT", 134, 145], ["air conditioning (HVAC) system", "TREATMENT", 151, 181], ["contaminated air", "OBSERVATION", 76, 92], ["main", "OBSERVATION_MODIFIER", 120, 124], ["air conditioning", "OBSERVATION", 151, 167], ["pressure", "OBSERVATION_MODIFIER", 196, 204]]], ["Supply vents were left open to passively supply air into the sealed gymnasium.M A T E R I A L S A N D M E T H O D SThe operational test evaluated the time needed to set up equipment.", [["O D", "CHEMICAL", 110, 113], ["Supply vents", "TREATMENT", 0, 12], ["operational test", "TEST", 119, 135]]], ["Any subjective difficulty with either setup Figure 1 .M A T E R I A L S A N D M E T H O D SArchitectural drawing of the physical therapy gymnasium illustrating its conversion to negative-pressure isolation room.", [["O D", "CHEMICAL", 86, 89], ["SArchitectural drawing", "TREATMENT", 90, 112], ["the physical therapy", "TREATMENT", 116, 136]]], ["The anteroom (1) is an enclosed area with access from the outside.", [["enclosed", "OBSERVATION", 23, 31], ["access", "OBSERVATION", 42, 48]]], ["Staff work area (2) and toilet (3) are isolated from the patient care area (4).", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64]]], ["Patient and EMS entrance is through the door adjacent to the vestibule (5).", [["vestibule", "ANATOMY", 61, 70], ["vestibule", "ORGANISM_SUBDIVISION", 61, 70], ["Patient", "SPECIES", 0, 7], ["vestibule", "ANATOMY", 61, 70]]], ["Air is exhausted after HEPA filtration through a fabricated steel insert placed in the doorway (6) .", [["HEPA filtration", "TREATMENT", 23, 38], ["a fabricated steel insert", "TREATMENT", 47, 72], ["steel", "OBSERVATION_MODIFIER", 60, 65], ["insert", "OBSERVATION_MODIFIER", 66, 72]]], ["The other doorway (7) may be used to avoid proximity to the air intake column (8), but room dimensions made this doorway less desirable.M A T E R I A L S A N D M E T H O D Sor operation of the equipment was noted.", [["O D", "CHEMICAL", 168, 171], ["D Sor operation", "TREATMENT", 170, 185], ["the equipment", "TREATMENT", 189, 202], ["air", "OBSERVATION", 60, 63]]], ["The ability of the equipment to generate a negative air pressure and the noise levels created during the use of different combinations of machines and power settings were measured.", [["a negative air pressure", "TEST", 41, 64], ["the noise levels", "TEST", 69, 85], ["different combinations of machines", "TREATMENT", 112, 146], ["air pressure", "OBSERVATION", 52, 64]]], ["The pressures were evaluated using a TSI DP-CALC micromanometer (model 8705; TSI, Inc., Shoreview, MN).", [["The pressures", "TEST", 0, 13], ["a TSI DP", "TEST", 35, 43], ["TSI", "TEST", 77, 80], ["pressures", "OBSERVATION_MODIFIER", 4, 13]]], ["The DP-CALC measures static, total, and velocity pressures, as well as pressure decreases across filters, coils, fans, and diffusers.", [["The DP", "TEST", 0, 6], ["velocity pressures", "TEST", 40, 58], ["pressure decreases across filters", "TREATMENT", 71, 104], ["DP", "ANATOMY", 4, 6], ["CALC", "OBSERVATION", 7, 11], ["total", "OBSERVATION_MODIFIER", 29, 34], ["velocity", "OBSERVATION_MODIFIER", 40, 48], ["pressures", "OBSERVATION_MODIFIER", 49, 58], ["pressure", "OBSERVATION_MODIFIER", 71, 79], ["decreases", "OBSERVATION_MODIFIER", 80, 89], ["across filters", "OBSERVATION", 90, 104], ["diffusers", "OBSERVATION_MODIFIER", 123, 132]]], ["The microprocessor-based DP-CALC uses the latest electronic pressure transducer technology, eliminating sensitivity caused by the orientation of the meter.", [["the latest electronic pressure transducer technology", "TREATMENT", 38, 90], ["CALC", "OBSERVATION", 28, 32]]], ["The micromanometer measures and displays differential pressure readings from 21,245 to 3,735 Pa (29.3 to 28.0 mm Hg, or 25 to 15 inches of H 2 O).", [["Hg", "CHEMICAL", 113, 115], ["H 2 O", "CHEMICAL", 139, 144], ["The micromanometer measures", "TEST", 0, 27], ["differential pressure readings", "TEST", 41, 71], ["Pa", "TEST", 93, 95], ["Hg", "TEST", 113, 115], ["differential", "OBSERVATION_MODIFIER", 41, 53], ["pressure", "OBSERVATION_MODIFIER", 54, 62]]], ["Zeroing function allows rapid and simple recalibration of the instrument.M A T E R I A L S A N D M E T H O D SNoise levels were measured with a Metrosonics db-3100 dosimeter sound level meter (Metrosonics, Inc., Oconomowoc, WI).", [["H O D", "CHEMICAL", 103, 108], ["A T E R I", "TEST", 75, 84], ["A L S A N D M E T H O D SNoise levels", "TEST", 85, 122], ["a Metrosonics db", "TEST", 142, 158]]], ["We obtained separate readings using 1, 2, 3, or 4 units at once using the ''high'' power setting and using 4 units at once on ''low'' power setting.R E S U L T SAfter the request for equipment setup, 1 hour was required to convert the physical therapy gymnasium into an operational negative-pressure environment, which included the time needed to move the equipment from a basement storage area, place the door insert, set up the airflow units, connect the ducts to the insert, block the air returns, and start the airflow machines.", [["basement storage area", "ANATOMY", 373, 394], ["ducts", "ANATOMY", 457, 462], ["ducts", "MULTI-TISSUE_STRUCTURE", 457, 462], ["the ''high'' power setting", "TREATMENT", 70, 96], ["equipment setup", "TREATMENT", 183, 198], ["a basement storage area", "TREATMENT", 371, 394], ["the door insert", "TREATMENT", 402, 417], ["the airflow units", "TREATMENT", 426, 443], ["the airflow machines", "TREATMENT", 511, 531], ["ducts", "ANATOMY", 457, 462], ["air", "OBSERVATION", 488, 491]]], ["Six workers were able to accomplish this task with minimal assistance from 2 other staff members.R E S U L T SThe pressure readings (in Pascal units), noise levels (in decibels), and calculated air changes per hour using 1, 2, 3, or 4 units at once at ''high'' power and using 4 units at once on ''low'' power setting are shown in the Table.", [["L T SThe pressure readings", "TREATMENT", 105, 131], ["noise levels", "TEST", 151, 163], ["air changes", "OBSERVATION", 194, 205]]], ["The calculated air changes per hour changed proportionately according to whether 1, 2, 3, or 4 units were used.", [["The calculated air changes", "PROBLEM", 0, 26], ["air changes", "OBSERVATION", 15, 26]]], ["The negative pressure reading increased with additional units.", [["additional units", "TREATMENT", 45, 61], ["negative", "OBSERVATION", 4, 12], ["pressure", "OBSERVATION_MODIFIER", 13, 21], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["The noise level did not appreciably change according to the number of units used or whether power was set at ''low'' or ''high.''L I M I T A T I O N SLimitations of the project include the test being conducted when patients were not scheduled to be present and that there was no measure of possible delays caused by patient movement or blockage of access to required areas.", [["patients", "ORGANISM", 215, 223], ["patient", "ORGANISM", 316, 323], ["patients", "SPECIES", 215, 223], ["patient", "SPECIES", 316, 323], ["the test", "TEST", 185, 193], ["blockage of access", "PROBLEM", 336, 354]]], ["Time requirements could vary, depending on the number of personnel available to perform the conversion of the room and movement of equipment.", [["movement of equipment", "TREATMENT", 119, 140]]], ["Different sizes or shapes of rooms may present different requirements, and further testing would be required to confirm the effectiveness of this technique in other locations.L I M I T A T I O N SOur estimate of a 30 patient-bed capacity was based on rough measurements, and we did not place any simulated patients in this area, nor did we simulate any medical procedures during this evaluation.", [["L", "CHEMICAL", 175, 176], ["patient", "ORGANISM", 217, 224], ["patients", "ORGANISM", 306, 314], ["patient", "SPECIES", 217, 224], ["patients", "SPECIES", 306, 314], ["further testing", "TEST", 75, 90], ["this technique", "TREATMENT", 141, 155], ["any medical procedures", "TREATMENT", 349, 371], ["this evaluation", "TEST", 379, 394], ["sizes", "OBSERVATION_MODIFIER", 10, 15], ["shapes", "OBSERVATION_MODIFIER", 19, 25], ["different requirements", "OBSERVATION_MODIFIER", 47, 69]]], ["These tests were conducted with new machines and filters; older machines or clogged filters could limit the effective air exchange Photograph of HEPA filtered forced air machine installation with door insert already in place. capacity.", [["These tests", "TEST", 0, 11], ["new machines", "TREATMENT", 32, 44], ["filters", "TREATMENT", 49, 56], ["older machines", "TREATMENT", 58, 72], ["clogged filters", "TREATMENT", 76, 91], ["the effective air exchange", "TREATMENT", 104, 130], ["HEPA filtered forced air machine installation", "TREATMENT", 145, 190], ["door insert", "TREATMENT", 196, 207]]], ["This, however, should be less of a problem, given that the environment will not have large particulate matter but only microscopic contaminants.", [["large particulate matter", "PROBLEM", 85, 109], ["microscopic contaminants", "PROBLEM", 119, 143], ["large", "OBSERVATION_MODIFIER", 85, 90], ["particulate matter", "OBSERVATION_MODIFIER", 91, 109]]], ["The CDC guidelines 4 specify that the exhaust system ''shall terminate above roof level either through an accessible HEPA filter or vertically through a self-draining stack discharging not less than 7 feet above the roof.''", [["an accessible HEPA filter", "TREATMENT", 103, 128], ["a self-draining stack discharging", "TREATMENT", 151, 184], ["HEPA filter", "OBSERVATION", 117, 128], ["roof", "ANATOMY_MODIFIER", 216, 220]]], ["We did not add this requirement to the project because it would have required a vertical stack approximately 80 feet high.", [["a vertical stack", "TREATMENT", 78, 94]]], ["Ideally, air should exhaust above the level of the roof, but the HEPA filtration should prevent contamination of the rest of the building.L I M I T A T I O N SAnother limitation is that we did not require testing, adjusting, and balancing by a qualified, independent, certified agency before acceptance as a certified negativepressure isolation room.", [["O N", "CHEMICAL", 154, 157], ["the HEPA filtration", "TREATMENT", 61, 80], ["testing", "TEST", 205, 212], ["air", "OBSERVATION", 9, 12], ["roof", "ANATOMY_MODIFIER", 51, 55]]], ["In actual practice, we would need to ascertain that the hallway outside the physical therapy room is free of infectious particles, which was not tested during our drill.D I S C U S S I O NIn a 1993 study, Fraser et al 5 surveyed 7 hospitals with a total of 3,574 hospital rooms and found that only 121 rooms (3.4%) were designed to have negative-pressure ventilation suitable for respiratory isolation.", [["respiratory", "ANATOMY", 380, 391], ["D", "CHEMICAL", 169, 170], ["D", "CHEMICAL", 169, 170], ["infectious particles", "PROBLEM", 109, 129], ["negative-pressure ventilation", "TREATMENT", 337, 366], ["respiratory isolation", "TREATMENT", 380, 401], ["infectious", "OBSERVATION", 109, 119], ["respiratory isolation", "OBSERVATION", 380, 401]]], ["Although only a small fraction of rooms were designated for respiratory isolation, the performance of these existing negative-pressure rooms was not tested regularly.", [["respiratory isolation", "TREATMENT", 60, 81], ["small", "OBSERVATION_MODIFIER", 16, 21], ["fraction", "OBSERVATION_MODIFIER", 22, 30], ["respiratory isolation", "OBSERVATION", 60, 81]]], ["Many high-risk areas, such as ICUs and emergency departments, were not equipped to provide any degree of respiratory isolation.D I S C U S S I O NIndustrial hygienists from the New York State Department of Health evaluated 140 designated isolation rooms in 38 facilities within New York State during 1992 to 1998.", [["respiratory", "ANATOMY", 105, 116], ["D", "CHEMICAL", 127, 128], ["D", "CHEMICAL", 127, 128], ["respiratory isolation", "PROBLEM", 105, 126], ["high", "OBSERVATION_MODIFIER", 5, 9], ["-risk", "OBSERVATION_MODIFIER", 9, 14], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["respiratory isolation", "OBSERVATION", 105, 126]]], ["Each room was tested with visible smoke for directional airflow into the patient room (ie, negative air pressure relative to adjacent areas).", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["air pressure", "OBSERVATION", 100, 112]]], ["Inappropriate outward airflow was observed in 38% of the isolation rooms tested.", [["Inappropriate outward airflow", "PROBLEM", 0, 29], ["outward", "OBSERVATION_MODIFIER", 14, 21], ["airflow", "OBSERVATION", 22, 29]]], ["These findings indicate that a balanced ventilation system does not guarantee inward airflow direction.", [["a balanced ventilation system", "TREATMENT", 29, 58]]], ["Devices that continuously monitor and, in some cases, control pressurization were noted to have poor reliability.", [["Devices", "TREATMENT", 0, 7]]], ["6 Infections among health care workers have been a common feature of SARS since its emergence.", [["Infections", "DISEASE", 2, 12], ["SARS", "DISEASE", 69, 73], ["SARS", "PROBLEM", 69, 73]]], ["The majority of these infections have occurred in locations where infection-control precautions either had not been instituted or had been instituted but were not followed.", [["infections", "DISEASE", 22, 32], ["infection", "DISEASE", 66, 75], ["these infections", "PROBLEM", 16, 32], ["infection-control precautions", "TREATMENT", 66, 95], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["infections", "OBSERVATION", 22, 32], ["infection", "OBSERVATION", 66, 75]]], ["Previously recommended infection-control precautions from 2002 included the use of negative-pressure isolation rooms; N95 or higher level of respiratory protection; gloves, gowns, and eye protection; and careful hand hygiene.", [["respiratory", "ANATOMY", 141, 152], ["eye", "ANATOMY", 184, 187], ["hand", "ANATOMY", 212, 216], ["infection", "DISEASE", 23, 32], ["eye", "ORGAN", 184, 187], ["hand", "ORGANISM_SUBDIVISION", 212, 216], ["infection", "PROBLEM", 23, 32], ["control precautions", "TREATMENT", 33, 52], ["negative-pressure isolation rooms", "TREATMENT", 83, 116], ["N95", "TREATMENT", 118, 121], ["respiratory protection", "TREATMENT", 141, 163], ["gloves", "TREATMENT", 165, 171], ["gowns", "TREATMENT", 173, 178], ["eye protection", "TREATMENT", 184, 198], ["infection", "OBSERVATION", 23, 32], ["respiratory protection", "OBSERVATION", 141, 163], ["eye", "ANATOMY", 184, 187]]], ["A 2003 report from the CDC demonstrated that a cluster of SARS cases among health care workers in a hospital occurred despite apparent compliance with recommended infection-control precautions.", [["SARS", "DISEASE", 58, 62], ["infection", "DISEASE", 163, 172], ["infection", "PROBLEM", 163, 172], ["control precautions", "TREATMENT", 173, 192], ["infection", "OBSERVATION", 163, 172]]], ["In fact, hospitals, because of infection of health care workers, appeared to be sites of SARS epidemic amplification during the epidemic of 2002 to 2003 7 ; therefore, HEPA filtration and ultraviolet germicidal irradiation are recommended as additional infection control measures.", [["infection", "DISEASE", 31, 40], ["SARS", "DISEASE", 89, 93], ["ultraviolet germicidal", "CHEMICAL", 188, 210], ["infection", "DISEASE", 253, 262], ["infection", "PROBLEM", 31, 40], ["SARS epidemic amplification", "PROBLEM", 89, 116], ["HEPA filtration", "TREATMENT", 168, 183], ["ultraviolet germicidal irradiation", "TREATMENT", 188, 222], ["additional infection control measures", "TREATMENT", 242, 279], ["infection", "OBSERVATION", 31, 40]]], ["4 Increasing hospital capacity to care for patients requiring respiratory isolation is a current focus of emergency preparedness efforts nationwide (Health Resources and Services Administration/CDC grant guidance 2003).", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["respiratory isolation", "TREATMENT", 62, 83]]], ["The recognition that a mass casualty incident as a result of an intentionally released agent or an epidemic from a naturally occurring outbreak of illness could overwhelm current isolation capabilities has resulted in many suggested plans to handle such an event.", [["illness", "DISEASE", 147, 154], ["a mass casualty", "PROBLEM", 21, 36], ["illness", "PROBLEM", 147, 154], ["mass", "OBSERVATION", 23, 27]]], ["Christiana Care Health System and the Delaware Health Care Preparedness Committee sought to examine these methods and design a system to meet our needs.D I S C U S S I O NWe began with a fundamental goal of maximizing the ability to provide care at current hospital sites before moving to an alternate location, which, by necessity, required us to search for surge capacity within the current physical plants of our hospitals.", [["surge capacity", "PROBLEM", 359, 373]]], ["Hospitals were asked to identify areas that were not continuously used for patient care but could be opened to provide patient care on an emergency basis.D I S C U S S I O NIdeal locations for a respiratory isolation unit were considered, and several characteristics were identified.", [["patient", "ORGANISM", 75, 82], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 75, 82], ["patient", "SPECIES", 119, 126], ["a respiratory isolation unit", "TREATMENT", 193, 221]]], ["The room should have immediate access from the outdoor environment and will almost certainly be on the ground floor, which limits the risk of contamination to other areas of the hospital and requires adequate door width, firm (concrete or paved) pathways, and accessibility to emergency medical services (EMS) units, with minimal stretcher movement requirements.", [["minimal stretcher movement requirements", "TREATMENT", 322, 361], ["firm", "OBSERVATION", 221, 225], ["minimal", "OBSERVATION_MODIFIER", 322, 329], ["stretcher movement", "OBSERVATION", 330, 348]]], ["The standards would match those for a hospital emergency exit.D I S C U S S I O NThe room should have doors or windows that can be replaced or fit with ventilation ducts to allow connection of the airflow units.", [["ventilation ducts", "ANATOMY", 152, 169], ["ducts", "MULTI-TISSUE_STRUCTURE", 164, 169], ["ventilation ducts", "TREATMENT", 152, 169], ["the airflow units", "TREATMENT", 193, 210]]], ["The room should be located at a peripheral location of the hospital to limit the number of air intake and return units affected.", [["air intake", "OBSERVATION", 91, 101]]], ["Blocking off an endpoint in the ventilation system presents far fewer difficulties than trying to isolate a more central area.D I S C U S S I O NBefore use, as many modifications as possible should be installed in the area chosen, which includes power modifications, ventilation duct installation or template fabrication, design of air-return barriers, and construction of shelving or any other structure or equipment that will be needed to operate the unit.", [["duct", "ANATOMY", 279, 283], ["duct", "MULTI-TISSUE_STRUCTURE", 279, 283], ["the ventilation system", "TREATMENT", 28, 50], ["power modifications", "TREATMENT", 246, 265], ["ventilation duct installation", "TREATMENT", 267, 296], ["template fabrication", "TREATMENT", 300, 320], ["air-return barriers", "TREATMENT", 332, 351], ["shelving", "TREATMENT", 373, 381], ["central", "ANATOMY_MODIFIER", 113, 120]]], ["Ideally, these modifications will not affect the current operation of the chosen unit.D I S C U S S I O NThe physical therapy gymnasium at Christiana Hospital met the specifications and was able to be fit with methods to seal the usual ventilation system.", [["physical therapy", "TREATMENT", 109, 125], ["ventilation system", "OBSERVATION", 236, 254]]], ["Removal of one exterior door and replacement with a plywood insert equipped with round collars for the flexible ductwork allowed the creation of negative air pressure within the gymnasium area and ventilation of filtered air to the outside of the hospital.", [["Removal", "TREATMENT", 0, 7], ["replacement", "TREATMENT", 33, 44], ["a plywood insert", "TREATMENT", 50, 66], ["round collars", "TREATMENT", 81, 94], ["the flexible ductwork", "TREATMENT", 99, 120], ["replacement", "OBSERVATION", 33, 44], ["negative", "OBSERVATION", 145, 153], ["air pressure", "OBSERVATION", 154, 166], ["filtered air", "OBSERVATION", 212, 224]]], ["In large health care facilities with central HVAC systems, sealed windows help to ensure the efficient operation of the system, especially with respect to creating and maintaining pressure differentials.", [["central HVAC systems", "TREATMENT", 37, 57], ["the efficient operation of the system", "TREATMENT", 89, 126], ["large", "OBSERVATION_MODIFIER", 3, 8]]], ["Sealing the windows in isolation areas helps minimize the risk of airborne contamination to the outside.", [["Sealing the windows", "TREATMENT", 0, 19], ["isolation areas", "TREATMENT", 23, 38], ["airborne contamination", "PROBLEM", 66, 88], ["windows", "OBSERVATION", 12, 19], ["airborne contamination", "OBSERVATION", 66, 88]]], ["4 There was some concern about the proximity of the exhaust ports to the elevated air intake shaft.", [["the elevated air intake shaft", "PROBLEM", 69, 98], ["exhaust ports", "OBSERVATION", 52, 65], ["elevated", "OBSERVATION_MODIFIER", 73, 81], ["air intake", "OBSERVATION", 82, 92], ["shaft", "OBSERVATION", 93, 98]]], ["In addition, the air intake shaft and the patient arrival area appear to be in close proximity to the exhaust from this space.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["the air intake shaft", "PROBLEM", 13, 33], ["air", "OBSERVATION", 17, 20], ["intake shaft", "OBSERVATION", 21, 33], ["exhaust", "OBSERVATION", 102, 109]]], ["The American Institute of Architects standards stipulate that for new or renovated construction (1) exhaust outlets be placed more than 25 feet from air intake systems;D I S C U S S I O N(2) the bottom of outdoor air intakes for HVAC systems be 6 feet above ground or 3 feet above roof level; and (3) exhaust outlets from contaminated areas be situated above the roof level and arranged to minimize the recirculation of exhausted air back into the building.", [["O N", "CHEMICAL", 184, 187], ["new or renovated construction", "TREATMENT", 66, 95], ["HVAC systems", "TEST", 229, 241]]], ["8 HEPA filtration of exhaust air from airborne isolation rooms is not required, providing that the exhaust is properly located to prevent reentry into the building.", [["HEPA filtration", "TREATMENT", 2, 17], ["exhaust air", "PROBLEM", 21, 32], ["airborne isolation rooms", "TREATMENT", 38, 62], ["exhaust air", "OBSERVATION", 21, 32], ["airborne isolation", "OBSERVATION", 38, 56]]], ["During planning, we determined that placement of exhaust outlets above the roof level was impractical for our ground floor conversion.", [["placement of exhaust outlets", "TREATMENT", 36, 64], ["our ground floor conversion", "TREATMENT", 106, 133]]], ["Instead, we chose to use HEPA filtration of the exhaust air as a precaution, noting that the air intake shaft is over 30 feet above ground, which is not apparent in the drawing.D I S C U S S I O NAir from toilet rooms or other soiled areas is usually exhausted directly to the atmosphere through a separate duct exhaust system.", [["duct", "ANATOMY", 307, 311], ["D", "CHEMICAL", 177, 178], ["D", "CHEMICAL", 177, 178], ["S I O", "CHEMICAL", 189, 194], ["duct", "MULTI-TISSUE_STRUCTURE", 307, 311], ["HEPA filtration", "TREATMENT", 25, 40], ["a precaution", "TREATMENT", 63, 75], ["the air intake shaft", "PROBLEM", 89, 109], ["NAir from toilet rooms", "TREATMENT", 195, 217], ["other soiled areas", "PROBLEM", 221, 239], ["exhaust air", "OBSERVATION", 48, 59], ["air intake", "OBSERVATION", 93, 103], ["not apparent", "UNCERTAINTY", 149, 161], ["duct", "ANATOMY", 307, 311]]], ["Air from rooms housing tuberculosis patients is exhausted to the outside if possible or passed through a HEPA filter before recirculation.", [["tuberculosis", "DISEASE", 23, 35], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["a HEPA filter", "TREATMENT", 103, 116], ["tuberculosis", "OBSERVATION", 23, 35], ["filter", "OBSERVATION", 110, 116]]], ["Ultraviolet germicidal irradiation can be used as an adjunct aircleaning measure, but it cannot replace HEPA filtration.", [["Ultraviolet germicidal irradiation", "TREATMENT", 0, 34], ["an adjunct aircleaning measure", "TREATMENT", 50, 80], ["HEPA filtration", "TREATMENT", 104, 119]]], ["9 We did not test an ultraviolet germicidal irradiation unit because the need for one in this setting is unclear.", [["an ultraviolet germicidal irradiation unit", "TREATMENT", 18, 60]]], ["The use of ultraviolet lamps and HEPA filtration in a single unit offers only minimal infection-control benefits over those provided by the use of a HEPA filter alone.", [["ultraviolet lamps", "CHEMICAL", 11, 28], ["infection", "DISEASE", 86, 95], ["ultraviolet lamps", "TREATMENT", 11, 28], ["HEPA filtration", "TREATMENT", 33, 48], ["minimal infection", "PROBLEM", 78, 95], ["a HEPA filter", "TREATMENT", 147, 160], ["minimal", "OBSERVATION_MODIFIER", 78, 85], ["infection", "OBSERVATION", 86, 95]]], ["10 The portable airflow units were used to draw air through the care area, creating air changes in excess of the current CDC guidelines that specify 12 air changes per hour for particles smaller than 5 mm.", [["The portable airflow units", "TREATMENT", 3, 29], ["the care area", "TREATMENT", 60, 73], ["creating air changes", "PROBLEM", 75, 95], ["the current CDC guidelines", "TREATMENT", 109, 135], ["air changes", "OBSERVATION", 84, 95]]], ["4 The pressure gradient generated was acceptable and exceeded the minimum of 5 Pa (20.02 inches of water) required for asbestos removal projects and on medical isolation facilities, which require a minimum of 2.5 Pa (20.01 inches of water) for an isolation room.", [["The pressure gradient", "TEST", 2, 23], ["asbestos removal", "TREATMENT", 119, 135], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["gradient", "OBSERVATION_MODIFIER", 15, 23], ["asbestos removal", "OBSERVATION", 119, 135]]], ["4, 8 This gradient indicated a pressure differential that would ensure isolation of air from this patient care area away from the rest of the hospital.", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["a pressure differential", "TEST", 29, 52], ["air", "OBSERVATION", 84, 87]]], ["The total cost of the project was less than $6,000, including the 4 portable airflow HEPA units, flexible ductwork, door and air return conversion, and installation of dedicated highoutput power outlets.", [["the 4 portable airflow HEPA units", "TREATMENT", 62, 95], ["flexible ductwork", "TREATMENT", 97, 114], ["air return conversion", "TREATMENT", 125, 146], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["We estimated that 30 patients could be cared for comfortably within this environment, and although they would be in close proximity, there would still be adequate separation between them to allow sufficient room for staff to work.D I S C U S S I O NNoise generation produced by the units was an area of concern.", [["D", "CHEMICAL", 230, 231], ["D", "CHEMICAL", 230, 231], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Total noise levels were well below the Occupational Safety and Health Administration (OSHA) standard for 8-hour or 16-hour work periods (90 and 85 dB, respectively; OSHA occupational noise exposure standard 29 CFR 1910.95) and would also fall below the 24-hour limit (approximately 83 dB).", [["Total noise levels", "TEST", 0, 18]]], ["This 24-hour level is a potentially important consideration for patient safety.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71]]], ["The level of 76 dB, although below maximal occupational levels, would be louder than operation of a household vacuum (70 dB per National Institute for Occupational Safety and Health 1973 source) and would still potentially be annoying.", [["The level", "TEST", 0, 9], ["dB", "TEST", 16, 18], ["a household vacuum", "TREATMENT", 98, 116]]], ["Methods to decrease the noise exposure could include using more units on the low setting, designing methods to deflect noise away from patient care areas, or maximizing the distance between patients and the airflow units.D I S C U S S I O NIn conclusion, this project describes the conversion of existing space and offers a significantly lower-cost The chosen rooms can be modified in advance to allow rapid conversion and generation of the negative-pressure environment.", [["patient", "ORGANISM", 135, 142], ["patients", "ORGANISM", 190, 198], ["patient", "SPECIES", 135, 142], ["patients", "SPECIES", 190, 198], ["Methods", "TREATMENT", 0, 7], ["the noise exposure", "PROBLEM", 20, 38], ["a significantly lower-cost", "TREATMENT", 322, 348], ["rapid conversion", "TREATMENT", 402, 418], ["the negative-pressure environment", "TREATMENT", 437, 470]]], ["This type of unit would allow treatment of many more patients than current hospital capability would permit and would be an important asset to meeting the needs that would be created by a bioterrorist attack or a naturally occurring epidemic.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["treatment", "TREATMENT", 30, 39]]], ["We conclude that use of portable HEPA filtered forced air units is an effective means of creating large patient care areas with negative-pressure environments.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["portable HEPA filtered forced air units", "TREATMENT", 24, 63], ["creating large patient care areas", "TREATMENT", 89, 122], ["negative-pressure environments", "TREATMENT", 128, 158], ["large", "OBSERVATION_MODIFIER", 98, 103]]]], "PMC3327440": [["IntroductionDispase, a proteolytic enzyme able to harvest and culture cells due to its ability to cleave the basal membrane in various tissues, can be used as an intravitreal injection material to induce proliferative vitreoretinopathy (PVR) in the eyes of mice [1,2] and rabbits [3-9].", [["cells", "ANATOMY", 70, 75], ["basal membrane", "ANATOMY", 109, 123], ["tissues", "ANATOMY", 135, 142], ["eyes", "ANATOMY", 249, 253], ["proliferative vitreoretinopathy", "DISEASE", 204, 235], ["cells", "CELL", 70, 75], ["basal membrane", "CELLULAR_COMPONENT", 109, 123], ["tissues", "TISSUE", 135, 142], ["eyes", "ORGAN", 249, 253], ["mice", "ORGANISM", 257, 261], ["rabbits", "ORGANISM", 272, 279], ["proteolytic enzyme", "PROTEIN", 23, 41], ["culture cells", "CELL_LINE", 62, 75], ["mice", "SPECIES", 257, 261], ["rabbits", "SPECIES", 272, 279], ["mice", "SPECIES", 257, 261], ["IntroductionDispase", "PROBLEM", 0, 19], ["a proteolytic enzyme", "PROBLEM", 21, 41], ["culture cells", "TEST", 62, 75], ["an intravitreal injection material", "TREATMENT", 159, 193], ["proliferative vitreoretinopathy", "PROBLEM", 204, 235], ["basal membrane", "ANATOMY", 109, 123], ["various tissues", "ANATOMY", 127, 142], ["proliferative", "OBSERVATION_MODIFIER", 204, 217], ["vitreoretinopathy", "OBSERVATION", 218, 235]]], ["PVR is the most common cause of recurrent retinal detachment after retinal detachment repair, occurring in 5%\u201311% of patients [10,11].", [["retinal", "ANATOMY", 42, 49], ["retinal", "ANATOMY", 67, 74], ["retinal detachment", "DISEASE", 42, 60], ["retinal detachment", "DISEASE", 67, 85], ["retinal", "MULTI-TISSUE_STRUCTURE", 42, 49], ["retinal", "MULTI-TISSUE_STRUCTURE", 67, 74], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["PVR", "TEST", 0, 3], ["recurrent retinal detachment", "PROBLEM", 32, 60], ["retinal detachment repair", "TREATMENT", 67, 92], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["recurrent", "OBSERVATION_MODIFIER", 32, 41], ["retinal", "ANATOMY", 42, 49], ["detachment", "OBSERVATION", 50, 60], ["retinal", "ANATOMY", 67, 74], ["detachment repair", "OBSERVATION", 75, 92]]], ["Basic research has indicated that PVR is characterized by the formation of scar-like fibrous tissue containing myofibroblasts derived from transdifferentiated retinal pigment epithelial (RPE) cells and other cell types, such as glial cells, that have entered the vitreous cavity and induced the contraction of cellular membranes within the vitreous cavity on both detached retinal surfaces [12-14].IntroductionDispase is a heterogeneous protein, and its intravitreal injection may cause some immune reaction and ocular change, not only in the vitreous and retina, but also in the anterior chamber.", [["scar", "ANATOMY", 75, 79], ["fibrous tissue", "ANATOMY", 85, 99], ["myofibroblasts", "ANATOMY", 111, 125], ["retinal pigment epithelial (RPE) cells", "ANATOMY", 159, 197], ["cell", "ANATOMY", 208, 212], ["glial cells", "ANATOMY", 228, 239], ["vitreous cavity", "ANATOMY", 263, 278], ["cellular membranes", "ANATOMY", 310, 328], ["vitreous cavity", "ANATOMY", 340, 355], ["retinal surfaces", "ANATOMY", 373, 389], ["ocular", "ANATOMY", 512, 518], ["vitreous", "ANATOMY", 543, 551], ["retina", "ANATOMY", 556, 562], ["anterior chamber", "ANATOMY", 580, 596], ["PVR", "GENE_OR_GENE_PRODUCT", 34, 37], ["scar-like fibrous tissue", "TISSUE", 75, 99], ["myofibroblasts", "CELL", 111, 125], ["retinal pigment epithelial (RPE) cells", "CELL", 159, 197], ["cell", "CELL", 208, 212], ["glial cells", "CELL", 228, 239], ["vitreous cavity", "MULTI-TISSUE_STRUCTURE", 263, 278], ["cellular membranes", "CELLULAR_COMPONENT", 310, 328], ["vitreous cavity", "MULTI-TISSUE_STRUCTURE", 340, 355], ["retinal surfaces", "TISSUE", 373, 389], ["vitreous", "TISSUE", 543, 551], ["retina", "MULTI-TISSUE_STRUCTURE", 556, 562], ["myofibroblasts", "CELL_TYPE", 111, 125], ["transdifferentiated retinal pigment epithelial (RPE) cells", "CELL_TYPE", 139, 197], ["glial cells", "CELL_TYPE", 228, 239], ["PVR", "PROBLEM", 34, 37], ["scar", "PROBLEM", 75, 79], ["fibrous tissue", "PROBLEM", 85, 99], ["transdifferentiated retinal pigment epithelial (RPE) cells", "PROBLEM", 139, 197], ["other cell types", "PROBLEM", 202, 218], ["glial cells", "PROBLEM", 228, 239], ["the vitreous cavity", "PROBLEM", 259, 278], ["a heterogeneous protein", "PROBLEM", 421, 444], ["its intravitreal injection", "TREATMENT", 450, 476], ["some immune reaction", "PROBLEM", 487, 507], ["ocular change", "PROBLEM", 512, 525], ["PVR", "OBSERVATION", 34, 37], ["scar", "OBSERVATION", 75, 79], ["fibrous tissue", "OBSERVATION", 85, 99], ["myofibroblasts", "OBSERVATION", 111, 125], ["retinal", "ANATOMY", 159, 166], ["pigment epithelial", "OBSERVATION", 167, 185], ["cell types", "OBSERVATION", 208, 218], ["glial cells", "OBSERVATION", 228, 239], ["vitreous cavity", "OBSERVATION", 263, 278], ["contraction", "OBSERVATION_MODIFIER", 295, 306], ["cellular membranes", "OBSERVATION", 310, 328], ["vitreous cavity", "OBSERVATION", 340, 355], ["retinal", "ANATOMY", 373, 380], ["surfaces", "OBSERVATION_MODIFIER", 381, 389], ["heterogeneous", "OBSERVATION_MODIFIER", 423, 436], ["protein", "OBSERVATION", 437, 444], ["immune reaction", "OBSERVATION", 492, 507], ["ocular change", "OBSERVATION", 512, 525], ["vitreous", "OBSERVATION", 543, 551], ["retina", "ANATOMY", 556, 562], ["anterior", "ANATOMY_MODIFIER", 580, 588], ["chamber", "ANATOMY_MODIFIER", 589, 596]]], ["The autoimmune hypothesis has been prompted by the observation that a PVR-like disease can be induced in rabbits by immunization with the retinal autoantigens opsin, antigen S, and interphotoreceptor retinoid-binding protein [15].", [["retinal", "ANATOMY", 138, 145], ["PVR-like disease", "DISEASE", 70, 86], ["retinoid", "CHEMICAL", 200, 208], ["PVR", "GENE_OR_GENE_PRODUCT", 70, 73], ["rabbits", "ORGANISM", 105, 112], ["retinal", "MULTI-TISSUE_STRUCTURE", 138, 145], ["opsin", "GENE_OR_GENE_PRODUCT", 159, 164], ["antigen S", "GENE_OR_GENE_PRODUCT", 166, 175], ["interphotoreceptor retinoid-binding protein [15]", "GENE_OR_GENE_PRODUCT", 181, 229], ["retinal autoantigens opsin", "PROTEIN", 138, 164], ["antigen S", "PROTEIN", 166, 175], ["interphotoreceptor retinoid-binding protein", "PROTEIN", 181, 224], ["rabbits", "SPECIES", 105, 112], ["rabbits", "SPECIES", 105, 112], ["The autoimmune hypothesis", "PROBLEM", 0, 25], ["a PVR-like disease", "PROBLEM", 68, 86], ["immunization", "TREATMENT", 116, 128], ["the retinal autoantigens opsin", "TEST", 134, 164], ["antigen S", "TEST", 166, 175], ["interphotoreceptor retinoid-binding protein", "TEST", 181, 224], ["autoimmune", "OBSERVATION", 4, 14], ["PVR", "OBSERVATION", 70, 73], ["retinal", "ANATOMY", 138, 145]]], ["Also apparently supporting the autoimmune hypothesis is the fact that PVR patients display signs of active immune processes in their epiretinal or subretinal membranes, vitreous cavities, subretinal fluids, and serum samples [16-22].", [["epiretinal", "ANATOMY", 133, 143], ["subretinal membranes", "ANATOMY", 147, 167], ["vitreous cavities", "ANATOMY", 169, 186], ["subretinal fluids", "ANATOMY", 188, 205], ["serum samples", "ANATOMY", 211, 224], ["patients", "ORGANISM", 74, 82], ["epiretinal", "MULTI-TISSUE_STRUCTURE", 133, 143], ["subretinal membranes", "CELLULAR_COMPONENT", 147, 167], ["vitreous cavities", "TISSUE", 169, 186], ["serum", "ORGANISM_SUBSTANCE", 211, 216], ["patients", "SPECIES", 74, 82], ["the autoimmune hypothesis", "PROBLEM", 27, 52], ["active immune processes", "PROBLEM", 100, 123], ["vitreous cavities", "TEST", 169, 186], ["subretinal fluids", "TEST", 188, 205], ["serum samples", "TEST", 211, 224], ["autoimmune", "OBSERVATION", 31, 41], ["PVR", "OBSERVATION", 70, 73], ["active", "OBSERVATION_MODIFIER", 100, 106], ["immune processes", "OBSERVATION", 107, 123], ["epiretinal", "ANATOMY_MODIFIER", 133, 143], ["subretinal membranes", "ANATOMY", 147, 167], ["vitreous cavities", "OBSERVATION", 169, 186], ["subretinal fluids", "OBSERVATION", 188, 205]]], ["Similar signs of immune activation have been reported for the cells present in the vitreous cavities and subretinal fluids of PVR patients [19,23-26].", [["cells", "ANATOMY", 62, 67], ["vitreous cavities", "ANATOMY", 83, 100], ["subretinal fluids", "ANATOMY", 105, 122], ["cells", "CELL", 62, 67], ["vitreous cavities", "MULTI-TISSUE_STRUCTURE", 83, 100], ["subretinal fluids", "ORGANISM_SUBSTANCE", 105, 122], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["immune activation", "PROBLEM", 17, 34], ["the cells", "PROBLEM", 58, 67], ["immune activation", "OBSERVATION", 17, 34], ["vitreous cavities", "ANATOMY", 83, 100], ["subretinal fluids", "OBSERVATION", 105, 122], ["PVR", "OBSERVATION", 126, 129]]], ["Sera of PVR patients have been reported to contain increased concentrations of S-antigen (S-Ag) [27] and S-Ag-specific autoantibodies [28].", [["Sera", "ANATOMY", 0, 4], ["S-Ag", "CHEMICAL", 90, 94], ["Ag", "CHEMICAL", 92, 94], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["patients", "ORGANISM", 12, 20], ["S-antigen", "GENE_OR_GENE_PRODUCT", 79, 88], ["S-Ag", "GENE_OR_GENE_PRODUCT", 90, 94], ["S-Ag", "SIMPLE_CHEMICAL", 105, 109], ["S-antigen", "PROTEIN", 79, 88], ["S", "PROTEIN", 90, 91], ["Ag", "PROTEIN", 92, 94], ["S-Ag", "PROTEIN", 105, 109], ["autoantibodies", "PROTEIN", 119, 133], ["patients", "SPECIES", 12, 20], ["increased concentrations", "PROBLEM", 51, 75], ["S-antigen (S-Ag", "TEST", 79, 94], ["S-Ag", "TEST", 105, 109], ["PVR", "OBSERVATION", 8, 11]]], ["The induction of these autoantibodies in particular implies that after iatrogenic eye injury, the exposure to S-Ag triggers an autoantigen-specific B cell response.", [["eye", "ANATOMY", 82, 85], ["B cell", "ANATOMY", 148, 154], ["iatrogenic eye injury", "DISEASE", 71, 92], ["S-Ag", "CHEMICAL", 110, 114], ["S-Ag", "CHEMICAL", 110, 114], ["eye", "ORGAN", 82, 85], ["S-Ag", "SIMPLE_CHEMICAL", 110, 114], ["B cell", "CELL", 148, 154], ["autoantibodies", "PROTEIN", 23, 37], ["S-Ag", "PROTEIN", 110, 114], ["these autoantibodies", "PROBLEM", 17, 37], ["iatrogenic eye injury", "PROBLEM", 71, 92], ["autoantibodies", "OBSERVATION", 23, 37]]], ["Since autoantibody production of protein self-antigens is strictly dependent on cluster of differentiation (CD)4 T cell help [29], the presence of these antibodies also implies an autoimmune T cell response against these self-proteins.", [["CD)4 T cell", "ANATOMY", 108, 119], ["autoimmune T cell", "ANATOMY", 180, 197], ["T cell", "CELL", 191, 197], ["protein self-antigens", "PROTEIN", 33, 54], ["antibodies", "PROTEIN", 153, 163], ["self-proteins", "PROTEIN", 221, 234], ["autoantibody production of protein self-antigens", "PROBLEM", 6, 54], ["T cell help", "TEST", 113, 124], ["these antibodies", "TEST", 147, 163], ["an autoimmune T cell response", "PROBLEM", 177, 206], ["strictly dependent", "OBSERVATION_MODIFIER", 58, 76], ["autoimmune T cell", "OBSERVATION", 180, 197]]], ["Thus, these autoreactive T and B cells could conceivably mediate the pathology underlying PVR.", [["autoreactive T", "ANATOMY", 12, 26], ["B cells", "ANATOMY", 31, 38], ["autoreactive T", "CELL", 12, 26], ["B cells", "CELL", 31, 38], ["autoreactive T and B cells", "CELL_TYPE", 12, 38], ["these autoreactive T and B cells", "PROBLEM", 6, 38], ["PVR", "PROBLEM", 90, 93], ["autoreactive", "OBSERVATION", 12, 24], ["PVR", "OBSERVATION", 90, 93]]], ["While the above findings are consistent with an autoimmune hypothesis for PVR, they do not prove it, and it has been difficult to establish whether the immune reactions seen represent the cause or merely an epiphenomenon of the disease [30].IntroductionCan dispase trigger autoreactive B or T cell response?", [["autoreactive B", "ANATOMY", 273, 287], ["T cell", "ANATOMY", 291, 297], ["autoreactive B", "CELL", 273, 287], ["T cell", "CELL", 291, 297], ["an autoimmune hypothesis", "PROBLEM", 45, 69], ["PVR", "PROBLEM", 74, 77], ["the immune reactions", "PROBLEM", 148, 168], ["an epiphenomenon of the disease", "PROBLEM", 204, 235], ["consistent with", "UNCERTAINTY", 29, 44], ["autoimmune", "OBSERVATION", 48, 58], ["PVR", "OBSERVATION", 74, 77], ["epiphenomenon", "OBSERVATION", 207, 220]]], ["To the best of our knowledge, the pathogenesis of the anterior chamber and immune reactions has not been well documented.", [["anterior chamber", "ANATOMY", 54, 70], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 54, 70], ["immune reactions", "PROBLEM", 75, 91], ["anterior", "ANATOMY_MODIFIER", 54, 62], ["chamber", "ANATOMY_MODIFIER", 63, 70]]], ["Therefore, it is important to study the ocular pathogenesis and immune reaction after intravitreal dispase injection in mice.", [["ocular", "ANATOMY", 40, 46], ["mice", "ORGANISM", 120, 124], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["the ocular pathogenesis", "PROBLEM", 36, 59], ["immune reaction", "PROBLEM", 64, 79], ["intravitreal dispase injection", "TREATMENT", 86, 116], ["ocular", "ANATOMY", 40, 46]]], ["In the present study, we analyzed these outcomes after intravitreal dispase injection during an 8 week observation period.Mice ::: MethodsFour- to six-week-old wild-type C57BL/6 mice were purchased from the South Medical University Animal Center (Guangzhou, China).", [["Mice", "ORGANISM", 122, 126], ["C57BL/6 mice", "ORGANISM", 170, 182], ["Mice", "SPECIES", 122, 126], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["the present study", "TEST", 3, 20], ["intravitreal dispase injection", "TREATMENT", 55, 85]]], ["Animal husbandry and experimental procedures were approved by the Animal Research Committee of the Zhongshan Ophthalmic Center, Sun Yat-sen University (Guangzhou, China).", [["experimental procedures", "TREATMENT", 21, 44]]], ["All animals were housed in a specific pathogen-free biohazard level-2 facility maintained by the Zhongshan Ophthalmic Center in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines.In vivo model of proliferative vitreoretinopathy induced by dispase intravitreal injection ::: MethodsThe murine PVR model was induced by dispase (Gibco, Tokyo, Japan), as previously described [1,2].", [["proliferative vitreoretinopathy", "DISEASE", 247, 278], ["murine", "ORGANISM", 336, 342], ["murine", "SPECIES", 336, 342], ["proliferative vitreoretinopathy", "PROBLEM", 247, 278], ["dispase intravitreal injection", "TREATMENT", 290, 320], ["Methods", "TREATMENT", 325, 332], ["The murine PVR model", "TEST", 332, 352], ["proliferative vitreoretinopathy", "OBSERVATION", 247, 278], ["PVR model", "OBSERVATION", 343, 352]]], ["Intravitreal injections were performed in the dorsonasal quadrant (1 o\u2019clock) 1.5 mm away from the corneal limbus of the right eye.", [["dorsonasal quadrant", "ANATOMY", 46, 65], ["corneal limbus", "ANATOMY", 99, 113], ["right eye", "ANATOMY", 121, 130], ["corneal limbus", "TISSUE", 99, 113], ["eye", "ORGAN", 127, 130], ["Intravitreal injections", "TREATMENT", 0, 23], ["dorsonasal", "ANATOMY_MODIFIER", 46, 56], ["quadrant", "ANATOMY", 57, 65], ["corneal", "ANATOMY", 99, 106], ["limbus", "ANATOMY_MODIFIER", 107, 113], ["right", "ANATOMY_MODIFIER", 121, 126], ["eye", "ANATOMY", 127, 130]]], ["Three \u03bcl of dispase at a concentration of 0.2 U/\u03bcl were injected into the vitreal cavities using a Hamilton syringe fitted with a 30 G needle.", [["vitreal cavities", "ANATOMY", 74, 90], ["vitreal cavities", "MULTI-TISSUE_STRUCTURE", 74, 90], ["dispase", "TREATMENT", 12, 19], ["a concentration of 0.2 U/\u03bcl", "TREATMENT", 23, 50], ["a Hamilton syringe", "TREATMENT", 97, 115], ["a 30 G needle", "TREATMENT", 128, 141], ["vitreal cavities", "ANATOMY", 74, 90]]], ["Control animals received 3 \u03bcl of sterile saline solution.", [["saline", "SIMPLE_CHEMICAL", 41, 47], ["sterile saline solution", "TREATMENT", 33, 56]]], ["Female mice, 4\u20136 weeks old, were anesthetized with 4.3% chloral hydrate (0.01 ml/g; Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China).", [["chloral hydrate", "CHEMICAL", 56, 71], ["chloral hydrate", "CHEMICAL", 56, 71], ["mice", "ORGANISM", 7, 11], ["chloral hydrate", "SIMPLE_CHEMICAL", 56, 71], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 7, 11], ["4.3% chloral hydrate", "TREATMENT", 51, 71]]], ["Pupils were dilated with 0.5% tropicamide (Shenyang Sinqi Pharmaceutical Co., Ltd).", [["tropicamide", "CHEMICAL", 30, 41], ["tropicamide", "CHEMICAL", 30, 41], ["tropicamide", "SIMPLE_CHEMICAL", 30, 41], ["dilated", "PROBLEM", 12, 19], ["0.5% tropicamide", "TREATMENT", 25, 41], ["dilated", "OBSERVATION", 12, 19]]], ["Intravitreal injections were performed in the dorsonasal quadrant (1 o\u2019clock) 1.5 mm away from the corneal limbus of the right eye.", [["dorsonasal quadrant", "ANATOMY", 46, 65], ["corneal limbus", "ANATOMY", 99, 113], ["right eye", "ANATOMY", 121, 130], ["corneal limbus", "TISSUE", 99, 113], ["eye", "ORGAN", 127, 130], ["Intravitreal injections", "TREATMENT", 0, 23], ["dorsonasal", "ANATOMY_MODIFIER", 46, 56], ["quadrant", "ANATOMY", 57, 65], ["corneal", "ANATOMY", 99, 106], ["limbus", "ANATOMY_MODIFIER", 107, 113], ["right", "ANATOMY_MODIFIER", 121, 126], ["eye", "ANATOMY", 127, 130]]], ["Three \u03bcl of dispase at a concentration of 0.02 U/\u03bcl were injected into the vitreal cavities using a Hamilton syringe fitted with a 30 G needle.", [["vitreal cavities", "ANATOMY", 75, 91], ["vitreal cavities", "MULTI-TISSUE_STRUCTURE", 75, 91], ["dispase", "TREATMENT", 12, 19], ["a concentration of 0.02 U/\u03bcl", "TREATMENT", 23, 51], ["a Hamilton syringe", "TREATMENT", 98, 116], ["a 30 G needle", "TREATMENT", 129, 142], ["vitreal cavities", "ANATOMY", 75, 91]]], ["Control animals received 3 \u03bcl of sterile saline solution.", [["saline", "SIMPLE_CHEMICAL", 41, 47], ["sterile saline solution", "TREATMENT", 33, 56]]], ["All experimental procedures adhered to the guidelines of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.Experimental groups ::: MethodsThe mice were divided into a dispase-injected group and a saline-injected control group (n=92, n=68).", [["mice", "ORGANISM", 216, 220], ["saline", "SIMPLE_CHEMICAL", 270, 276], ["mice", "SPECIES", 216, 220], ["mice", "SPECIES", 216, 220], ["All experimental procedures", "TREATMENT", 0, 27], ["Methods", "TREATMENT", 205, 212], ["a dispase", "TREATMENT", 239, 248], ["a saline-injected control group", "TREATMENT", 268, 299], ["Ophthalmic", "ANATOMY", 150, 160]]], ["These two groups were then equally divided into seven subgroups (n=6, n=4) at the 0 h, 4 h, 8 h, 12 h, 24 h, 48 h, and 5 day time points and five subgroups (n=10, n=8) at the 1, 2, 4, 6, and 8 week time points.Follow-up examinations and the development of proliferative vitreoretinopathy ::: MethodsThe injected eyes were examined and assessed\u2014including the cornea, lens opacity, intravitreal hemorrhages, and the fundus\u2014using a surgical microscope at each time point after intravitreal injection.", [["eyes", "ANATOMY", 312, 316], ["cornea", "ANATOMY", 358, 364], ["lens", "ANATOMY", 366, 370], ["vitreoretinopathy", "DISEASE", 270, 287], ["hemorrhages", "DISEASE", 393, 404], ["eyes", "ORGAN", 312, 316], ["cornea", "TISSUE", 358, 364], ["lens", "TISSUE", 366, 370], ["Follow-up examinations", "TEST", 210, 232], ["proliferative vitreoretinopathy", "PROBLEM", 256, 287], ["Methods", "TREATMENT", 292, 299], ["lens opacity", "PROBLEM", 366, 378], ["intravitreal hemorrhages", "PROBLEM", 380, 404], ["a surgical microscope", "TREATMENT", 427, 448], ["intravitreal injection", "TREATMENT", 474, 496], ["proliferative vitreoretinopathy", "OBSERVATION", 256, 287], ["cornea", "ANATOMY", 358, 364], ["lens", "ANATOMY", 366, 370], ["opacity", "OBSERVATION", 371, 378], ["intravitreal hemorrhages", "OBSERVATION", 380, 404]]], ["Because intravitreal hemorrhages and cataracts have often occurred in various studies [31], clinical PVR-like signs were defined as the presence of one of the following three symptoms: retinal folds, epiretinal membranes, and an uneven iris at 1, 2, 4, 6, and 8 weeks during this experiment.", [["retinal folds", "ANATOMY", 185, 198], ["epiretinal membranes", "ANATOMY", 200, 220], ["iris", "ANATOMY", 236, 240], ["hemorrhages", "DISEASE", 21, 32], ["cataracts", "DISEASE", 37, 46], ["retinal folds", "DISEASE", 185, 198], ["retinal", "MULTI-TISSUE_STRUCTURE", 185, 192], ["epiretinal membranes", "CELLULAR_COMPONENT", 200, 220], ["intravitreal hemorrhages", "PROBLEM", 8, 32], ["cataracts", "PROBLEM", 37, 46], ["various studies", "TEST", 70, 85], ["clinical PVR", "TEST", 92, 104], ["retinal folds", "PROBLEM", 185, 198], ["epiretinal membranes", "PROBLEM", 200, 220], ["intravitreal", "OBSERVATION_MODIFIER", 8, 20], ["hemorrhages", "OBSERVATION", 21, 32], ["cataracts", "OBSERVATION", 37, 46], ["retinal folds", "ANATOMY", 185, 198], ["epiretinal membranes", "ANATOMY", 200, 220]]], ["This evaluation system was modified from Cant\u00f3 Soler MV [1,2].Tissue preparation and histological and immunofluorescence analysis ::: MethodsMice used for histological studies were sacrificed at 0 h, 4 h, 8 h, 12 h, 24 h, 48 h, and 5 days or 1, 2, 4, 6, or 8 weeks after injection, and dissected eyes were cryopreserved using the optimal cutting temperature (Sakura Finetechnical, Torrance, CA) compound.", [["Tissue", "ANATOMY", 62, 68], ["eyes", "ANATOMY", 296, 300], ["Tissue", "TISSUE", 62, 68], ["eyes", "ORGAN", 296, 300], ["This evaluation system", "TEST", 0, 22], ["Tissue preparation", "TEST", 62, 80], ["histological and immunofluorescence analysis", "TEST", 85, 129], ["histological studies", "TEST", 155, 175], ["injection", "TREATMENT", 271, 280], ["the optimal cutting temperature (Sakura Finetechnical", "TREATMENT", 326, 379], ["eyes", "ANATOMY", 296, 300]]], ["For immunofluorescence analysis and hematoxylin and eosin (H&E) staining, consecutive 6 \u03bcm thick sections of each sample were cut and thaw-mounted onto poly-L-lysine-coated glass slides.", [["sections", "ANATOMY", 97, 105], ["sample", "ANATOMY", 114, 120], ["poly-L-lysine", "CHEMICAL", 152, 165], ["hematoxylin", "CHEMICAL", 36, 47], ["eosin", "CHEMICAL", 52, 57], ["poly-L-lysine", "CHEMICAL", 152, 165], ["hematoxylin", "SIMPLE_CHEMICAL", 36, 47], ["sections", "MULTI-TISSUE_STRUCTURE", 97, 105], ["poly-L-lysine", "SIMPLE_CHEMICAL", 152, 165], ["immunofluorescence analysis", "TEST", 4, 31], ["hematoxylin", "TREATMENT", 36, 47], ["eosin (H&E) staining", "TREATMENT", 52, 72], ["poly-L-lysine-coated glass slides", "TREATMENT", 152, 185]]], ["For confocal microscopy, double immunostaining was performed using two primary antibodies incubated respectively for about 20 h at room temperature and then incubated with secondary antibodies for about 1 h in the dark.", [["primary antibodies", "PROTEIN", 71, 89], ["secondary antibodies", "PROTEIN", 172, 192], ["confocal microscopy", "TEST", 4, 23], ["double immunostaining", "TEST", 25, 46], ["secondary antibodies", "PROBLEM", 172, 192]]], ["Primary antibodies served as markers, including glial acidic fibrillary protein (GFAP), glutamine synthase (GS), retinal pigment epithelium 65 (RPE65), alpha smooth muscle actin (a-SMA), F4/80, anti-CD3, and anti-CD56.", [["retinal pigment epithelium", "ANATOMY", 113, 139], ["glutamine", "CHEMICAL", 88, 97], ["glutamine", "CHEMICAL", 88, 97], ["glial acidic fibrillary protein", "GENE_OR_GENE_PRODUCT", 48, 79], ["GFAP", "GENE_OR_GENE_PRODUCT", 81, 85], ["glutamine synthase", "GENE_OR_GENE_PRODUCT", 88, 106], ["GS", "GENE_OR_GENE_PRODUCT", 108, 110], ["retinal pigment epithelium 65", "GENE_OR_GENE_PRODUCT", 113, 142], ["RPE65", "GENE_OR_GENE_PRODUCT", 144, 149], ["alpha smooth muscle actin", "GENE_OR_GENE_PRODUCT", 152, 177], ["a-SMA", "GENE_OR_GENE_PRODUCT", 179, 184], ["F4/80", "GENE_OR_GENE_PRODUCT", 187, 192], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 194, 202], ["anti-CD56", "GENE_OR_GENE_PRODUCT", 208, 217], ["glial acidic fibrillary protein", "PROTEIN", 48, 79], ["GFAP", "PROTEIN", 81, 85], ["glutamine synthase", "PROTEIN", 88, 106], ["GS", "PROTEIN", 108, 110], ["retinal pigment epithelium 65", "PROTEIN", 113, 142], ["RPE65", "PROTEIN", 144, 149], ["alpha smooth muscle actin", "PROTEIN", 152, 177], ["a-SMA", "PROTEIN", 179, 184], ["F4", "PROTEIN", 187, 189], ["anti-CD3", "PROTEIN", 194, 202], ["anti-CD56", "PROTEIN", 208, 217], ["Primary antibodies", "TEST", 0, 18], ["markers", "TEST", 29, 36], ["glial acidic fibrillary protein", "TEST", 48, 79], ["GFAP", "TEST", 81, 85], ["glutamine synthase (GS", "TEST", 88, 110], ["retinal pigment epithelium", "TEST", 113, 139], ["RPE65", "TEST", 144, 149], ["alpha smooth muscle actin", "PROBLEM", 152, 177], ["anti-CD3", "TREATMENT", 194, 202], ["anti-CD56", "TREATMENT", 208, 217], ["retinal", "ANATOMY", 113, 120], ["pigment epithelium", "OBSERVATION", 121, 139], ["smooth muscle", "ANATOMY", 158, 171]]], ["Dilutions and the source of each primary antibody are described in Table 1.", [["primary antibody", "PROTEIN", 33, 49], ["Dilutions", "TREATMENT", 0, 9], ["each primary antibody", "PROBLEM", 28, 49]]], ["Negative controls were made by omitting the primary antibodies.", [["primary antibodies", "PROTEIN", 44, 62]]], ["Three secondary antibodies were used in this study: R-phycoerythrin-conjugated goat antirat IgG (1:10; Southern Biotechnology Associates, Inc., Birmingham, AL), R-phycoerythrin-conjugated goat antimouse IgG (1:10; Southern Biotechnology Associates, Inc.), and fluorescein isothiocyanate\u2013labeled goat antirabbit IgG (1:10; KPL, Gaithersburg, MD).", [["fluorescein", "CHEMICAL", 260, 271], ["fluorescein", "CHEMICAL", 260, 271], ["R-phycoerythrin", "SIMPLE_CHEMICAL", 52, 67], ["goat", "ORGANISM", 79, 83], ["R-phycoerythrin", "SIMPLE_CHEMICAL", 161, 176], ["goat", "ORGANISM", 188, 192], ["fluorescein", "SIMPLE_CHEMICAL", 260, 271], ["secondary antibodies", "PROTEIN", 6, 26], ["phycoerythrin-conjugated goat antirat IgG", "PROTEIN", 54, 95], ["phycoerythrin-conjugated goat antimouse IgG", "PROTEIN", 163, 206], ["fluorescein isothiocyanate\u2013labeled goat antirabbit IgG", "PROTEIN", 260, 314], ["goat", "SPECIES", 79, 83], ["goat", "SPECIES", 188, 192], ["antimouse", "SPECIES", 193, 202], ["goat", "SPECIES", 295, 299], ["goat", "SPECIES", 79, 83], ["goat", "SPECIES", 188, 192], ["goat", "SPECIES", 295, 299], ["Three secondary antibodies", "PROBLEM", 0, 26], ["this study", "TEST", 40, 50], ["R-phycoerythrin", "TREATMENT", 52, 67], ["conjugated goat antirat IgG", "TREATMENT", 68, 95], ["R-phycoerythrin", "TREATMENT", 161, 176], ["conjugated goat antimouse IgG", "TREATMENT", 177, 206]]], ["Sections were washed four times in PBS (5 min each time) and mounted under coverslips in antifade solution (Applygen Technologies Inc., Beijing, China) for observation with a fluorescence microscope (Carl Zeiss Far East Co. Ltd., HK).Electroretinograms ::: MethodsElectroretinograms (ERGs) of dispase-injected PVR mice (n=14) and saline-injected control mice (n=14) were performed at 6 and 8 weeks in a full-field dome, using methods similar to those used in the clinic and stimuli comparable to those specified by the International Society for Clinical Electrophysiology of Vision [32].", [["mice", "ORGANISM", 314, 318], ["saline", "SIMPLE_CHEMICAL", 330, 336], ["mice", "ORGANISM", 354, 358], ["mice", "SPECIES", 314, 318], ["mice", "SPECIES", 354, 358], ["mice", "SPECIES", 354, 358], ["Electroretinograms", "TEST", 234, 252], ["MethodsElectroretinograms", "TEST", 257, 282], ["dispase", "TEST", 293, 300], ["PVR mice", "TREATMENT", 310, 318], ["saline", "TREATMENT", 330, 336], ["methods", "TREATMENT", 426, 433]]], ["The eyes were dilated with 0.5% tropicamide and dark-adapted for at least 30 min.", [["eyes", "ANATOMY", 4, 8], ["tropicamide", "CHEMICAL", 32, 43], ["tropicamide", "CHEMICAL", 32, 43], ["eyes", "ORGAN", 4, 8], ["tropicamide", "SIMPLE_CHEMICAL", 32, 43], ["dilated", "PROBLEM", 14, 21], ["0.5% tropicamide", "TREATMENT", 27, 43], ["eyes", "ANATOMY", 4, 8], ["dilated", "OBSERVATION", 14, 21]]], ["Mice were anesthetized with a saline solution containing ketamine hydrochloride (30 mg/kg) and chlorpromazine hydrochloride (15 mg/kg).", [["ketamine hydrochloride", "CHEMICAL", 57, 79], ["chlorpromazine hydrochloride", "CHEMICAL", 95, 123], ["ketamine hydrochloride", "CHEMICAL", 57, 79], ["chlorpromazine hydrochloride", "CHEMICAL", 95, 123], ["Mice", "ORGANISM", 0, 4], ["ketamine", "SIMPLE_CHEMICAL", 57, 65], ["hydrochloride", "SIMPLE_CHEMICAL", 66, 79], ["chlorpromazine hydrochloride", "SIMPLE_CHEMICAL", 95, 123], ["Mice", "SPECIES", 0, 4], ["a saline solution containing ketamine hydrochloride", "TREATMENT", 28, 79], ["chlorpromazine hydrochloride", "TREATMENT", 95, 123]]], ["A gold-wire coil placed on one cornea was referenced to a needle electrode in the scalp.", [["cornea", "ANATOMY", 31, 37], ["scalp", "ANATOMY", 82, 87], ["cornea", "ORGAN", 31, 37], ["scalp", "ORGAN", 82, 87], ["A gold-wire coil", "TREATMENT", 0, 16], ["a needle electrode in the scalp", "TREATMENT", 56, 87], ["gold", "OBSERVATION_MODIFIER", 2, 6], ["wire coil", "OBSERVATION", 7, 16], ["cornea", "ANATOMY", 31, 37], ["scalp", "ANATOMY", 82, 87]]], ["A needle electrode in the tail served as ground.", [["tail", "ANATOMY", 26, 30], ["tail", "ORGANISM_SUBDIVISION", 26, 30], ["A needle electrode in the tail", "TREATMENT", 0, 30], ["needle electrode", "OBSERVATION", 2, 18], ["tail", "ANATOMY", 26, 30]]], ["The recordings were made using the Roland Ganzfeld system and PC-based signal acquisition and analysis software (Fa.", [["The recordings", "TEST", 0, 14], ["the Roland Ganzfeld system", "TEST", 31, 57], ["PC-based signal acquisition", "TEST", 62, 89], ["analysis software", "TEST", 94, 111]]], ["Scotopic, mesopic, photopic, and oscillatory potentials, as well as 30 Hz flicker ERG responses were recorded.", [["Scotopic", "TEST", 0, 8], ["oscillatory potentials", "TEST", 33, 55], ["30 Hz flicker ERG responses", "TEST", 68, 95], ["mesopic", "OBSERVATION", 10, 17], ["oscillatory potentials", "OBSERVATION", 33, 55]]], ["The bright-flash response was elicited using the ISCEV standard flash of 2.4 cd/m2 (settings: \u221225dB flash, fix on, backlight off 0.5HZ).", [["25dB flash", "TREATMENT", 95, 105], ["fix", "TREATMENT", 107, 110]]], ["After light adaptation of 10 min with a steady background illumination of 10 cd/m2, photopic responses (settings: 0dB standard flash, fix on, backlight off 0.2HZ) and 30 Hz flicker ERGs were recorded.", [["photopic responses", "TEST", 84, 102], ["0dB standard flash", "TREATMENT", 114, 132], ["fix", "TREATMENT", 134, 137], ["backlight", "TEST", 142, 151], ["30 Hz flicker ERGs", "TEST", 167, 185]]], ["In this way, the a- and b-wave amplitudes and the implicit times of the standard responses were determined [33].Enzyme-linked immunospot assay ::: MethodsMice were sacrificed at 1, 2, 4, 6, or 8 weeks after injection.", [["Mice", "ORGANISM", 154, 158], ["Mice", "SPECIES", 154, 158], ["Enzyme", "TEST", 112, 118], ["immunospot assay", "TEST", 126, 142], ["MethodsMice", "TREATMENT", 147, 158]]], ["An enzyme-linked immunospot (Enzyme-Linked ImmunoSpot assay [ELISpot], Cellular Technology Ltd, Cleveland, OH) assay was performed, as described by Jager et al. [34].", [["enzyme", "PROTEIN", 3, 9], ["An enzyme-linked immunospot", "TEST", 0, 27], ["Enzyme", "TEST", 29, 35], ["ImmunoSpot assay", "TEST", 43, 59], ["ELISpot", "TEST", 61, 68], ["Cleveland, OH) assay", "TEST", 96, 116]]], ["In brief, single-cell suspensions were prepared from the spleens of individual mice.", [["cell", "ANATOMY", 17, 21], ["spleens", "ANATOMY", 57, 64], ["spleens", "ORGAN", 57, 64], ["mice", "ORGANISM", 79, 83], ["single-cell suspensions", "CELL_LINE", 10, 33], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["single-cell suspensions", "TREATMENT", 10, 33], ["spleens", "ANATOMY", 57, 64]]], ["The immunospot plates (MAHAS45; Millipore, Bedford, MA) had the regular format of 96 wells.", [["The immunospot plates", "TEST", 0, 21], ["MAHAS45", "TEST", 23, 30]]], ["Ethanol (70%) was added at 15 \u03bcl per well for prewetting, and the plates were washed three times with PBS.", [["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["Ethanol", "TREATMENT", 0, 7], ["the plates", "TREATMENT", 62, 72], ["PBS", "TREATMENT", 102, 105]]], ["After washing, the plates were coated with antimouse-interferon (IFN)-\u03b3 capture Ab (BD, San Diego, CA) at 5 \u03bcg/ml in PBS and antimouse-interleukin (IL)-2 capture Ab (BD) at 5 \u03bcg/ml in PBS, respectively; they were then stored overnight at 4 \u00b0C. The plates were then blocked with Roswell Park Memorial Institute (RPMI) 1640 medium for 2 h at room temperature and washed three times with PBS.", [["antimouse-interferon", "GENE_OR_GENE_PRODUCT", 43, 63], ["IFN)-\u03b3", "SIMPLE_CHEMICAL", 65, 71], ["BD", "SIMPLE_CHEMICAL", 84, 86], ["antimouse-interleukin (IL)-2", "GENE_OR_GENE_PRODUCT", 125, 153], ["BD", "GENE_OR_GENE_PRODUCT", 166, 168], ["antimouse-interferon (IFN)-\u03b3 capture Ab", "PROTEIN", 43, 82], ["BD", "PROTEIN", 84, 86], ["interleukin (IL)-2 capture Ab", "PROTEIN", 135, 164], ["BD", "PROTEIN", 166, 168], ["the plates", "TREATMENT", 15, 25], ["antimouse-interferon (IFN)", "TREATMENT", 43, 69], ["CA)", "TREATMENT", 99, 102], ["antimouse-interleukin (IL)", "TREATMENT", 125, 151], ["Ab (BD)", "TREATMENT", 162, 169], ["PBS", "TREATMENT", 385, 388]]], ["The single-cell suspensions were plated in complete RPMI 1640 and added at 1\u00d7105 cells per well to the 96-well plates.", [["cell", "ANATOMY", 11, 15], ["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["1\u00d7105 cells", "CELL_LINE", 75, 86], ["The single-cell suspensions", "TREATMENT", 0, 27]]], ["In each well, dispase (Gibco, Tokyo, Japan) was added as a stimulus at 0.02 U/ml; as a positive control, 2 \u03bcg/ml phytohemagglutinin (PHA; Fluka, Sigma, Carlsbad, CA) was added in the absence of dispase.", [["PHA", "CHEMICAL", 133, 136], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 113, 131], ["PHA", "SIMPLE_CHEMICAL", 133, 136], ["Fluka", "SIMPLE_CHEMICAL", 138, 143], ["Carlsbad, CA", "ORGANISM", 152, 164], ["dispase", "GENE_OR_GENE_PRODUCT", 194, 201], ["phytohemagglutinin", "PROTEIN", 113, 131], ["PHA", "PROTEIN", 133, 136], ["a positive control", "TREATMENT", 85, 103], ["PHA", "TEST", 133, 136], ["Sigma, Carlsbad, CA)", "TREATMENT", 145, 165], ["dispase", "PROBLEM", 194, 201]]], ["Finally, as a negative control, PBS was added in the absence of dispase.", [["PBS", "SIMPLE_CHEMICAL", 32, 35], ["dispase", "GENE_OR_GENE_PRODUCT", 64, 71], ["PBS", "TREATMENT", 32, 35], ["dispase", "PROBLEM", 64, 71], ["dispase", "OBSERVATION", 64, 71]]], ["After 20 h incubation at 37 \u00b0C in CO2 incubators and washing, 2 \u03bcg/ml of biotinylated antimouse-IFN-\u03b3 detection Ab (BD) in PBS/BSA (BSA)/Tween (10 g/l BSA with 0.5% Tween) and 2 \u03bcg/ml antimouse-IL-2 detection Ab (BD) in PBS/BSA/Tween (10 g/l BSA with 0.5% Tween) were added.", [["CO2", "CHEMICAL", 34, 37], ["CO2", "CHEMICAL", 34, 37], ["Tween", "CHEMICAL", 137, 142], ["Tween", "CHEMICAL", 165, 170], ["Tween", "CHEMICAL", 228, 233], ["Tween", "CHEMICAL", 256, 261], ["CO2", "SIMPLE_CHEMICAL", 34, 37], ["antimouse-IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 86, 101], ["BD", "SIMPLE_CHEMICAL", 116, 118], ["PBS/BSA", "SIMPLE_CHEMICAL", 123, 130], ["BSA", "SIMPLE_CHEMICAL", 132, 135], ["Tween", "SIMPLE_CHEMICAL", 137, 142], ["BSA", "SIMPLE_CHEMICAL", 151, 154], ["IL-2", "GENE_OR_GENE_PRODUCT", 194, 198], ["BD", "SIMPLE_CHEMICAL", 213, 215], ["BSA", "SIMPLE_CHEMICAL", 224, 227], ["BSA", "SIMPLE_CHEMICAL", 242, 245], ["biotinylated antimouse", "PROTEIN", 73, 95], ["IFN", "PROTEIN", 96, 99], ["\u03b3 detection Ab", "PROTEIN", 100, 114], ["BD", "PROTEIN", 116, 118], ["IL-2 detection Ab", "PROTEIN", 194, 211], ["BD", "PROTEIN", 213, 215], ["antimouse", "SPECIES", 86, 95], ["CO2 incubators", "TREATMENT", 34, 48], ["washing", "TREATMENT", 53, 60], ["biotinylated antimouse", "TREATMENT", 73, 95], ["IFN", "TREATMENT", 96, 99], ["BSA", "TEST", 127, 130], ["BSA", "TEST", 132, 135], ["Tween", "TEST", 137, 142], ["BSA", "TEST", 151, 154], ["antimouse", "TEST", 184, 193], ["IL", "TEST", 194, 196], ["PBS", "TEST", 220, 223], ["BSA", "TEST", 224, 227], ["Tween", "TEST", 228, 233], ["BSA", "TEST", 242, 245], ["BSA", "ANATOMY", 127, 130]]], ["After 2 h incubation at room temperature and washing three times with PBS/Tween, 100 uL/well of streptavidin- horseradish peroxidase (HRP; 1:100 dilution; BD) in PBS/BSA/Tween was added for 1 h at room temperature and then washed with PBS/Tween, followed by PBS.", [["Tween", "CHEMICAL", 74, 79], ["Tween", "CHEMICAL", 170, 175], ["Tween", "CHEMICAL", 239, 244], ["streptavidin", "SIMPLE_CHEMICAL", 96, 108], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 110, 132], ["HRP", "SIMPLE_CHEMICAL", 134, 137], ["BD", "SIMPLE_CHEMICAL", 155, 157], ["BSA", "SIMPLE_CHEMICAL", 166, 169], ["Tween", "SIMPLE_CHEMICAL", 170, 175], ["streptavidin", "PROTEIN", 96, 108], ["horseradish peroxidase", "PROTEIN", 110, 132], ["HRP", "PROTEIN", 134, 137], ["BD", "PROTEIN", 155, 157], ["horseradish", "SPECIES", 110, 121], ["PBS/Tween", "TREATMENT", 70, 79], ["streptavidin- horseradish peroxidase (HRP", "TREATMENT", 96, 137], ["PBS/BSA/Tween", "TREATMENT", 162, 175], ["PBS/Tween", "TREATMENT", 235, 244]]], ["The 3-amino-9-ethylcarba (AEC) working solution was freshly prepared by mixing 9.8 ml AEC substrate solution (BD) with 200 \u03bcl AEC chromogen solution (BD); 100 ul of the mixture was plated per well.", [["3-amino-9-ethylcarba", "CHEMICAL", 4, 24], ["3-amino-9-ethylcarba", "CHEMICAL", 4, 24], ["chromogen", "CHEMICAL", 130, 139], ["3-amino-9-ethylcarba", "SIMPLE_CHEMICAL", 4, 24], ["AEC", "SIMPLE_CHEMICAL", 26, 29], ["The 3-amino-9-ethylcarba (AEC) working solution", "TREATMENT", 0, 47], ["AEC substrate solution (BD)", "TREATMENT", 86, 113], ["200 \u03bcl AEC chromogen solution", "TREATMENT", 119, 148]]], ["The plates were developed for 15\u201320 min, after which the reaction was stopped by rinsing with tap water.", [["the reaction", "PROBLEM", 53, 65], ["tap water", "TREATMENT", 94, 103], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The plates were air dried overnight and read by the Champ Spot II ELISpot reader (Sage Creation, Beijing, China).", [["plates", "OBSERVATION_MODIFIER", 4, 10], ["air dried", "OBSERVATION", 16, 25]]], ["The indicated spot numbers per well represent the mean values of three replicates.Intracellular staining and flow cytometry ::: MethodsIntracellular staining and a flow cytometry assay were performed, as previously described [35].", [["Intracellular", "ANATOMY", 82, 95], ["Intracellular", "ANATOMY", 135, 148], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["spot numbers", "TEST", 14, 26], ["Intracellular staining", "TEST", 82, 104], ["flow cytometry", "TEST", 109, 123], ["MethodsIntracellular staining", "TEST", 128, 157], ["a flow cytometry assay", "TEST", 162, 184], ["staining", "OBSERVATION", 96, 104], ["flow cytometry", "OBSERVATION", 109, 123]]], ["Single-cell suspensions from the spleens of model mice at 4 weeks were prepared.", [["cell", "ANATOMY", 7, 11], ["spleens", "ANATOMY", 33, 40], ["Single-cell", "CELL", 0, 11], ["spleens", "ORGAN", 33, 40], ["mice", "ORGANISM", 50, 54], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["Single-cell suspensions", "TREATMENT", 0, 23], ["-cell", "OBSERVATION_MODIFIER", 6, 11], ["suspensions", "OBSERVATION_MODIFIER", 12, 23], ["spleens", "ANATOMY", 33, 40]]], ["Dispase was added as a stimulus at 0.02 U/ml; as a positive control, 2 \u03bcg/ml PHA (Fluka; Sigma, Louis, MO) were added in the absence of dispase.", [["Dispase", "CHEMICAL", 0, 7], ["PHA", "CHEMICAL", 77, 80], ["PHA", "CHEMICAL", 77, 80], ["Fluka", "CHEMICAL", 82, 87], ["PHA", "SIMPLE_CHEMICAL", 77, 80], ["Fluka", "SIMPLE_CHEMICAL", 82, 87], ["Louis, MO", "SIMPLE_CHEMICAL", 96, 105], ["dispase", "GENE_OR_GENE_PRODUCT", 136, 143], ["PHA", "PROTEIN", 77, 80], ["a positive control", "TREATMENT", 49, 67], ["Sigma, Louis, MO)", "TREATMENT", 89, 106], ["dispase", "PROBLEM", 136, 143]]], ["As a negative control, PBS was added in the absence of dispase.", [["PBS", "SIMPLE_CHEMICAL", 23, 26], ["dispase", "GENE_OR_GENE_PRODUCT", 55, 62], ["PBS", "TREATMENT", 23, 26], ["dispase", "PROBLEM", 55, 62], ["negative", "OBSERVATION", 5, 13], ["dispase", "OBSERVATION", 55, 62]]], ["After 1 h of incubation, Brefeldin A (Sigma) at a final concentration of 10 \u03bcg/ml was added to cultures to enable intracellular protein to accumulate in all stimulations.", [["intracellular", "ANATOMY", 114, 127], ["Brefeldin A", "CHEMICAL", 25, 36], ["Brefeldin A", "CHEMICAL", 25, 36], ["Brefeldin A", "SIMPLE_CHEMICAL", 25, 36], ["Sigma", "SIMPLE_CHEMICAL", 38, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["incubation", "TREATMENT", 13, 23], ["a final concentration", "TREATMENT", 48, 69], ["cultures", "TEST", 95, 103], ["intracellular protein", "TEST", 114, 135]]], ["After incubation for a total of 5 h, the cells were harvested, washed twice with PBS, fixed with 4% paraformaldehyde, and permeabilized with PBS containing 0.1% saponin (Fluka) plus 0.5% BSA buffer overnight at 4 \u00b0C. They were then stained with anti-CD4, anti-CD8, anti-IFN-\u03b3, or isotype control Abs (BD) for 30 min at 4 \u00b0C and washed twice with PBS before being resuspended in PBS containing 0.5% BSA and 0.1% NaN3.", [["cells", "ANATOMY", 41, 46], ["Fluka", "CHEMICAL", 170, 175], ["BSA", "CHEMICAL", 398, 401], ["NaN3", "CHEMICAL", 411, 415], ["paraformaldehyde", "CHEMICAL", 100, 116], ["saponin", "CHEMICAL", 161, 168], ["NaN3", "CHEMICAL", 411, 415], ["cells", "CELL", 41, 46], ["paraformaldehyde", "SIMPLE_CHEMICAL", 100, 116], ["saponin", "SIMPLE_CHEMICAL", 161, 168], ["Fluka", "SIMPLE_CHEMICAL", 170, 175], ["BSA", "SIMPLE_CHEMICAL", 187, 190], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 245, 253], ["anti-CD8", "SIMPLE_CHEMICAL", 255, 263], ["anti-IFN-\u03b3", "SIMPLE_CHEMICAL", 265, 275], ["BSA", "SIMPLE_CHEMICAL", 398, 401], ["NaN3", "SIMPLE_CHEMICAL", 411, 415], ["anti-CD4", "PROTEIN", 245, 253], ["anti-CD8", "PROTEIN", 255, 263], ["anti-IFN", "PROTEIN", 265, 273], ["\u03b3", "PROTEIN", 274, 275], ["isotype control Abs", "PROTEIN", 280, 299], ["BD", "PROTEIN", 301, 303], ["the cells", "TREATMENT", 37, 46], ["PBS", "TREATMENT", 81, 84], ["4% paraformaldehyde", "TREATMENT", 97, 116], ["PBS", "TREATMENT", 141, 144], ["0.1% saponin (Fluka)", "TREATMENT", 156, 176], ["anti-CD4", "TREATMENT", 245, 253], ["anti-CD8", "TREATMENT", 255, 263], ["anti-IFN", "TREATMENT", 265, 273], ["isotype control Abs", "TREATMENT", 280, 299], ["PBS", "TREATMENT", 346, 349], ["PBS", "TREATMENT", 378, 381]]], ["Cells were acquired using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA), and FACS data were analyzed using FlowJo (BD Biosciences).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["a FACSCalibur flow cytometer", "TEST", 26, 54], ["FACS data", "TEST", 92, 101]]], ["Isotype-matched controls for cytokines were included in each staining.Data and statistical analysis ::: MethodsResults are expressed as mean\u00b1standard deviation (SD).", [["cytokines", "PROTEIN", 29, 38], ["Isotype", "TREATMENT", 0, 7], ["cytokines", "PROBLEM", 29, 38]]], ["ERG data were compared using the Student t test.", [["ERG", "DNA", 0, 3], ["ERG data", "TEST", 0, 8], ["the Student t test", "TEST", 29, 47]]], ["A value of p<0.05 was considered statistically significant.Early inflammatory infiltration (occurring at 0, 4, 8, 12, 24, and 48 h, and 5 days) ::: ResultsIn the dispase-injected group, the results of H&E-stained sections of the model eyes showed early inflammatory infiltration after dispase injection at 0, 4, 8, 12, 24, and 48 h and 5 days.", [["sections", "ANATOMY", 213, 221], ["eyes", "ANATOMY", 235, 239], ["H&E", "SIMPLE_CHEMICAL", 201, 204], ["sections", "MULTI-TISSUE_STRUCTURE", 213, 221], ["eyes", "ORGAN", 235, 239], ["A value", "TEST", 0, 7], ["Early inflammatory infiltration", "PROBLEM", 59, 90], ["H&E", "TEST", 201, 204], ["early inflammatory infiltration", "PROBLEM", 247, 278], ["dispase injection", "TREATMENT", 285, 302], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["infiltration", "OBSERVATION", 78, 90], ["eyes", "ANATOMY", 235, 239], ["early", "OBSERVATION_MODIFIER", 247, 252], ["inflammatory", "OBSERVATION_MODIFIER", 253, 265], ["infiltration", "OBSERVATION", 266, 278]]], ["Neutrophils were the main inflammatory infiltrating cells appearing at the anterior chamber (Figure 1) instead of the vitreous cavity (Figure 2) during early inflammatory infiltration.", [["Neutrophils", "ANATOMY", 0, 11], ["inflammatory infiltrating cells", "ANATOMY", 26, 57], ["anterior chamber", "ANATOMY", 75, 91], ["vitreous cavity", "ANATOMY", 118, 133], ["Neutrophils", "CELL", 0, 11], ["inflammatory infiltrating cells", "CELL", 26, 57], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 75, 91], ["vitreous cavity", "MULTI-TISSUE_STRUCTURE", 118, 133], ["Neutrophils", "CELL_TYPE", 0, 11], ["inflammatory infiltrating cells", "CELL_TYPE", 26, 57], ["Neutrophils", "TEST", 0, 11], ["the main inflammatory infiltrating cells", "PROBLEM", 17, 57], ["early inflammatory infiltration", "PROBLEM", 152, 183], ["main", "OBSERVATION_MODIFIER", 21, 25], ["inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["infiltrating cells", "OBSERVATION", 39, 57], ["anterior", "ANATOMY_MODIFIER", 75, 83], ["chamber", "ANATOMY_MODIFIER", 84, 91], ["vitreous cavity", "ANATOMY", 118, 133], ["early", "OBSERVATION_MODIFIER", 152, 157], ["inflammatory", "OBSERVATION_MODIFIER", 158, 170], ["infiltration", "OBSERVATION", 171, 183]]], ["The neutrophils appeared from hour 8 to hour 48 at the anterior chamber, as shown in Figure 1 and Figure 2.", [["neutrophils", "ANATOMY", 4, 15], ["anterior chamber", "ANATOMY", 55, 71], ["neutrophils", "CELL", 4, 15], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 55, 71], ["neutrophils", "CELL_TYPE", 4, 15], ["neutrophils", "OBSERVATION", 4, 15], ["anterior", "ANATOMY_MODIFIER", 55, 63], ["chamber", "ANATOMY_MODIFIER", 64, 71]]], ["However, in the saline-injected control groups, the H&E-stained sections exhibited normal eye morphology, without inflammatory infiltration cells, at all time points.", [["sections", "ANATOMY", 64, 72], ["eye", "ANATOMY", 90, 93], ["cells", "ANATOMY", 140, 145], ["saline", "SIMPLE_CHEMICAL", 16, 22], ["H&E", "SIMPLE_CHEMICAL", 52, 55], ["sections", "MULTI-TISSUE_STRUCTURE", 64, 72], ["eye", "ORGAN", 90, 93], ["cells", "CELL", 140, 145], ["inflammatory infiltration cells", "CELL_TYPE", 114, 145], ["the saline-injected control groups", "TREATMENT", 12, 46], ["the H&E-stained sections", "TEST", 48, 72], ["inflammatory infiltration cells", "PROBLEM", 114, 145], ["normal eye morphology", "OBSERVATION", 83, 104], ["without", "UNCERTAINTY", 106, 113], ["inflammatory", "OBSERVATION_MODIFIER", 114, 126], ["infiltration cells", "OBSERVATION", 127, 145]]], ["No CD3+ labeled T cells, F4/80+ labeled macrophages, or CD56+ labeled natural killer (NK) cells were observed in the vitreous cavities or retinas at any early time point in either of the two groups (Figure 3).Proliferative vitreoretinopathy development at 1, 2, 4, 6, and 8 weeks ::: ResultsAfter dispase injection, hemorrhages, cataracts, and PVR were observed in the dispase-injected groups (Figure 4).", [["CD3+ labeled T cells", "ANATOMY", 3, 23], ["macrophages", "ANATOMY", 40, 51], ["CD56+ labeled natural killer (NK) cells", "ANATOMY", 56, 95], ["vitreous cavities", "ANATOMY", 117, 134], ["retinas", "ANATOMY", 138, 145], ["vitreoretinopathy", "DISEASE", 223, 240], ["hemorrhages", "DISEASE", 316, 327], ["cataracts", "DISEASE", 329, 338], ["CD3", "GENE_OR_GENE_PRODUCT", 3, 6], ["T cells", "CELL", 16, 23], ["macrophages", "CELL", 40, 51], ["CD56", "GENE_OR_GENE_PRODUCT", 56, 60], ["natural killer", "CELL", 70, 84], ["NK) cells", "CELL", 86, 95], ["vitreous cavities", "MULTI-TISSUE_STRUCTURE", 117, 134], ["retinas", "MULTI-TISSUE_STRUCTURE", 138, 145], ["CD3", "PROTEIN", 3, 6], ["T cells", "CELL_TYPE", 16, 23], ["macrophages", "CELL_TYPE", 40, 51], ["CD56+ labeled natural killer (NK) cells", "CELL_TYPE", 56, 95], ["CD3", "TEST", 3, 6], ["labeled T cells", "TEST", 8, 23], ["F4", "TEST", 25, 27], ["macrophages", "TEST", 40, 51], ["CD56", "TEST", 56, 60], ["retinas", "PROBLEM", 138, 145], ["Proliferative vitreoretinopathy development", "PROBLEM", 209, 252], ["dispase injection", "TREATMENT", 297, 314], ["hemorrhages", "PROBLEM", 316, 327], ["cataracts", "PROBLEM", 329, 338], ["PVR", "PROBLEM", 344, 347], ["CD3", "OBSERVATION", 3, 6], ["vitreous cavities", "ANATOMY", 117, 134], ["retinas", "ANATOMY", 138, 145], ["vitreoretinopathy", "OBSERVATION", 223, 240], ["hemorrhages", "OBSERVATION", 316, 327], ["cataracts", "OBSERVATION", 329, 338], ["PVR", "OBSERVATION", 344, 347]]], ["PVR-like signs first appeared at 2 weeks; subsequently, they gradually increased and reached their peak values at 8 weeks.", [["PVR", "TEST", 0, 3], ["increased", "OBSERVATION_MODIFIER", 71, 80]]], ["The PVR percentages at 1, 2, 4, 6, and 8 weeks were 0%, 23%, 44%, 70%, and 75%, respectively, in the dispase-injected groups.", [["The PVR percentages", "TEST", 0, 19], ["PVR", "OBSERVATION_MODIFIER", 4, 7], ["percentages", "OBSERVATION_MODIFIER", 8, 19]]], ["H&E-stained frozen sections clearly showed marked proliferative membranes, retinal detachment, serous fluid between the RPE and the sensory retinas, and destructed retinas and lenses.", [["sections", "ANATOMY", 19, 27], ["proliferative membranes", "ANATOMY", 50, 73], ["retinal", "ANATOMY", 75, 82], ["serous fluid", "ANATOMY", 95, 107], ["RPE", "ANATOMY", 120, 123], ["sensory retinas", "ANATOMY", 132, 147], ["retinas", "ANATOMY", 164, 171], ["retinal detachment", "DISEASE", 75, 93], ["H&E", "SIMPLE_CHEMICAL", 0, 3], ["proliferative membranes", "CELLULAR_COMPONENT", 50, 73], ["retinal", "MULTI-TISSUE_STRUCTURE", 75, 82], ["serous fluid", "ORGANISM_SUBSTANCE", 95, 107], ["RPE", "TISSUE", 120, 123], ["sensory retinas", "TISSUE", 132, 147], ["retinas", "MULTI-TISSUE_STRUCTURE", 164, 171], ["stained frozen sections", "TEST", 4, 27], ["marked proliferative membranes", "PROBLEM", 43, 73], ["retinal detachment", "PROBLEM", 75, 93], ["serous fluid", "PROBLEM", 95, 107], ["destructed retinas and lenses", "PROBLEM", 153, 182], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["proliferative membranes", "OBSERVATION", 50, 73], ["retinal", "ANATOMY", 75, 82], ["detachment", "OBSERVATION", 83, 93], ["serous", "OBSERVATION_MODIFIER", 95, 101], ["fluid", "OBSERVATION", 102, 107], ["RPE", "ANATOMY_MODIFIER", 120, 123], ["sensory retinas", "ANATOMY", 132, 147], ["destructed retinas", "OBSERVATION", 153, 171], ["lenses", "OBSERVATION_MODIFIER", 176, 182]]], ["In the process of PVR development, the RPE65, GFAP, GS, and a-SMA labeled cells were involved in the PVR eyes of mice (Figure 5).", [["cells", "ANATOMY", 74, 79], ["PVR eyes", "ANATOMY", 101, 109], ["PVR", "GENE_OR_GENE_PRODUCT", 18, 21], ["RPE65", "GENE_OR_GENE_PRODUCT", 39, 44], ["GFAP", "GENE_OR_GENE_PRODUCT", 46, 50], ["GS", "GENE_OR_GENE_PRODUCT", 52, 54], ["a-SMA", "GENE_OR_GENE_PRODUCT", 60, 65], ["cells", "CELL", 74, 79], ["eyes", "ORGAN", 105, 109], ["mice", "ORGANISM", 113, 117], ["RPE65", "PROTEIN", 39, 44], ["GFAP", "PROTEIN", 46, 50], ["GS", "PROTEIN", 52, 54], ["a-SMA", "PROTEIN", 60, 65], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["PVR development", "TEST", 18, 33], ["the RPE65", "TEST", 35, 44], ["GFAP", "TEST", 46, 50], ["GS", "TEST", 52, 54], ["a-SMA labeled cells", "TEST", 60, 79], ["PVR", "OBSERVATION", 18, 21]]], ["No structural abnormalities were found in the control eyes at the same time points.Electroretinogram results ::: ResultsAs shown in Figure 6 and Table 2, mesopic ERG (0dB standard flash, fix on, backlight off 0.2HZ) data showed decreases in the amplitude of the a-wave in dispase-injected PVR eyes, suggesting photoreceptor dysfunction, as well as reductions in b-wave amplitudes, indicating that retinal interneurons (bipolar cell function) were affected as well.", [["eyes", "ANATOMY", 54, 58], ["PVR eyes", "ANATOMY", 289, 297], ["photoreceptor", "ANATOMY", 310, 323], ["retinal interneurons", "ANATOMY", 397, 417], ["cell", "ANATOMY", 427, 431], ["photoreceptor dysfunction", "DISEASE", 310, 335], ["eyes", "ORGAN", 54, 58], ["eyes", "ORGAN", 293, 297], ["photoreceptor", "MULTI-TISSUE_STRUCTURE", 310, 323], ["retinal interneurons", "CELL", 397, 417], ["bipolar cell", "CELL", 419, 431], ["mesopic ERG", "PROTEIN", 154, 165], ["structural abnormalities", "PROBLEM", 3, 27], ["Electroretinogram", "TEST", 83, 100], ["ResultsAs", "TEST", 113, 122], ["mesopic ERG", "TEST", 154, 165], ["backlight", "TEST", 195, 204], ["photoreceptor dysfunction", "PROBLEM", 310, 335], ["b-wave amplitudes", "TEST", 362, 379], ["retinal interneurons (bipolar cell function", "PROBLEM", 397, 440], ["structural", "OBSERVATION_MODIFIER", 3, 13], ["abnormalities", "OBSERVATION", 14, 27], ["decreases", "OBSERVATION_MODIFIER", 228, 237], ["amplitude", "OBSERVATION_MODIFIER", 245, 254], ["a-wave", "OBSERVATION_MODIFIER", 262, 268], ["suggesting", "UNCERTAINTY", 299, 309], ["photoreceptor dysfunction", "OBSERVATION", 310, 335], ["b-wave amplitudes", "OBSERVATION", 362, 379], ["retinal", "ANATOMY", 397, 404], ["interneurons", "ANATOMY_MODIFIER", 405, 417], ["bipolar cell", "OBSERVATION", 419, 431]]], ["However, scotopic ERGs (\u221225dB flash, fix on, backlight off 0.5HZ) also showed significant decreases in the b-wave amplitudes of dispase-injected PVR eyes, but no decreases in the a-wave amplitudes of dispase-injected PVR eyes, indicating that rod cell function was partially preserved.Enzyme-linked immunospot assay ::: ResultsAt the 1, 2, 4, 6, and 8 week time points, IFN-\u03b3 values were only detected in the single-cell suspensions of the T cells of dispase-injected mice at 4 and 8 weeks.", [["PVR eyes", "ANATOMY", 145, 153], ["PVR eyes", "ANATOMY", 217, 225], ["rod cell", "ANATOMY", 243, 251], ["cell", "ANATOMY", 416, 420], ["T cells", "ANATOMY", 440, 447], ["eyes", "ORGAN", 149, 153], ["dispase", "GENE_OR_GENE_PRODUCT", 200, 207], ["eyes", "ORGAN", 221, 225], ["rod cell", "CELL", 243, 251], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 370, 375], ["T cells", "CELL", 440, 447], ["dispase", "GENE_OR_GENE_PRODUCT", 451, 458], ["mice", "ORGANISM", 468, 472], ["IFN", "PROTEIN", 370, 373], ["\u03b3", "PROTEIN", 374, 375], ["T cells", "CELL_TYPE", 440, 447], ["mice", "SPECIES", 468, 472], ["mice", "SPECIES", 468, 472], ["scotopic ERGs", "TEST", 9, 22], ["significant decreases in the b-wave amplitudes of dispase", "PROBLEM", 78, 135], ["dispase", "PROBLEM", 200, 207], ["rod cell function", "PROBLEM", 243, 260], ["Enzyme", "TEST", 285, 291], ["immunospot assay", "TEST", 299, 315], ["ResultsAt", "TEST", 320, 329], ["IFN-\u03b3 values", "TEST", 370, 382], ["scotopic ERGs", "OBSERVATION", 9, 22], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["decreases", "OBSERVATION_MODIFIER", 90, 99], ["b-wave amplitudes", "OBSERVATION", 107, 124], ["no", "UNCERTAINTY", 159, 161], ["decreases", "OBSERVATION_MODIFIER", 162, 171], ["a-wave amplitudes", "OBSERVATION", 179, 196], ["rod cell function", "OBSERVATION", 243, 260]]], ["However, when compared with those in the positive control (stimulated with PHA), there was no immune reaction in dispase-injected mice or in saline-injected mice (Figure 7).", [["PHA", "CHEMICAL", 75, 78], ["PHA", "CHEMICAL", 75, 78], ["PHA", "SIMPLE_CHEMICAL", 75, 78], ["dispase", "SIMPLE_CHEMICAL", 113, 120], ["mice", "ORGANISM", 130, 134], ["saline", "SIMPLE_CHEMICAL", 141, 147], ["mice", "ORGANISM", 157, 161], ["PHA", "PROTEIN", 75, 78], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 157, 161], ["immune reaction", "PROBLEM", 94, 109], ["dispase", "PROBLEM", 113, 120], ["saline", "TREATMENT", 141, 147], ["no", "UNCERTAINTY", 91, 93], ["immune reaction", "OBSERVATION", 94, 109]]], ["IL-2 was not detected at 1, 2, 4, 6, or 8 weeks in either dispase-injected mice or saline-injected mice.Intracellular staining ::: ResultsTo test if IFN-\u03b3 was secreted from the spleens of the dispase-injected mice at 4 weeks, intracellular staining was performed.", [["Intracellular", "ANATOMY", 104, 117], ["spleens", "ANATOMY", 177, 184], ["intracellular", "ANATOMY", 226, 239], ["IL-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["dispase", "GENE_OR_GENE_PRODUCT", 58, 65], ["mice", "ORGANISM", 75, 79], ["saline", "SIMPLE_CHEMICAL", 83, 89], ["mice", "ORGANISM", 99, 103], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 149, 154], ["spleens", "ORGAN", 177, 184], ["dispase", "GENE_OR_GENE_PRODUCT", 192, 199], ["mice", "ORGANISM", 209, 213], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 226, 239], ["IL", "PROTEIN", 0, 2], ["IFN", "PROTEIN", 149, 152], ["\u03b3", "PROTEIN", 153, 154], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 209, 213], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 209, 213], ["saline", "TREATMENT", 83, 89], ["Intracellular staining", "TEST", 104, 126], ["IFN", "TEST", 149, 152], ["the dispase", "TREATMENT", 188, 199], ["intracellular staining", "TEST", 226, 248], ["spleens", "ANATOMY", 177, 184]]], ["As shown in Figure 8, there were IFN-\u03b3+/CD4+ (0.061%) or IFN-\u03b3+/CD8+ (0.23%) T cells in the single-cell suspensions from the spleens of dispase-injected mice at 4 weeks.", [["IFN-\u03b3+/CD4+", "ANATOMY", 33, 44], ["IFN-\u03b3+/CD8+ (0.23%) T cells", "ANATOMY", 57, 84], ["single-cell suspensions", "ANATOMY", 92, 115], ["spleens", "ANATOMY", 125, 132], ["IFN", "GENE_OR_GENE_PRODUCT", 33, 36], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 36, 38], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["T cells", "CELL", 77, 84], ["single-cell", "CELL", 92, 103], ["spleens", "ORGAN", 125, 132], ["dispase", "GENE_OR_GENE_PRODUCT", 136, 143], ["mice", "ORGANISM", 153, 157], ["IFN", "PROTEIN", 33, 36], ["-\u03b3", "PROTEIN", 36, 38], ["CD4", "PROTEIN", 40, 43], ["IFN", "PROTEIN", 57, 60], ["CD8", "PROTEIN", 64, 67], ["T cells", "CELL_TYPE", 77, 84], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["IFN", "TEST", 33, 36], ["CD4", "TEST", 40, 43], ["IFN", "TEST", 57, 60], ["CD8", "TEST", 64, 67], ["T cells", "TEST", 77, 84], ["the single-cell suspensions", "TREATMENT", 88, 115], ["cell suspensions", "OBSERVATION", 99, 115], ["spleens", "ANATOMY", 125, 132]]], ["The above results indicate that IFN-\u03b3 was not secreted by CD4+ or CD8+ labeled T cells in dispase-injected mice.DiscussionRecently, there has been an increasing trend to induce the PVR model using dispase [1-9].", [["CD4+", "ANATOMY", 58, 62], ["CD8+ labeled T cells", "ANATOMY", 66, 86], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 32, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["T cells", "CELL", 79, 86], ["dispase", "GENE_OR_GENE_PRODUCT", 90, 97], ["mice", "ORGANISM", 107, 111], ["IFN", "PROTEIN", 32, 35], ["\u03b3", "PROTEIN", 36, 37], ["CD4", "PROTEIN", 58, 61], ["CD8", "PROTEIN", 66, 69], ["T cells", "CELL_TYPE", 79, 86], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["IFN", "TEST", 32, 35], ["CD4", "TEST", 58, 61], ["CD8", "TEST", 66, 69], ["an increasing trend", "PROBLEM", 147, 166], ["the PVR model", "TEST", 177, 190], ["dispase", "TEST", 197, 204], ["increasing", "OBSERVATION_MODIFIER", 150, 160], ["PVR", "OBSERVATION", 181, 184]]], ["In our study, we successfully replicated the murine PVR model and observed the ocular pathogenesis and immune reaction after intravitreal injection of dispase.", [["ocular", "ANATOMY", 79, 85], ["murine", "ORGANISM", 45, 51], ["murine", "SPECIES", 45, 51], ["our study", "TEST", 3, 12], ["the murine PVR model", "TEST", 41, 61], ["the ocular pathogenesis", "PROBLEM", 75, 98], ["immune reaction", "PROBLEM", 103, 118], ["intravitreal injection of dispase", "TREATMENT", 125, 158], ["murine PVR", "OBSERVATION", 45, 55], ["ocular", "ANATOMY", 79, 85]]], ["This was the first demonstration indicating that neutrophil cells appeared in the anterior chamber of eyes and that specific immune reactions were not involved after intravitreal dispase injection in mice.DiscussionPVR can be induced via intravitreal injection of different revulsants, such as RPE cells [36,37], macrophages [38,39], and fibroblasts [40].", [["neutrophil cells", "ANATOMY", 49, 65], ["anterior chamber", "ANATOMY", 82, 98], ["eyes", "ANATOMY", 102, 106], ["RPE cells", "ANATOMY", 294, 303], ["macrophages", "ANATOMY", 313, 324], ["fibroblasts", "ANATOMY", 338, 349], ["neutrophil cells", "CELL", 49, 65], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 82, 98], ["eyes", "ORGAN", 102, 106], ["mice", "ORGANISM", 200, 204], ["RPE cells", "CELL", 294, 303], ["macrophages", "CELL", 313, 324], ["fibroblasts", "CELL", 338, 349], ["neutrophil cells", "CELL_TYPE", 49, 65], ["RPE cells", "CELL_TYPE", 294, 303], ["macrophages", "CELL_TYPE", 313, 324], ["fibroblasts", "CELL_TYPE", 338, 349], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 200, 204], ["neutrophil cells", "PROBLEM", 49, 65], ["specific immune reactions", "PROBLEM", 116, 141], ["intravitreal dispase injection", "TREATMENT", 166, 196], ["intravitreal injection of different revulsants", "TREATMENT", 238, 284], ["RPE cells", "TEST", 294, 303], ["macrophages", "TEST", 313, 324], ["neutrophil cells", "OBSERVATION", 49, 65], ["anterior", "ANATOMY_MODIFIER", 82, 90], ["chamber", "ANATOMY_MODIFIER", 91, 98], ["eyes", "ANATOMY", 102, 106]]], ["Compared with these revulsants, dispase is easily available and does not lead to exogenous cell development in the PVR model.", [["cell", "ANATOMY", 91, 95], ["cell", "CELL", 91, 95], ["the PVR model", "TEST", 111, 124], ["exogenous cell", "OBSERVATION", 81, 95], ["PVR model", "OBSERVATION", 115, 124]]], ["Hence, in the mouse PVR model, dispase induced a PVR-like condition with a strong contribution of macrophage- and glial-derived cells [1].", [["macrophage", "ANATOMY", 98, 108], ["glial-derived cells", "ANATOMY", 114, 133], ["mouse", "ORGANISM", 14, 19], ["macrophage", "CELL", 98, 108], ["glial-derived cells", "CELL", 114, 133], ["macrophage", "CELL_TYPE", 98, 108], ["glial-derived cells", "CELL_TYPE", 114, 133], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["dispase", "PROBLEM", 31, 38], ["a PVR-like condition", "PROBLEM", 47, 67], ["macrophage", "TEST", 98, 108], ["PVR", "OBSERVATION", 49, 52], ["macrophage", "OBSERVATION", 98, 108]]], ["Regarding the rabbit PVR model, several authors have reported effects of matrix metalloproteinases [4] and a DNA-RNA chimeric ribozyme-targeted proliferating cell nuclear antigen [5].", [["rabbit", "ORGANISM", 14, 20], ["matrix metalloproteinases [4", "GENE_OR_GENE_PRODUCT", 73, 101], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["proliferating cell nuclear antigen", "GENE_OR_GENE_PRODUCT", 144, 178], ["matrix metalloproteinases", "PROTEIN", 73, 98], ["DNA-RNA chimeric ribozyme", "PROTEIN", 109, 134], ["proliferating cell nuclear antigen", "PROTEIN", 144, 178], ["rabbit", "SPECIES", 14, 20], ["rabbit", "SPECIES", 14, 20], ["the rabbit PVR model", "TEST", 10, 30], ["matrix metalloproteinases", "PROBLEM", 73, 98], ["a DNA", "TEST", 107, 112], ["RNA chimeric ribozyme", "TREATMENT", 113, 134], ["targeted proliferating cell nuclear antigen", "PROBLEM", 135, 178], ["rabbit PVR", "OBSERVATION", 14, 24], ["proliferating cell", "OBSERVATION", 144, 162]]], ["Researchers have also reported M\u00fcller glial cells displaying upregulation of purinergic P2 receptor\u2013mediated responses [6,7] and the interaction of cell surface molecules, extracellular matrix proteins, cytoskeletal elements [8], and a foldable capsular vitreous body [9] in PVR.", [["M\u00fcller glial cells", "ANATOMY", 31, 49], ["cell surface", "ANATOMY", 148, 160], ["extracellular matrix", "ANATOMY", 172, 192], ["cytoskeletal", "ANATOMY", 203, 215], ["vitreous body", "ANATOMY", 254, 267], ["M\u00fcller glial cells", "CELL", 31, 49], ["cell", "CELL", 148, 152], ["extracellular matrix", "CELLULAR_COMPONENT", 172, 192], ["M\u00fcller glial cells", "CELL_TYPE", 31, 49], ["cell surface molecules", "PROTEIN", 148, 170], ["extracellular matrix proteins", "PROTEIN", 172, 201], ["extracellular matrix proteins", "TEST", 172, 201], ["cytoskeletal elements", "TEST", 203, 224], ["a foldable capsular vitreous body", "TREATMENT", 234, 267], ["PVR", "TEST", 275, 278], ["glial cells", "OBSERVATION", 38, 49], ["cytoskeletal elements", "OBSERVATION", 203, 224], ["PVR", "OBSERVATION", 275, 278]]], ["However, due to complications such as cataracts and lens dissolution after dispase injection, the eye fundi of mice have been impossible to observe via microscope in this and other studies [31].", [["lens", "ANATOMY", 52, 56], ["eye", "ANATOMY", 98, 101], ["cataracts", "DISEASE", 38, 47], ["eye", "ORGAN", 98, 101], ["mice", "ORGANISM", 111, 115], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["complications", "PROBLEM", 16, 29], ["cataracts", "PROBLEM", 38, 47], ["lens dissolution", "TREATMENT", 52, 68], ["dispase injection", "TREATMENT", 75, 92], ["microscope", "TEST", 152, 162], ["other studies", "TEST", 175, 188], ["cataracts", "OBSERVATION", 38, 47], ["lens", "OBSERVATION_MODIFIER", 52, 56], ["dissolution", "OBSERVATION_MODIFIER", 57, 68]]], ["Therefore, we modified the PVR development from the five scores used by Suburo\u2019s group [1] to three scores.", [["the PVR development", "TREATMENT", 23, 42], ["PVR", "OBSERVATION", 27, 30]]], ["Once cataracts and uneven irises occur, tractional retinal detachment is inevitable in model eyes.", [["retinal", "ANATOMY", 51, 58], ["eyes", "ANATOMY", 93, 97], ["cataracts", "DISEASE", 5, 14], ["retinal detachment", "DISEASE", 51, 69], ["retinal", "MULTI-TISSUE_STRUCTURE", 51, 58], ["eyes", "ORGAN", 93, 97], ["cataracts", "PROBLEM", 5, 14], ["uneven irises", "PROBLEM", 19, 32], ["tractional retinal detachment", "PROBLEM", 40, 69], ["cataracts", "OBSERVATION", 5, 14], ["tractional", "OBSERVATION_MODIFIER", 40, 50], ["retinal", "ANATOMY", 51, 58], ["detachment", "OBSERVATION", 59, 69]]], ["We confirmed this result based on the H&E and immunofluorescence analysis of the frozen sections.DiscussionRegarding the early stage of PVR, we first reported that neutrophils were the main inflammatory infiltrating cells appearing at the anterior chamber instead of the vitreous cavity during early inflammatory infiltration (i.e., before 5 days), as shown in Figure 1, Figure 2 and Figure 3.", [["sections", "ANATOMY", 88, 96], ["neutrophils", "ANATOMY", 164, 175], ["inflammatory infiltrating cells", "ANATOMY", 190, 221], ["anterior chamber", "ANATOMY", 239, 255], ["vitreous cavity", "ANATOMY", 271, 286], ["neutrophils", "CELL", 164, 175], ["inflammatory infiltrating cells", "CELL", 190, 221], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 239, 255], ["vitreous cavity", "MULTI-TISSUE_STRUCTURE", 271, 286], ["neutrophils", "CELL_TYPE", 164, 175], ["inflammatory infiltrating cells", "CELL_TYPE", 190, 221], ["the H&E", "TEST", 34, 41], ["immunofluorescence analysis", "TEST", 46, 73], ["the frozen sections", "TEST", 77, 96], ["PVR", "TEST", 136, 139], ["neutrophils", "TEST", 164, 175], ["the main inflammatory infiltrating cells", "PROBLEM", 181, 221], ["early inflammatory infiltration", "PROBLEM", 294, 325], ["PVR", "OBSERVATION", 136, 139], ["main", "OBSERVATION_MODIFIER", 185, 189], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["infiltrating cells", "OBSERVATION", 203, 221], ["anterior", "ANATOMY_MODIFIER", 239, 247], ["chamber", "ANATOMY_MODIFIER", 248, 255], ["vitreous cavity", "ANATOMY", 271, 286], ["early", "OBSERVATION_MODIFIER", 294, 299], ["inflammatory", "OBSERVATION_MODIFIER", 300, 312], ["infiltration", "OBSERVATION", 313, 325]]], ["One explanation for these infiltrating cells during the time between 8 h and 48 h after dispase injection might be a break of the blood vessel integrity near the ciliary body caused by dispase itself or methodological variations.", [["infiltrating cells", "ANATOMY", 26, 44], ["blood vessel", "ANATOMY", 130, 142], ["ciliary body", "ANATOMY", 162, 174], ["infiltrating cells", "CELL", 26, 44], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 130, 142], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 162, 174], ["infiltrating cells", "CELL_TYPE", 26, 44], ["these infiltrating cells", "PROBLEM", 20, 44], ["dispase injection", "TREATMENT", 88, 105], ["methodological variations", "PROBLEM", 203, 228], ["infiltrating", "OBSERVATION", 26, 38], ["blood vessel", "ANATOMY", 130, 142], ["ciliary body", "ANATOMY", 162, 174], ["dispase", "OBSERVATION", 185, 192]]], ["These neutrophils might represent separate events in the etiology of PVR.", [["neutrophils", "ANATOMY", 6, 17], ["PVR", "DISEASE", 69, 72], ["neutrophils", "CELL", 6, 17], ["neutrophils", "CELL_TYPE", 6, 17], ["separate events", "PROBLEM", 34, 49], ["PVR", "PROBLEM", 69, 72], ["might represent", "UNCERTAINTY", 18, 33], ["PVR", "OBSERVATION", 69, 72]]], ["In addition, no CD3+ labeled T cells, F4/80+ labeled macrophages, or CD56+ labeled NK cells appeared in the vitreous cavities or retinas before 5 days.", [["CD3+ labeled T cells", "ANATOMY", 16, 36], ["macrophages", "ANATOMY", 53, 64], ["NK cells", "ANATOMY", 83, 91], ["vitreous cavities", "ANATOMY", 108, 125], ["retinas", "ANATOMY", 129, 136], ["CD3", "GENE_OR_GENE_PRODUCT", 16, 19], ["T cells", "CELL", 29, 36], ["macrophages", "CELL", 53, 64], ["CD56", "GENE_OR_GENE_PRODUCT", 69, 73], ["NK cells", "CELL", 83, 91], ["vitreous cavities", "MULTI-TISSUE_STRUCTURE", 108, 125], ["retinas", "MULTI-TISSUE_STRUCTURE", 129, 136], ["CD3", "PROTEIN", 16, 19], ["T cells", "CELL_TYPE", 29, 36], ["macrophages", "CELL_TYPE", 53, 64], ["CD56+ labeled NK cells", "CELL_TYPE", 69, 91], ["CD3", "TEST", 16, 19], ["labeled T cells", "TEST", 21, 36], ["F4", "TEST", 38, 40], ["macrophages", "TEST", 53, 64], ["CD56", "TEST", 69, 73], ["NK cells", "TEST", 83, 91], ["no", "UNCERTAINTY", 13, 15], ["labeled NK cells", "OBSERVATION", 75, 91], ["vitreous cavities", "ANATOMY", 108, 125], ["retinas", "ANATOMY", 129, 136]]], ["This is likely due to the strong digestive functions of the dispase enzyme.DiscussionThe role of inflammatory and immune cells in PVR membranes in the late stage of PVR has been reported in several studies [1,18,26,41].", [["digestive", "ANATOMY", 33, 42], ["immune cells", "ANATOMY", 114, 126], ["PVR membranes", "ANATOMY", 130, 143], ["dispase enzyme", "GENE_OR_GENE_PRODUCT", 60, 74], ["immune cells", "CELL", 114, 126], ["PVR membranes", "CELLULAR_COMPONENT", 130, 143], ["dispase enzyme", "PROTEIN", 60, 74], ["inflammatory and immune cells", "CELL_TYPE", 97, 126], ["the dispase enzyme", "TEST", 56, 74], ["inflammatory and immune cells", "PROBLEM", 97, 126], ["PVR membranes", "TREATMENT", 130, 143], ["PVR", "PROBLEM", 165, 168], ["likely due to", "UNCERTAINTY", 8, 21], ["inflammatory", "OBSERVATION_MODIFIER", 97, 109], ["immune cells", "OBSERVATION", 114, 126], ["PVR membranes", "OBSERVATION", 130, 143], ["late stage", "OBSERVATION_MODIFIER", 151, 161], ["PVR", "OBSERVATION", 165, 168]]], ["Suburo\u2019s group showed that CD3 immunoreactivity was not detected in saline- or dispase-injected eyes [1].", [["eyes", "ANATOMY", 96, 100], ["CD3", "GENE_OR_GENE_PRODUCT", 27, 30], ["saline", "SIMPLE_CHEMICAL", 68, 74], ["dispase", "SIMPLE_CHEMICAL", 79, 86], ["eyes", "ORGAN", 96, 100], ["CD3", "PROTEIN", 27, 30], ["CD3 immunoreactivity", "TEST", 27, 47], ["dispase", "PROBLEM", 79, 86]]], ["T lymphocytes were found in five of the eight subretinal membranes.", [["T lymphocytes", "ANATOMY", 0, 13], ["subretinal membranes", "ANATOMY", 46, 66], ["T lymphocytes", "CELL", 0, 13], ["subretinal membranes", "CELLULAR_COMPONENT", 46, 66], ["T lymphocytes", "CELL_TYPE", 0, 13], ["T lymphocytes", "TEST", 0, 13], ["lymphocytes", "OBSERVATION", 2, 13], ["five", "ANATOMY_MODIFIER", 28, 32], ["eight", "ANATOMY_MODIFIER", 40, 45], ["subretinal membranes", "OBSERVATION", 46, 66]]], ["CD4+ T cells were demonstrated in four of the membranes and CD8+ T cells in one of the membranes.", [["CD4+ T cells", "ANATOMY", 0, 12], ["membranes", "ANATOMY", 46, 55], ["CD8+", "ANATOMY", 60, 64], ["T cells", "ANATOMY", 65, 72], ["membranes", "ANATOMY", 87, 96], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["T cells", "CELL", 65, 72], ["membranes", "CELLULAR_COMPONENT", 87, 96], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["CD8", "PROTEIN", 60, 63], ["T cells", "CELL_TYPE", 65, 72], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["T cells", "OBSERVATION", 5, 12], ["CD8", "OBSERVATION", 60, 63], ["one of", "ANATOMY_MODIFIER", 76, 82], ["membranes", "ANATOMY_MODIFIER", 87, 96]]], ["T cells bearing the IL-2 receptor were found in two of four membranes studied.", [["T cells", "ANATOMY", 0, 7], ["membranes", "ANATOMY", 60, 69], ["T cells", "CELL", 0, 7], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 20, 33], ["membranes", "CELLULAR_COMPONENT", 60, 69], ["T cells", "CELL_TYPE", 0, 7], ["IL-2 receptor", "PROTEIN", 20, 33], ["four membranes", "ANATOMY_MODIFIER", 55, 69]]], ["Macrophages were found in four membranes.", [["Macrophages", "ANATOMY", 0, 11], ["membranes", "ANATOMY", 31, 40], ["Macrophages", "CELL", 0, 11], ["membranes", "CELLULAR_COMPONENT", 31, 40], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "PROBLEM", 0, 11], ["four membranes", "OBSERVATION_MODIFIER", 26, 40]]], ["No B lymphocytes or neutrophils were observed, and there were no significant deposits of complement or immunoglobulins [18].", [["B lymphocytes", "ANATOMY", 3, 16], ["neutrophils", "ANATOMY", 20, 31], ["B lymphocytes", "CELL", 3, 16], ["neutrophils", "CELL", 20, 31], ["complement", "GENE_OR_GENE_PRODUCT", 89, 99], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 103, 118], ["B lymphocytes", "CELL_TYPE", 3, 16], ["neutrophils", "CELL_TYPE", 20, 31], ["immunoglobulins", "PROTEIN", 103, 118], ["B lymphocytes", "PROBLEM", 3, 16], ["neutrophils", "PROBLEM", 20, 31], ["significant deposits of complement", "PROBLEM", 65, 99], ["immunoglobulins", "TEST", 103, 118], ["B lymphocytes", "OBSERVATION", 3, 16], ["neutrophils", "OBSERVATION", 20, 31], ["no", "UNCERTAINTY", 62, 64], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["deposits", "OBSERVATION", 77, 85]]], ["The findings of Canataroglu et al. suggest that IL-6 and IL-8 may be involved in the pathogenesis of proliferative diabetic retinopathy (PDR), PVR, and traumatic PVR.", [["proliferative diabetic retinopathy", "DISEASE", 101, 135], ["PDR", "DISEASE", 137, 140], ["PVR", "DISEASE", 143, 146], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-8", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-6", "PROTEIN", 48, 52], ["IL-8", "PROTEIN", 57, 61], ["Canataroglu et al", "TREATMENT", 16, 33], ["IL", "TEST", 48, 50], ["proliferative diabetic retinopathy", "PROBLEM", 101, 135], ["PVR", "TEST", 143, 146], ["traumatic PVR", "PROBLEM", 152, 165], ["proliferative", "OBSERVATION_MODIFIER", 101, 114], ["diabetic retinopathy", "OBSERVATION", 115, 135], ["traumatic PVR", "OBSERVATION", 152, 165]]], ["Cytological examination of the vitreous specimens revealed a predominance of macrophages (50%) in the PDR samples and a predominance of RPE cells (60%) in the PVR samples.", [["vitreous specimens", "ANATOMY", 31, 49], ["macrophages", "ANATOMY", 77, 88], ["samples", "ANATOMY", 106, 113], ["RPE cells", "ANATOMY", 136, 145], ["PVR samples", "ANATOMY", 159, 170], ["PDR", "DISEASE", 102, 105], ["vitreous specimens", "CANCER", 31, 49], ["macrophages", "CELL", 77, 88], ["RPE cells", "CELL", 136, 145], ["PVR samples", "CANCER", 159, 170], ["macrophages", "CELL_TYPE", 77, 88], ["RPE cells", "CELL_TYPE", 136, 145], ["Cytological examination", "TEST", 0, 23], ["the vitreous specimens", "TEST", 27, 49], ["macrophages", "PROBLEM", 77, 88], ["the PDR samples", "TEST", 98, 113], ["RPE cells", "TEST", 136, 145], ["the PVR samples", "TEST", 155, 170], ["predominance", "OBSERVATION_MODIFIER", 61, 73], ["macrophages", "OBSERVATION", 77, 88], ["RPE cells", "OBSERVATION", 136, 145], ["PVR", "OBSERVATION", 159, 162]]], ["In contrast, neutrophils predominated (88%) in the traumatic PVR samples [26].", [["neutrophils", "ANATOMY", 13, 24], ["PVR samples", "ANATOMY", 61, 72], ["neutrophils", "CELL", 13, 24], ["neutrophils", "CELL_TYPE", 13, 24], ["neutrophils", "TEST", 13, 24], ["the traumatic PVR samples", "TEST", 47, 72], ["traumatic PVR", "OBSERVATION", 51, 64]]], ["Using the monoclonal antibodies EBM11 (pan macrophage) and 27E10 (early inflammatory stage marker), Esser et al. [41] observed that macrophages were predominantly found in traumatic PVR.", [["macrophages", "ANATOMY", 132, 143], ["EBM11", "GENE_OR_GENE_PRODUCT", 32, 37], ["macrophages", "CELL", 132, 143], ["monoclonal antibodies", "PROTEIN", 10, 31], ["EBM11", "PROTEIN", 32, 37], ["27E10", "PROTEIN", 59, 64], ["macrophages", "CELL_TYPE", 132, 143], ["the monoclonal antibodies", "TEST", 6, 31], ["traumatic PVR", "PROBLEM", 172, 185], ["inflammatory", "OBSERVATION_MODIFIER", 72, 84], ["traumatic PVR", "OBSERVATION", 172, 185]]], ["Inflammatory stage macrophages could not be detected in PVR following rhegmatogenous retinal detachment and idiopathic macular pucker.", [["Inflammatory stage macrophages", "ANATOMY", 0, 30], ["retinal", "ANATOMY", 85, 92], ["macular", "ANATOMY", 119, 126], ["rhegmatogenous retinal detachment", "DISEASE", 70, 103], ["idiopathic macular pucker", "DISEASE", 108, 133], ["macrophages", "CELL", 19, 30], ["retinal", "MULTI-TISSUE_STRUCTURE", 85, 92], ["macular", "TISSUE", 119, 126], ["Inflammatory stage macrophages", "CELL_TYPE", 0, 30], ["Inflammatory stage macrophages", "PROBLEM", 0, 30], ["PVR", "PROBLEM", 56, 59], ["rhegmatogenous retinal detachment", "PROBLEM", 70, 103], ["idiopathic macular pucker", "PROBLEM", 108, 133], ["macrophages", "OBSERVATION", 19, 30], ["could not be detected", "UNCERTAINTY", 31, 52], ["PVR", "OBSERVATION", 56, 59], ["rhegmatogenous retinal detachment", "OBSERVATION", 70, 103], ["idiopathic", "OBSERVATION_MODIFIER", 108, 118], ["macular pucker", "OBSERVATION", 119, 133]]], ["In a previous study, T lymphocytes were found in 18 of the 21 PVR specimens and generally constituted a small percentage of the total cell number.", [["T lymphocytes", "ANATOMY", 21, 34], ["PVR specimens", "ANATOMY", 62, 75], ["cell", "ANATOMY", 134, 138], ["T lymphocytes", "CELL", 21, 34], ["cell", "CELL", 134, 138], ["T lymphocytes", "CELL_TYPE", 21, 34], ["a previous study", "TEST", 3, 19], ["T lymphocytes", "TEST", 21, 34], ["the 21 PVR specimens", "TEST", 55, 75], ["small", "OBSERVATION_MODIFIER", 104, 109], ["percentage", "OBSERVATION_MODIFIER", 110, 120], ["total cell number", "OBSERVATION", 128, 145]]], ["CD4+ T cells were found in 14 of the 18 membranes containing T cells.", [["CD4+ T cells", "ANATOMY", 0, 12], ["membranes", "ANATOMY", 40, 49], ["T cells", "ANATOMY", 61, 68], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["membranes", "CELLULAR_COMPONENT", 40, 49], ["T cells", "CELL", 61, 68], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["T cells", "CELL_TYPE", 61, 68], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["T cells", "OBSERVATION", 5, 12], ["T cells", "OBSERVATION", 61, 68]]], ["Three of six frozen membranes contained T cells that were positive for the IL-2 receptor.", [["membranes", "ANATOMY", 20, 29], ["T cells", "ANATOMY", 40, 47], ["T cells", "CELL", 40, 47], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 75, 88], ["T cells", "CELL_TYPE", 40, 47], ["IL-2 receptor", "PROTEIN", 75, 88], ["T cells", "PROBLEM", 40, 47], ["the IL", "TREATMENT", 71, 77], ["frozen membranes", "OBSERVATION", 13, 29]]], ["Cells positive for the macrophage/monocyte marker were found in five of the 16 membranes studied.", [["Cells", "ANATOMY", 0, 5], ["macrophage", "ANATOMY", 23, 33], ["monocyte", "ANATOMY", 34, 42], ["membranes", "ANATOMY", 79, 88], ["Cells", "CELL", 0, 5], ["macrophage", "CELL", 23, 33], ["monocyte", "CELL", 34, 42], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["Cells", "TEST", 0, 5], ["the macrophage/monocyte marker", "TEST", 19, 49], ["macrophage", "OBSERVATION_MODIFIER", 23, 33], ["monocyte marker", "OBSERVATION", 34, 49], ["16 membranes", "OBSERVATION_MODIFIER", 76, 88]]], ["No B lymphocytes or neutrophils were observed, and there were no deposits of complement or immunoglobulins [42].DiscussionOur observations yielded similar results; that is, the intravitreal dispase injection induced PVR-like signs.", [["B lymphocytes", "ANATOMY", 3, 16], ["neutrophils", "ANATOMY", 20, 31], ["B lymphocytes", "CELL", 3, 16], ["neutrophils", "CELL", 20, 31], ["complement", "GENE_OR_GENE_PRODUCT", 77, 87], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 91, 106], ["B lymphocytes", "CELL_TYPE", 3, 16], ["neutrophils", "CELL_TYPE", 20, 31], ["immunoglobulins", "PROTEIN", 91, 106], ["B lymphocytes", "PROBLEM", 3, 16], ["neutrophils", "PROBLEM", 20, 31], ["deposits of complement", "PROBLEM", 65, 87], ["immunoglobulins", "TEST", 91, 106], ["the intravitreal dispase injection", "TREATMENT", 173, 207], ["PVR", "TEST", 216, 219], ["B", "OBSERVATION_MODIFIER", 3, 4], ["lymphocytes", "OBSERVATION", 5, 16], ["neutrophils", "OBSERVATION", 20, 31], ["no", "UNCERTAINTY", 62, 64], ["PVR", "OBSERVATION", 216, 219]]], ["Clinically significant PVR with retinal detachment developed in 75% of mice at 8 weeks, which is very similar to the 75% of mice [1] and 76% of rabbits [4] previously reported.", [["retinal", "ANATOMY", 32, 39], ["retinal detachment", "DISEASE", 32, 50], ["retinal", "MULTI-TISSUE_STRUCTURE", 32, 39], ["mice", "ORGANISM", 71, 75], ["mice", "ORGANISM", 124, 128], ["rabbits", "ORGANISM", 144, 151], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 124, 128], ["rabbits", "SPECIES", 144, 151], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 124, 128], ["significant PVR", "PROBLEM", 11, 26], ["retinal detachment", "PROBLEM", 32, 50], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["PVR", "OBSERVATION", 23, 26], ["retinal", "ANATOMY", 32, 39], ["detachment", "OBSERVATION", 40, 50]]], ["In our study, for confocal microscopy, double immunostaining for RPE65, GFAP, GS, and a-SMA labeled cells was involved in the development of PVR, which is very similar to other studies [1,43].", [["cells", "ANATOMY", 100, 105], ["RPE65", "GENE_OR_GENE_PRODUCT", 65, 70], ["GFAP", "GENE_OR_GENE_PRODUCT", 72, 76], ["GS", "GENE_OR_GENE_PRODUCT", 78, 80], ["a-SMA", "GENE_OR_GENE_PRODUCT", 86, 91], ["cells", "CELL", 100, 105], ["RPE65", "PROTEIN", 65, 70], ["GFAP", "PROTEIN", 72, 76], ["GS", "PROTEIN", 78, 80], ["a-SMA", "PROTEIN", 86, 91], ["our study", "TEST", 3, 12], ["confocal microscopy", "TEST", 18, 37], ["double immunostaining", "TEST", 39, 60], ["RPE65", "TEST", 65, 70], ["GFAP", "TEST", 72, 76], ["GS", "TEST", 78, 80], ["a-SMA labeled cells", "TEST", 86, 105], ["PVR", "TEST", 141, 144], ["other studies", "TEST", 171, 184], ["PVR", "OBSERVATION", 141, 144]]], ["GFAP is mainly expressed by astrocytes in the normal retinas of several species.", [["astrocytes", "ANATOMY", 28, 38], ["retinas", "ANATOMY", 53, 60], ["GFAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["astrocytes", "CELL", 28, 38], ["retinas", "MULTI-TISSUE_STRUCTURE", 53, 60], ["GFAP", "PROTEIN", 0, 4], ["astrocytes", "CELL_TYPE", 28, 38], ["GFAP", "TEST", 0, 4], ["astrocytes", "OBSERVATION", 28, 38], ["normal retinas", "OBSERVATION", 46, 60], ["several", "OBSERVATION_MODIFIER", 64, 71], ["species", "OBSERVATION_MODIFIER", 72, 79]]], ["M\u00fcller cells\u2019 staining for GFAP in normal retinas is very faint.", [["M\u00fcller cells", "ANATOMY", 0, 12], ["retinas", "ANATOMY", 42, 49], ["M\u00fcller cells", "CELL", 0, 12], ["GFAP", "GENE_OR_GENE_PRODUCT", 27, 31], ["retinas", "MULTI-TISSUE_STRUCTURE", 42, 49], ["M\u00fcller cells", "CELL_LINE", 0, 12], ["GFAP", "PROTEIN", 27, 31], ["GFAP", "TEST", 27, 31], ["normal retinas", "OBSERVATION", 35, 49], ["very", "OBSERVATION_MODIFIER", 53, 57], ["faint", "OBSERVATION", 58, 63]]], ["However, in pathologically changed retinas, M\u00fcller cells become immunopositive for GFAP in retinal detachment and PVR.", [["retinas", "ANATOMY", 35, 42], ["M\u00fcller cells", "ANATOMY", 44, 56], ["retinal", "ANATOMY", 91, 98], ["retinal detachment", "DISEASE", 91, 109], ["retinas", "CELL", 35, 42], ["M\u00fcller cells", "CELL", 44, 56], ["GFAP", "GENE_OR_GENE_PRODUCT", 83, 87], ["retinal", "MULTI-TISSUE_STRUCTURE", 91, 98], ["M\u00fcller cells", "CELL_TYPE", 44, 56], ["GFAP", "PROTEIN", 83, 87], ["M\u00fcller cells", "PROBLEM", 44, 56], ["GFAP", "TEST", 83, 87], ["retinal detachment", "PROBLEM", 91, 109], ["PVR", "PROBLEM", 114, 117], ["pathologically", "OBSERVATION", 12, 26], ["retinas", "ANATOMY", 35, 42], ["M\u00fcller cells", "OBSERVATION", 44, 56], ["retinal", "ANATOMY", 91, 98], ["detachment", "OBSERVATION", 99, 109], ["PVR", "OBSERVATION", 114, 117]]], ["GS is a marker for astrocytes.", [["astrocytes", "ANATOMY", 19, 29], ["astrocytes", "CELL", 19, 29], ["astrocytes", "CELL_TYPE", 19, 29], ["astrocytes", "PROBLEM", 19, 29]]], ["In retinas, many astrocytes with contact to ganglion cells also express GS.", [["retinas", "ANATOMY", 3, 10], ["astrocytes", "ANATOMY", 17, 27], ["ganglion cells", "ANATOMY", 44, 58], ["retinas", "MULTI-TISSUE_STRUCTURE", 3, 10], ["astrocytes", "CELL", 17, 27], ["ganglion cells", "CELL", 44, 58], ["GS", "GENE_OR_GENE_PRODUCT", 72, 74], ["astrocytes", "CELL_TYPE", 17, 27], ["ganglion cells", "CELL_TYPE", 44, 58], ["GS", "PROTEIN", 72, 74], ["retinas", "ANATOMY", 3, 10], ["many", "OBSERVATION_MODIFIER", 12, 16], ["astrocytes", "OBSERVATION", 17, 27], ["ganglion cells", "OBSERVATION", 44, 58]]], ["A-SMA is expressed by myofibroblasts.", [["myofibroblasts", "ANATOMY", 22, 36], ["A-SMA", "GENE_OR_GENE_PRODUCT", 0, 5], ["myofibroblasts", "CELL", 22, 36], ["SMA", "PROTEIN", 2, 5], ["myofibroblasts", "CELL_TYPE", 22, 36], ["myofibroblasts", "PROBLEM", 22, 36], ["SMA", "ANATOMY", 2, 5], ["myofibroblasts", "OBSERVATION", 22, 36]]], ["However, transdifferentiated RPE cells or macroglial cells (astrocytes as well as M\u00fcller cells) in epiretinal membranes of PVR eyes can also express this molecule.", [["RPE cells", "ANATOMY", 29, 38], ["macroglial cells", "ANATOMY", 42, 58], ["astrocytes", "ANATOMY", 60, 70], ["M\u00fcller cells", "ANATOMY", 82, 94], ["epiretinal membranes", "ANATOMY", 99, 119], ["PVR eyes", "ANATOMY", 123, 131], ["RPE cells", "CELL", 29, 38], ["macroglial cells", "CELL", 42, 58], ["astrocytes", "CELL", 60, 70], ["M\u00fcller cells", "CELL", 82, 94], ["epiretinal membranes", "MULTI-TISSUE_STRUCTURE", 99, 119], ["eyes", "ORGAN", 127, 131], ["transdifferentiated RPE cells", "CELL_LINE", 9, 38], ["macroglial cells", "CELL_TYPE", 42, 58], ["astrocytes", "CELL_TYPE", 60, 70], ["M\u00fcller cells", "CELL_TYPE", 82, 94], ["transdifferentiated RPE cells", "PROBLEM", 9, 38], ["macroglial cells (astrocytes", "PROBLEM", 42, 70], ["M\u00fcller cells", "PROBLEM", 82, 94], ["RPE cells", "OBSERVATION", 29, 38], ["macroglial cells", "OBSERVATION", 42, 58], ["epiretinal membranes", "OBSERVATION", 99, 119], ["PVR eyes", "OBSERVATION", 123, 131]]], ["The ERG results further confirmed that the retinal functions of mice had been significantly damaged.DiscussionOur results regarding the ELISpot assay and intracellular staining first showed that specific immune systems do not play a major role in the pathogenesis of PVR.", [["retinal", "ANATOMY", 43, 50], ["intracellular", "ANATOMY", 154, 167], ["PVR", "DISEASE", 267, 270], ["retinal", "MULTI-TISSUE_STRUCTURE", 43, 50], ["mice", "ORGANISM", 64, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 167], ["ERG", "PROTEIN", 4, 7], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["the ELISpot assay", "TEST", 132, 149], ["intracellular staining", "TEST", 154, 176], ["specific immune systems", "PROBLEM", 195, 218], ["PVR", "PROBLEM", 267, 270], ["retinal", "ANATOMY", 43, 50], ["PVR", "OBSERVATION", 267, 270]]], ["Although a great deal of information supports the role of the immune system in the development of PVR, the role of the immune system in the pathogenesis of PVR is still unclear.", [["immune system", "ANATOMY", 62, 75], ["immune system", "ANATOMY", 119, 132], ["PVR", "DISEASE", 156, 159], ["immune system", "ANATOMICAL_SYSTEM", 62, 75], ["PVR", "GENE_OR_GENE_PRODUCT", 98, 101], ["PVR", "PROBLEM", 98, 101], ["PVR", "PROBLEM", 156, 159], ["PVR", "OBSERVATION", 98, 101], ["PVR", "OBSERVATION", 156, 159]]], ["Data are sometimes contradictory, and it is difficult to establish whether the immune alterations seen in PVR are causes or consequences [30].", [["the immune alterations", "PROBLEM", 75, 97], ["PVR", "PROBLEM", 106, 109], ["PVR", "OBSERVATION", 106, 109]]], ["The results of a recent study did not support the assumption that CD44 has a functional role in the pathogenesis of PVR [8].", [["CD44", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD44", "PROTEIN", 66, 70], ["a recent study", "TEST", 15, 29], ["PVR", "TEST", 116, 119], ["PVR", "OBSERVATION", 116, 119]]], ["Although our ELISpot assay showed that INF-\u03b3 was detected in the single-cell suspensions of the T cells of dispase-injected mice at 4 and 8 weeks, when compared with those in the positive control (stimulated with PHA), there were no immune reactions in dispase- or in saline-injected mice (Figure 7).", [["cell", "ANATOMY", 72, 76], ["T cells", "ANATOMY", 96, 103], ["PHA", "CHEMICAL", 213, 216], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 39, 44], ["cell", "CELL", 72, 76], ["T cells", "CELL", 96, 103], ["dispase", "GENE_OR_GENE_PRODUCT", 107, 114], ["mice", "ORGANISM", 124, 128], ["PHA", "SIMPLE_CHEMICAL", 213, 216], ["saline", "SIMPLE_CHEMICAL", 268, 274], ["mice", "ORGANISM", 284, 288], ["INF-\u03b3", "PROTEIN", 39, 44], ["T cells", "CELL_TYPE", 96, 103], ["PHA", "PROTEIN", 213, 216], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 284, 288], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 284, 288], ["our ELISpot assay", "TEST", 9, 26], ["INF-\u03b3", "PROBLEM", 39, 44], ["immune reactions", "PROBLEM", 233, 249], ["dispase", "PROBLEM", 253, 260], ["saline", "TREATMENT", 268, 274], ["no", "UNCERTAINTY", 230, 232]]], ["Interestingly, there were few IFN-\u03b3+/CD4+ or IFN-\u03b3+/CD8+ T cells determined by intracellular staining at a maximum of 4 weeks in dispase-injected mice.", [["T cells", "ANATOMY", 57, 64], ["intracellular", "ANATOMY", 79, 92], ["IFN", "GENE_OR_GENE_PRODUCT", 30, 33], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 33, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["IFN", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 52, 55], ["T cells", "CELL", 57, 64], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 92], ["dispase", "GENE_OR_GENE_PRODUCT", 129, 136], ["mice", "ORGANISM", 146, 150], ["IFN", "PROTEIN", 30, 33], ["-\u03b3", "PROTEIN", 33, 35], ["CD4", "PROTEIN", 37, 40], ["IFN", "PROTEIN", 45, 48], ["CD8", "PROTEIN", 52, 55], ["T cells", "CELL_TYPE", 57, 64], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["IFN", "TEST", 30, 33], ["CD4", "TEST", 37, 40], ["IFN", "TEST", 45, 48], ["T cells", "PROBLEM", 57, 64], ["intracellular staining", "PROBLEM", 79, 101], ["intracellular staining", "OBSERVATION", 79, 101]]], ["Thus, the IFN-\u03b3 found was not secreted by CD4+ or CD8+ T cells in these mice.", [["CD4+", "ANATOMY", 42, 46], ["CD8+", "ANATOMY", 50, 54], ["T cells", "ANATOMY", 55, 62], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 10, 15], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["T cells", "CELL", 55, 62], ["mice", "ORGANISM", 72, 76], ["IFN", "PROTEIN", 10, 13], ["\u03b3", "PROTEIN", 14, 15], ["CD4", "PROTEIN", 42, 45], ["CD8", "PROTEIN", 50, 53], ["T cells", "CELL_TYPE", 55, 62], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["the IFN", "TEST", 6, 13], ["CD4", "TEST", 42, 45]]], ["It was concluded from these results that specific immune systems do not play a major role in the murine dispase-induced PVR model.DiscussionWhen compared with human PVR diseases, the murine dispase-induced PVR models expressed cardinal features of PVR in this study.", [["PVR diseases", "DISEASE", 165, 177], ["murine", "ORGANISM", 97, 103], ["human", "ORGANISM", 159, 164], ["murine", "ORGANISM", 183, 189], ["murine", "SPECIES", 97, 103], ["human", "SPECIES", 159, 164], ["murine", "SPECIES", 183, 189], ["human", "SPECIES", 159, 164], ["the murine dispase", "TREATMENT", 93, 111], ["PVR model", "TREATMENT", 120, 129], ["human PVR diseases", "PROBLEM", 159, 177], ["the murine dispase", "TREATMENT", 179, 197], ["PVR models", "PROBLEM", 206, 216], ["PVR", "PROBLEM", 248, 251], ["this study", "TEST", 255, 265], ["PVR", "OBSERVATION", 120, 123], ["PVR", "OBSERVATION", 206, 209], ["PVR", "OBSERVATION", 248, 251]]], ["Our data clearly showed that specific immune systems were not involved in the development of PVR.", [["PVR", "GENE_OR_GENE_PRODUCT", 93, 96], ["Our data", "TEST", 0, 8], ["specific immune systems", "PROBLEM", 29, 52], ["PVR", "PROBLEM", 93, 96], ["PVR", "OBSERVATION", 93, 96]]], ["Despite the prevalence of the autoimmune hypothesis for PVR, the present treatment of human PVR in clinics targets inflammation and proliferation.", [["inflammation", "DISEASE", 115, 127], ["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["the autoimmune hypothesis", "PROBLEM", 26, 51], ["PVR", "PROBLEM", 56, 59], ["human PVR", "TREATMENT", 86, 95], ["inflammation", "PROBLEM", 115, 127], ["proliferation", "PROBLEM", 132, 145], ["autoimmune", "OBSERVATION", 30, 40], ["human PVR", "OBSERVATION", 86, 95], ["proliferation", "OBSERVATION_MODIFIER", 132, 145]]], ["Triamcinolone acetonide is being used as an anti-inflammatory drug for early-stage treatment, and 5-Fluorouracil (5-FU) is being used as an antiproliferation drug in advanced-stage treatment [44,45].", [["Triamcinolone acetonide", "CHEMICAL", 0, 23], ["5-Fluorouracil", "CHEMICAL", 98, 112], ["5-FU", "CHEMICAL", 114, 118], ["Triamcinolone acetonide", "CHEMICAL", 0, 23], ["5-Fluorouracil", "CHEMICAL", 98, 112], ["5-FU", "CHEMICAL", 114, 118], ["Triamcinolone acetonide", "SIMPLE_CHEMICAL", 0, 23], ["5-Fluorouracil", "SIMPLE_CHEMICAL", 98, 112], ["5-FU", "SIMPLE_CHEMICAL", 114, 118], ["Triamcinolone acetonide", "TREATMENT", 0, 23], ["an anti-inflammatory drug", "TREATMENT", 41, 66], ["early-stage treatment", "TREATMENT", 71, 92], ["Fluorouracil (5-FU)", "TREATMENT", 100, 119], ["an antiproliferation drug", "TREATMENT", 137, 162], ["advanced-stage treatment", "TREATMENT", 166, 190]]], ["Therefore, dispase-induced murine PVR indeed models the human disease and can help us select drugs to treat PVR successfully.DiscussionIn conclusion, our data show that neutrophils in the anterior chamber and PVR-like signs in the retinas were found and that specific immune reactions were not involved after intravitreal dispase injection in mice.", [["neutrophils", "ANATOMY", 169, 180], ["anterior chamber", "ANATOMY", 188, 204], ["retinas", "ANATOMY", 231, 238], ["PVR", "DISEASE", 108, 111], ["murine", "ORGANISM", 27, 33], ["human", "ORGANISM", 56, 61], ["neutrophils", "CELL", 169, 180], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 188, 204], ["PVR", "GENE_OR_GENE_PRODUCT", 209, 212], ["retinas", "ORGAN", 231, 238], ["mice", "ORGANISM", 343, 347], ["neutrophils", "CELL_TYPE", 169, 180], ["murine", "SPECIES", 27, 33], ["human", "SPECIES", 56, 61], ["mice", "SPECIES", 343, 347], ["human", "SPECIES", 56, 61], ["mice", "SPECIES", 343, 347], ["dispase", "TEST", 11, 18], ["the human disease", "PROBLEM", 52, 69], ["drugs", "TREATMENT", 93, 98], ["PVR", "PROBLEM", 108, 111], ["our data", "TEST", 150, 158], ["neutrophils", "TEST", 169, 180], ["PVR", "TEST", 209, 212], ["signs in the retinas", "PROBLEM", 218, 238], ["specific immune reactions", "PROBLEM", 259, 284], ["intravitreal dispase injection", "TREATMENT", 309, 339], ["murine PVR", "OBSERVATION", 27, 37], ["PVR", "OBSERVATION", 108, 111], ["neutrophils", "OBSERVATION", 169, 180], ["anterior", "ANATOMY_MODIFIER", 188, 196], ["chamber", "ANATOMY_MODIFIER", 197, 204], ["PVR", "OBSERVATION", 209, 212], ["retinas", "ANATOMY", 231, 238]]]], "d3fc6dc0d94d4c3976dc3ceeaac0b74618412d91": [["We investigate the Brownian diffusion of particles in one spatial dimension and in the presence of finite regions within which particles can either evaporate or be reset to a given location.", [["the Brownian diffusion of particles", "PROBLEM", 15, 50], ["Brownian", "OBSERVATION_MODIFIER", 19, 27], ["diffusion", "OBSERVATION_MODIFIER", 28, 37], ["particles", "OBSERVATION_MODIFIER", 41, 50], ["one spatial dimension", "OBSERVATION_MODIFIER", 54, 75]]], ["For open boundary conditions, we highlight the appearance of a Brownian yet non-Gaussian diffusion: at long times, the particle distribution is non-Gaussian but its variance grows linearly in time.", [["open boundary conditions", "PROBLEM", 4, 28], ["a Brownian yet non-Gaussian diffusion", "PROBLEM", 61, 98]]], ["Moreover, we show that the effective diffusion coefficient of the particles in such systems is bounded from below by (1 \u2212 2/\u03c0) times their bare diffusion coefficient.", [["the effective diffusion coefficient of the particles in such systems", "PROBLEM", 23, 91], ["particles", "OBSERVATION_MODIFIER", 66, 75]]], ["For periodic boundary conditions, i.e., for diffusion on a ring with resetting, we demonstrate a \"gauge invariance\" of the spatial particle distribution for different choices of the resetting probability currents, in both stationary and non-stationary regimes.", [["periodic boundary conditions", "PROBLEM", 4, 32], ["non-stationary regimes", "TREATMENT", 237, 259], ["spatial", "OBSERVATION_MODIFIER", 123, 130], ["particle", "OBSERVATION_MODIFIER", 131, 139]]], ["Finally, we apply our findings to a stochastic biophysical model for the motion of RNA polymerases during transcriptional pauses, deriving analytically the distribution of the length of cleaved RNA transcripts and the efficiency of RNA cleavage in backtrack recovery.", [["RNA polymerases", "PROTEIN", 83, 98], ["cleaved RNA transcripts", "RNA", 186, 209], ["RNA polymerases", "PROBLEM", 83, 98], ["transcriptional pauses", "PROBLEM", 106, 128], ["cleaved RNA transcripts", "PROBLEM", 186, 209], ["RNA cleavage", "PROBLEM", 232, 244], ["RNA cleavage", "OBSERVATION", 232, 244]]]], "PMC7120959": [["PurposeProtect staff, patients, other persons and the environment against infection [1\u201310].Comprise", [["infection", "DISEASE", 74, 83], ["patients", "ORGANISM", 22, 30], ["persons", "ORGANISM", 38, 45], ["patients", "SPECIES", 22, 30], ["persons", "SPECIES", 38, 45], ["infection", "PROBLEM", 74, 83]]]], "PMC7092935": [], "d7c95cb99b73d1523194da0299c9b29799500d19": [["Introductioninto a multiprotein RNAi-induced silencing complex (RISC).", [["multiprotein RNAi-induced silencing complex", "PROTEIN", 19, 62], ["RISC", "PROTEIN", 64, 68], ["a multiprotein RNAi", "TREATMENT", 17, 36], ["multiprotein RNAi", "OBSERVATION", 19, 36]]], ["A catalytic component of RISC, Argonaute-2, then specifically cleaves the target RNA strand within RISC, thus destroying the target (2) .", [["RISC", "GENE_OR_GENE_PRODUCT", 25, 29], ["Argonaute-2", "GENE_OR_GENE_PRODUCT", 31, 42], ["RISC", "GENE_OR_GENE_PRODUCT", 99, 103], ["RISC", "PROTEIN", 25, 29], ["Argonaute", "PROTEIN", 31, 40], ["target RNA strand", "RNA", 74, 91], ["RISC", "CELL_TYPE", 99, 103], ["Argonaute", "TEST", 31, 40], ["catalytic", "OBSERVATION_MODIFIER", 2, 11], ["component", "OBSERVATION_MODIFIER", 12, 21], ["RISC", "OBSERVATION", 25, 29], ["Argonaute", "OBSERVATION", 31, 40], ["target", "OBSERVATION_MODIFIER", 74, 80], ["RNA strand", "OBSERVATION", 81, 91], ["RISC", "OBSERVATION_MODIFIER", 99, 103], ["target", "OBSERVATION_MODIFIER", 125, 131]]], ["Clearly, RNAi offers high specificity and efficacy in turning off the expression of target genes.IntroductionThe first successful antiviral application of siRNA in mammals was demonstrated against RSV (4) in cell culture, and the efficacy was later translated into the mouse model of RSV infection (5) .", [["cell culture", "ANATOMY", 208, 220], ["RSV infection", "DISEASE", 284, 297], ["RSV", "ORGANISM", 197, 200], ["cell culture", "CELL", 208, 220], ["mouse", "ORGANISM", 269, 274], ["RSV", "ORGANISM", 284, 287], ["target genes", "DNA", 84, 96], ["mouse", "SPECIES", 269, 274], ["RSV", "SPECIES", 197, 200], ["mouse", "SPECIES", 269, 274], ["RSV", "SPECIES", 284, 287], ["The first successful antiviral application of siRNA in mammals", "TREATMENT", 109, 171], ["RSV", "PROBLEM", 197, 200], ["cell culture", "TEST", 208, 220], ["RSV infection", "PROBLEM", 284, 297], ["RSV infection", "OBSERVATION", 284, 297]]], ["RSV is a nonsegmented single-stranded RNA virus of the Paramyxoviridae family.", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["In addition to RSV, a number of serious and life-threatening human and domestic animal viruses (e.g., mumps, measles, parainfluenza, borna, rabies, ebola, Hendra and Nipah) belong to this family (6) .", [["RSV", "DISEASE", 15, 18], ["mumps, measles, parainfluenza, borna, rabies, ebola, Hendra and Nipah)", "DISEASE", 102, 172], ["RSV", "ORGANISM", 15, 18], ["human", "ORGANISM", 61, 66], ["parainfluenza", "ORGANISM", 118, 131], ["borna", "ORGANISM", 133, 138], ["rabies", "ORGANISM", 140, 146], ["Hendra", "ORGANISM", 155, 161], ["Nipah", "ORGANISM", 166, 171], ["human", "SPECIES", 61, 66], ["parainfluenza", "SPECIES", 118, 131], ["RSV", "SPECIES", 15, 18], ["human", "SPECIES", 61, 66], ["RSV", "PROBLEM", 15, 18], ["mumps", "PROBLEM", 102, 107], ["parainfluenza", "PROBLEM", 118, 131], ["RSV", "OBSERVATION", 15, 18], ["serious", "OBSERVATION_MODIFIER", 32, 39], ["animal viruses", "OBSERVATION", 80, 94]]], ["Of note, the influenza (Flu) virus, belonging to the Orthomyxoviridae family, is also an RNA virus but contains a segmented genome.", [["influenza", "DISEASE", 13, 22], ["Flu", "CHEMICAL", 24, 27], ["influenza (Flu) virus", "ORGANISM", 13, 34], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 53, 69], ["segmented genome", "DNA", 114, 130], ["the influenza (Flu) virus", "PROBLEM", 9, 34], ["an RNA virus", "PROBLEM", 86, 98], ["RNA virus", "OBSERVATION", 89, 98], ["segmented genome", "OBSERVATION", 114, 130]]], ["Thus, an intranasal RNAi approach can also be effective against all respiratory viral diseases (7, 8) , including Flu (9) and SARS (10).IntroductionThe nasal route represents an improved siRNA delivery regimen compared to systemic approaches such as intravenous, intraperitoneal, or hydrodynamic tail vein injections, since it is convenient, noninvasive, and therapeutically effective.", [["nasal", "ANATOMY", 152, 157], ["intravenous", "ANATOMY", 250, 261], ["intraperitoneal", "ANATOMY", 263, 278], ["tail vein", "ANATOMY", 296, 305], ["respiratory viral diseases", "DISEASE", 68, 94], ["Flu", "CHEMICAL", 114, 117], ["SARS", "DISEASE", 126, 130], ["Flu", "CHEMICAL", 114, 117], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 261], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 263, 278], ["tail vein", "MULTI-TISSUE_STRUCTURE", 296, 305], ["an intranasal RNAi approach", "TREATMENT", 6, 33], ["all respiratory viral diseases", "PROBLEM", 64, 94], ["Flu", "TEST", 114, 117], ["SARS", "TEST", 126, 130], ["The nasal route", "TREATMENT", 148, 163], ["an improved siRNA delivery regimen", "TREATMENT", 175, 209], ["systemic approaches", "TREATMENT", 222, 241], ["intravenous, intraperitoneal", "TREATMENT", 250, 278], ["hydrodynamic tail vein injections", "TREATMENT", 283, 316], ["respiratory", "ANATOMY", 68, 79], ["viral", "OBSERVATION", 80, 85], ["nasal", "ANATOMY", 152, 157], ["improved", "OBSERVATION_MODIFIER", 178, 186], ["siRNA", "OBSERVATION", 187, 192], ["intraperitoneal", "ANATOMY", 263, 278], ["tail vein", "ANATOMY", 296, 305]]], ["It may also prove useful in treating debilitating noninfectious respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, and perhaps some forms of lung cancer, when combined with existing anticancer drugs.Introduction1. siRNA protected with 2\u00a2-ACE (5\u00a2-silyl-2\u00a2-acetoxy ethyl orthoester) chemistry (see Notes 1-4).Introduction2.", [["respiratory", "ANATOMY", 64, 75], ["pulmonary", "ANATOMY", 113, 122], ["cystic", "ANATOMY", 139, 145], ["lung cancer", "ANATOMY", 190, 201], ["anticancer", "ANATOMY", 231, 241], ["respiratory diseases", "DISEASE", 64, 84], ["chronic obstructive pulmonary disease", "DISEASE", 93, 130], ["COPD", "DISEASE", 132, 136], ["cystic fibrosis", "DISEASE", 139, 154], ["asthma", "DISEASE", 156, 162], ["lung cancer", "DISEASE", 190, 201], ["2\u00a2-ACE (5\u00a2-silyl-2\u00a2-acetoxy ethyl orthoester", "CHEMICAL", 284, 328], ["2\u00a2-ACE", "CHEMICAL", 284, 290], ["5\u00a2-silyl-2\u00a2-acetoxy ethyl orthoester", "CHEMICAL", 292, 328], ["pulmonary", "ORGAN", 113, 122], ["lung cancer", "CANCER", 190, 201], ["anticancer", "CANCER", 231, 241], ["2\u00a2-ACE", "SIMPLE_CHEMICAL", 284, 290], ["5\u00a2-silyl-2\u00a2-acetoxy ethyl orthoester", "SIMPLE_CHEMICAL", 292, 328], ["debilitating noninfectious respiratory diseases", "PROBLEM", 37, 84], ["chronic obstructive pulmonary disease", "PROBLEM", 93, 130], ["COPD)", "PROBLEM", 132, 137], ["cystic fibrosis", "PROBLEM", 139, 154], ["asthma", "PROBLEM", 156, 162], ["lung cancer", "PROBLEM", 190, 201], ["existing anticancer drugs", "TREATMENT", 222, 247], ["siRNA", "TEST", 263, 268], ["ACE", "TREATMENT", 287, 290], ["silyl", "TREATMENT", 295, 300], ["debilitating", "OBSERVATION_MODIFIER", 37, 49], ["noninfectious", "OBSERVATION_MODIFIER", 50, 63], ["respiratory diseases", "OBSERVATION", 64, 84], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["obstructive", "OBSERVATION_MODIFIER", 101, 112], ["pulmonary", "ANATOMY", 113, 122], ["disease", "OBSERVATION", 123, 130], ["COPD", "OBSERVATION", 132, 136], ["cystic", "OBSERVATION_MODIFIER", 139, 145], ["fibrosis", "OBSERVATION", 146, 154], ["asthma", "OBSERVATION", 156, 162], ["lung", "ANATOMY", 190, 194], ["cancer", "OBSERVATION", 195, 201]]], ["DEPC-treated water.Introduction3.", [["DEPC", "CHEMICAL", 0, 4], ["DEPC", "CHEMICAL", 0, 4], ["DEPC", "SIMPLE_CHEMICAL", 0, 4], ["DEPC", "TEST", 0, 4]]], ["RNase-free aerosol resistant pipette tips.Introduction4.", [["RNase", "GENE_OR_GENE_PRODUCT", 0, 5], ["RNase", "PROTEIN", 0, 5], ["RNase", "TEST", 0, 5], ["free aerosol resistant pipette tips", "TREATMENT", 6, 41], ["free", "OBSERVATION_MODIFIER", 6, 10], ["aerosol resistant", "OBSERVATION", 11, 28], ["pipette tips", "OBSERVATION", 29, 41]]], ["RNase-free microfuge tubes.", [["RNase", "GENE_OR_GENE_PRODUCT", 0, 5], ["RNase", "PROTEIN", 0, 5], ["RNase", "TEST", 0, 5], ["free microfuge tubes", "TREATMENT", 6, 26], ["free", "OBSERVATION_MODIFIER", 6, 10], ["microfuge tubes", "OBSERVATION", 11, 26]]], ["The dry pellet can be stored at \u221220\u00b0C until use or resuspended in the siRNA buffer or another appropriately buffered solution.IntroductionPrepare the siRNA-vehicle complex immediately before nasal administration.", [["nasal", "ANATOMY", 191, 196], ["nasal", "ORGANISM_SUBDIVISION", 191, 196], ["The dry pellet", "PROBLEM", 0, 14], ["the siRNA buffer", "TREATMENT", 66, 82], ["the siRNA-vehicle complex", "TREATMENT", 146, 171], ["nasal administration", "TREATMENT", 191, 211]]], ["Determine the optimal siRNA amount by titering from 3 to 15 nmol per mouse.Introduction1.", [["mouse", "ORGANISM", 69, 74], ["mouse", "SPECIES", 69, 74], ["mouse", "SPECIES", 69, 74]]], ["In a sterile, RNase-free plastic tube, add 35 mL of Opti-MEM reduced-serum medium.Introduction2.", [["serum", "ANATOMY", 69, 74], ["RNase", "GENE_OR_GENE_PRODUCT", 14, 19], ["tube", "TISSUE", 33, 37], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["RNase", "PROTEIN", 14, 19], ["RNase-free plastic tube", "TREATMENT", 14, 37], ["Opti-MEM reduced-serum medium", "TREATMENT", 52, 81], ["tube", "OBSERVATION", 33, 37], ["serum medium", "OBSERVATION_MODIFIER", 69, 81]]], ["Add 5 mL of the TransIT-TKO transfection reagent into the tube containing Opti-MEM medium.Introduction3.", [["tube", "ANATOMY", 58, 62], ["TransIT", "SIMPLE_CHEMICAL", 16, 23], ["tube", "TISSUE", 58, 62], ["the TransIT-TKO transfection reagent", "TREATMENT", 12, 48], ["the tube containing Opti-MEM medium", "TREATMENT", 54, 89], ["tube", "OBSERVATION", 58, 62]]], ["Incubate at room temperature for 10 min.siRNA-Vehicle Complex Formulation5.", [["siRNA", "TREATMENT", 40, 45]]], ["Add the desired amount of siRNA in 1 mL of siRNA buffer to the diluted TransIT-TKO reagent.siRNA-Vehicle Complex Formulation6.", [["TransIT", "SIMPLE_CHEMICAL", 71, 78], ["TransIT", "PROTEIN", 71, 78], ["siRNA", "TREATMENT", 26, 31], ["siRNA buffer", "TREATMENT", 43, 55], ["the diluted TransIT", "TREATMENT", 59, 78], ["amount", "OBSERVATION_MODIFIER", 16, 22], ["siRNA", "OBSERVATION", 26, 31]]], ["Carefully mix by gentle pipetting.siRNA-Vehicle Complex Formulation7.", [["gentle pipetting", "TREATMENT", 17, 33], ["siRNA", "TREATMENT", 34, 39]]], ["Incubate at room temperature for 20 min.siRNA-Vehicle Complex FormulationPrior to nasal administration of siRNA, mice (see Note 5) must be anesthetized to minimize any pain or discomfort.", [["nasal", "ANATOMY", 82, 87], ["pain", "DISEASE", 168, 172], ["nasal", "ORGANISM_SUBDIVISION", 82, 87], ["mice", "ORGANISM", 113, 117], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["nasal administration of siRNA", "TREATMENT", 82, 111], ["any pain", "PROBLEM", 164, 172], ["discomfort", "PROBLEM", 176, 186], ["nasal", "ANATOMY", 82, 87]]], ["Nembutal is administered by intraperitoneal (IP) injection at a recommended drug dosage of 50 mg/kg.", [["intraperitoneal", "ANATOMY", 28, 43], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 43], ["Nembutal", "TREATMENT", 0, 8], ["intraperitoneal (IP) injection", "TREATMENT", 28, 58]]], ["Test for the desired RNAi effect at appropriate intervals.", [["Test", "TEST", 0, 4]]], ["For antiviral studies, instill virus through the nostril as well.", [["nostril", "ANATOMY", 49, 56], ["nostril", "ORGAN", 49, 56], ["antiviral studies", "TEST", 4, 21], ["instill virus through the nostril", "TREATMENT", 23, 56], ["nostril", "ANATOMY", 49, 56]]], ["For human RSV, which does not infect mice well, use 10 7 -10 8 virus particles per animal, and measure standard lung titer assay and clinical symptoms, such as body weight and respiration rate.siRNA Administration1.", [["lung", "ANATOMY", 112, 116], ["body", "ANATOMY", 160, 164], ["human", "ORGANISM", 4, 9], ["RSV", "ORGANISM", 10, 13], ["mice", "ORGANISM", 37, 41], ["lung", "ORGAN", 112, 116], ["body", "ORGANISM_SUBDIVISION", 160, 164], ["human", "SPECIES", 4, 9], ["mice", "SPECIES", 37, 41], ["human", "SPECIES", 4, 9], ["RSV", "SPECIES", 10, 13], ["mice", "SPECIES", 37, 41], ["human RSV", "PROBLEM", 4, 13], ["standard lung titer assay", "TEST", 103, 128], ["clinical symptoms", "PROBLEM", 133, 150], ["body weight", "TEST", 160, 171], ["respiration rate", "TEST", 176, 192], ["RSV", "OBSERVATION", 10, 13], ["lung", "ANATOMY", 112, 116], ["titer", "OBSERVATION", 117, 122]]], ["It is assumed that the reader has expertise in designing siRNA against a given target.", [["siRNA", "TREATMENT", 57, 62]]], ["We also try to avoid the relatively strong immunogenic sequence: 5\u00a2GUCCUUCAA3\u00a2 (11).siRNA Administration2.", [["siRNA Administration2", "TREATMENT", 84, 105]]], ["Essentially all RNA viral genes are essential for robust virus growth, and hence the siRNA designed against any viral mRNA will inhibit virus replication.", [["RNA viral genes", "DNA", 16, 31], ["viral mRNA", "RNA", 112, 122], ["Essentially all RNA viral genes", "PROBLEM", 0, 31], ["robust virus growth", "PROBLEM", 50, 69], ["the siRNA", "TREATMENT", 81, 90], ["any viral mRNA", "PROBLEM", 108, 122], ["virus replication", "TREATMENT", 136, 153], ["viral genes", "OBSERVATION", 20, 31]]], ["Nonetheless, we generally target components of the viral RNA synthesis machinery; for Paramyxoviridae, they are: L (Large protein; RNA-dependent RNA polymerase), P (Phosphoprotein; a transcription factor for L), and N (Nucleocapsid protein; essential for the template function of the viral genomic RNA).siRNA Administration3.", [["Large protein", "GENE_OR_GENE_PRODUCT", 116, 129], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 131, 159], ["N (Nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 216, 239], ["Large protein", "PROTEIN", 116, 129], ["RNA-dependent RNA polymerase", "PROTEIN", 131, 159], ["P", "PROTEIN", 162, 163], ["Phosphoprotein", "PROTEIN", 165, 179], ["transcription factor", "PROTEIN", 183, 203], ["L", "PROTEIN", 208, 209], ["N", "PROTEIN", 216, 217], ["Nucleocapsid protein", "PROTEIN", 219, 239], ["viral genomic RNA", "RNA", 284, 301], ["the viral RNA synthesis machinery", "TREATMENT", 47, 80], ["Paramyxoviridae", "TREATMENT", 86, 101], ["RNA", "TEST", 131, 134], ["dependent RNA polymerase", "PROBLEM", 135, 159], ["a transcription factor", "TEST", 181, 203], ["N (Nucleocapsid protein", "TREATMENT", 216, 239], ["siRNA Administration3", "TREATMENT", 303, 324], ["viral genomic RNA", "OBSERVATION", 284, 301]]], ["For reasons of animal ethics and cost-saving, we always test a new siRNA sequence in cell culture for antiviral potency by measuring the progeny viral titer.", [["cell", "ANATOMY", 85, 89], ["cell culture", "CELL", 85, 97], ["siRNA sequence", "DNA", 67, 81], ["cost-saving", "TREATMENT", 33, 44], ["a new siRNA sequence", "TEST", 61, 81], ["cell culture", "TEST", 85, 97], ["antiviral potency", "TREATMENT", 102, 119], ["viral titer", "OBSERVATION", 145, 156]]], ["Use a range of concentrations from 2 to 200 nM; a potent siRNA should exhibit 90% inhibition at low nM concentrations (e.g., at a concentration below 20 nM).", [["a range of concentrations", "TREATMENT", 4, 29], ["a potent siRNA", "TREATMENT", 48, 62], ["low nM concentrations", "TREATMENT", 96, 117]]], ["With this criteria and using the design recommendations in Note 1, we have experienced a success rate of 80% (8 out of 10 siRNAs) over the years.siRNA Administration4.", [["a success rate", "TEST", 87, 101]]], ["Steps in Subheading 3.1 are not needed if fully deprotected, annealed, ready-to-use siRNA is purchased commercially, which are more expensive.", [["siRNA", "TREATMENT", 84, 89]]], ["To save cost, we usually purchase 2\u00a2-ACE protected RNA and deprotect it.", [["2\u00a2-ACE", "GENE_OR_GENE_PRODUCT", 34, 40], ["2\u00a2-ACE protected RNA", "RNA", 34, 54], ["ACE protected RNA", "TREATMENT", 37, 54]]], ["The 2\u00a2-ACE modification increases stability of the RNA during shipment and storage.", [["2\u00a2-ACE", "GENE_OR_GENE_PRODUCT", 4, 10], ["The 2\u00a2-ACE modification", "TREATMENT", 0, 23], ["the RNA", "PROBLEM", 47, 54], ["stability", "OBSERVATION_MODIFIER", 34, 43], ["RNA", "ANATOMY", 51, 54]]], ["We have described a simple method of nasal delivery of siRNA in the mouse model, but it can be successfully scaled up or down to use in other laboratory animals.", [["nasal", "ANATOMY", 37, 42], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["mouse", "ORGANISM", 68, 73], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 68, 73], ["nasal delivery of siRNA in the mouse model", "TREATMENT", 37, 79], ["simple", "OBSERVATION_MODIFIER", 20, 26], ["nasal", "ANATOMY", 37, 42], ["siRNA", "OBSERVATION", 55, 60]]], ["To diminish any possible toxic effect of delivery reagents, siRNA can be introduced \"naked,\" i.e., without transfection reagent, which exhibits about 70-80% activity of the reagentcomplexed siRNA.", [["delivery reagents", "TREATMENT", 41, 58], ["siRNA", "TREATMENT", 60, 65], ["transfection reagent", "TREATMENT", 107, 127], ["the reagentcomplexed siRNA", "PROBLEM", 169, 195], ["possible", "UNCERTAINTY", 16, 24], ["toxic", "OBSERVATION_MODIFIER", 25, 30], ["siRNA", "OBSERVATION", 190, 195]]], ["It is best not to use polyethyleneimine (PEI).", [["polyethyleneimine", "CHEMICAL", 22, 39], ["PEI", "CHEMICAL", 41, 44], ["polyethyleneimine", "CHEMICAL", 22, 39], ["PEI", "CHEMICAL", 41, 44], ["polyethyleneimine", "SIMPLE_CHEMICAL", 22, 39], ["PEI", "SIMPLE_CHEMICAL", 41, 44], ["polyethyleneimine (PEI", "TREATMENT", 22, 44]]], ["Although PEI is often used to form complexes with nucleic acids, mice do not tolerate PEI through the nose, although delivery through other avenues, such as intravenous, are well tolerated.", [["nose", "ANATOMY", 102, 106], ["intravenous", "ANATOMY", 157, 168], ["PEI", "CHEMICAL", 9, 12], ["nucleic acids", "CHEMICAL", 50, 63], ["PEI", "CHEMICAL", 86, 89], ["PEI", "CHEMICAL", 9, 12], ["PEI", "CHEMICAL", 86, 89], ["PEI", "SIMPLE_CHEMICAL", 9, 12], ["nucleic acids", "SIMPLE_CHEMICAL", 50, 63], ["mice", "ORGANISM", 65, 69], ["PEI", "SIMPLE_CHEMICAL", 86, 89], ["nose", "ORGAN", 102, 106], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 168], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["PEI", "TREATMENT", 9, 12], ["nucleic acids", "TREATMENT", 50, 63], ["PEI", "TREATMENT", 86, 89], ["delivery", "TREATMENT", 117, 125], ["nose", "ANATOMY", 102, 106]]], ["In our attempts, essentially all mice died within minutes of inhalation of PEI-siRNA complex.", [["PEI", "CHEMICAL", 75, 78], ["PEI", "CHEMICAL", 75, 78], ["mice", "ORGANISM", 33, 37], ["PEI", "GENE_OR_GENE_PRODUCT", 75, 78], ["siRNA complex", "PROTEIN", 79, 92], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["PEI-siRNA complex", "TREATMENT", 75, 92], ["siRNA complex", "OBSERVATION", 79, 92]]], ["New generation of transfection reagents are constantly being reported (12, 13) that may provide better delivery.Notes7.", [["Notes7", "PROTEIN", 112, 118], ["transfection reagents", "TREATMENT", 18, 39], ["transfection reagents", "OBSERVATION", 18, 39]]], ["Administration of excessive liquid will \"drown\" the mouse and cause death.", [["death", "DISEASE", 68, 73], ["mouse", "ORGANISM", 52, 57], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 52, 57], ["excessive liquid", "TREATMENT", 18, 34], ["death", "PROBLEM", 68, 73]]], ["Try to keep the total volume under 45 mL in routine application although up to 100 mL may be tolerated.", [["the total volume", "TREATMENT", 12, 28], ["routine application", "TREATMENT", 44, 63]]], ["The intranasal procedure also works in an aerosolized application.", [["The intranasal procedure", "TREATMENT", 0, 24], ["an aerosolized application", "TREATMENT", 39, 65]]], ["We have used small homemade enclosures in which the anesthetized mouse is placed and the siRNA complex (made as in Subheading 3.2) is sprayed by a hand-held nebulizer (the common type used as an inhaler by asthmatics).", [["hand", "ANATOMY", 147, 151], ["mouse", "ORGANISM", 65, 70], ["siRNA complex", "PROTEIN", 89, 102], ["mouse", "SPECIES", 65, 70], ["mouse", "SPECIES", 65, 70], ["small homemade enclosures", "TREATMENT", 13, 38], ["the anesthetized mouse", "TREATMENT", 48, 70], ["the siRNA complex", "PROBLEM", 85, 102], ["a hand-held nebulizer", "TREATMENT", 145, 166], ["small", "OBSERVATION_MODIFIER", 13, 18], ["homemade enclosures", "OBSERVATION", 19, 38]]], ["In this method, however, a larger amount of siRNA is needed because most of the mist gets wasted and only a small fraction is inhaled by the animal.", [["a larger amount of siRNA", "PROBLEM", 25, 49], ["a small fraction", "PROBLEM", 106, 122], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["amount", "OBSERVATION_MODIFIER", 34, 40], ["siRNA", "OBSERVATION", 44, 49], ["small", "OBSERVATION_MODIFIER", 108, 113], ["fraction", "OBSERVATION", 114, 122]]], ["To optimize cost vs. benefit, it is recommended that various amounts of mist and duration of exposure is tested and optimized for a given enclosure volume.", [["a given enclosure volume", "TREATMENT", 130, 154]]], ["If this method is to be routinely used, a commercial motorized nebulizer can be easily optimized.", [["a commercial motorized nebulizer", "TREATMENT", 40, 72]]], ["Modify the system by removing the plastic face cup (or mask) at the delivery end and insert the tube directly into the mouse enclosure.", [["face cup", "ANATOMY", 42, 50], ["tube", "ANATOMY", 96, 100], ["tube", "TISSUE", 96, 100], ["mouse", "ORGANISM", 119, 124], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 119, 124], ["the plastic face cup", "TREATMENT", 30, 50], ["mask", "TREATMENT", 55, 59], ["the tube", "TREATMENT", 92, 100], ["the mouse enclosure", "TREATMENT", 115, 134], ["tube", "OBSERVATION", 96, 100], ["mouse enclosure", "OBSERVATION", 119, 134]]], ["Reagent cost can be reduced by designing a smaller face cup to snugly fit the mouse nose area.", [["face cup", "ANATOMY", 51, 59], ["nose area", "ANATOMY", 84, 93], ["mouse", "ORGANISM", 78, 83], ["nose", "ORGANISM_SUBDIVISION", 84, 88], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["Reagent cost", "TREATMENT", 0, 12], ["a smaller face cup", "TREATMENT", 41, 59], ["reduced", "OBSERVATION_MODIFIER", 20, 27]]]], "a91212fd4e07887ce55f63a416af3f79140d3ec1": [["SummaryUnderstanding which arms of the immune response are responsible for protection against SARS-CoV-2 infection is key to predicting long-term immunity and to inform vaccine design.", [["SARS", "DISEASE", 94, 98], ["infection", "DISEASE", 105, 114], ["SARS-CoV-2", "ORGANISM", 94, 104], ["CoV-2", "SPECIES", 99, 104], ["SARS-CoV-2", "SPECIES", 94, 104], ["SARS", "PROBLEM", 94, 98], ["CoV", "PROBLEM", 99, 102], ["2 infection", "PROBLEM", 103, 114]]], ["Two studies in this issue of Cell collectively suggest that although SARS-CoV-2 infection may blunt long-lived antibody responses, immune memory might still be achieved through virus-specific memory T cells.MainCurrent limited data suggests that SARS-CoV-2 induces some degree of immunity.", [["Cell", "ANATOMY", 29, 33], ["memory T cells", "ANATOMY", 192, 206], ["infection", "DISEASE", 80, 89], ["SARS", "DISEASE", 246, 250], ["Cell", "CELL", 29, 33], ["SARS-CoV-2", "ORGANISM", 69, 79], ["memory T cells", "CELL", 192, 206], ["SARS-CoV-2", "ORGANISM", 246, 256], ["memory T cells", "CELL_TYPE", 192, 206], ["SARS-CoV", "SPECIES", 69, 77], ["Two studies", "TEST", 0, 11], ["SARS", "PROBLEM", 69, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["blunt long-lived antibody responses", "PROBLEM", 94, 129], ["immune memory", "PROBLEM", 131, 144], ["virus", "PROBLEM", 177, 182], ["SARS", "PROBLEM", 246, 250], ["CoV", "TEST", 251, 254]]], ["To date, there is only one definitive report of reinfection within 4 months, proven by genetic sequencing of the virus , and in one small study rhesus macaques appeared protected against reinfection (Deng et al., 2020) .", [["rhesus", "ORGANISM", 144, 150], ["macaques", "ORGANISM", 151, 159], ["rhesus macaques", "SPECIES", 144, 159], ["rhesus macaques", "SPECIES", 144, 159], ["reinfection", "PROBLEM", 48, 59], ["the virus", "PROBLEM", 109, 118], ["reinfection", "PROBLEM", 187, 198], ["reinfection", "OBSERVATION", 48, 59]]], ["Although it is early days, and this immunity may not last long, it is good news for the prospects of having an effective vaccine, which should ideally generate the type of immune response that affords protection from reinfection.CD8 + T cells, CD4 + T cells and B cells play important roles in the clearance of most viral infectionsand immunological T and B cell memory generated after recovery is instrumental in protecting the host from severe disease upon re-exposure.", [["CD8 + T cells", "ANATOMY", 229, 242], ["CD4 + T cells", "ANATOMY", 244, 257], ["B cells", "ANATOMY", 262, 269], ["B cell", "ANATOMY", 356, 362], ["CD8", "GENE_OR_GENE_PRODUCT", 229, 232], ["CD4", "GENE_OR_GENE_PRODUCT", 244, 247], ["B cells", "CELL", 262, 269], ["T", "CELL", 350, 351], ["B cell", "CELL", 356, 362], ["CD8", "PROTEIN", 229, 232], ["T cells", "CELL_TYPE", 235, 242], ["CD4 + T cells", "CELL_TYPE", 244, 257], ["B cells", "CELL_TYPE", 262, 269], ["an effective vaccine", "TREATMENT", 108, 128], ["immune response", "PROBLEM", 172, 187], ["reinfection", "PROBLEM", 217, 228], ["CD8", "TEST", 229, 232], ["T cells", "TEST", 235, 242], ["CD4", "TEST", 244, 247], ["T cells", "PROBLEM", 250, 257], ["B cells", "PROBLEM", 262, 269], ["severe disease", "PROBLEM", 439, 453], ["early days", "OBSERVATION_MODIFIER", 15, 25], ["reinfection", "OBSERVATION", 217, 228], ["T cells", "OBSERVATION", 235, 242], ["severe", "OBSERVATION_MODIFIER", 439, 445], ["disease", "OBSERVATION", 446, 453]]], ["However, the success of most effective vaccines to date largely hinges on the generation of a potent and lasting antibody response, by virtue of the induction of memory B cells and long-lived plasma cells that provide a continuous supply of high affinity antibodies that circulate and survey our bloodstream and mucosal surfaces.", [["memory B cells", "ANATOMY", 162, 176], ["plasma cells", "ANATOMY", 192, 204], ["bloodstream", "ANATOMY", 296, 307], ["mucosal", "ANATOMY", 312, 319], ["memory B cells", "CELL", 162, 176], ["long-lived plasma cells", "CELL", 181, 204], ["mucosal surfaces", "TISSUE", 312, 328], ["memory B cells", "CELL_TYPE", 162, 176], ["long-lived plasma cells", "CELL_TYPE", 181, 204], ["high affinity antibodies", "PROTEIN", 241, 265], ["most effective vaccines", "TREATMENT", 24, 47], ["a potent and lasting antibody response", "PROBLEM", 92, 130], ["memory B cells", "PROBLEM", 162, 176], ["long-lived plasma cells", "PROBLEM", 181, 204], ["high affinity antibodies", "PROBLEM", 241, 265], ["mucosal surfaces", "OBSERVATION", 312, 328]]], ["These antibodies can bind to and neutralise the virus even at minute concentrations.J o u r n a l P r e -p r o o fWhile a lot of attention has been placed in antibody-based immunity, there is increasing evidence that T cells play a major role in the resolution of COVID-19 (Chen and John Wherry, 2020), but whether SARS-CoV-2 generates long-term memory T cell responses, and whether these are important for lasting immunity is still unclear.", [["T cells", "ANATOMY", 217, 224], ["T cell", "ANATOMY", 353, 359], ["T cells", "CELL", 217, 224], ["SARS-CoV-2", "ORGANISM", 315, 325], ["memory T cell", "CELL", 346, 359], ["antibodies", "PROTEIN", 6, 16], ["T cells", "CELL_TYPE", 217, 224], ["the virus", "PROBLEM", 44, 53], ["T cells", "PROBLEM", 217, 224]]], ["These questions are important because vaccines are generally less effective at eliciting CD8 T cell responses.J o u r n a l P r e -p r o o fIn this issue, two separate studies address the formation of long-lived immunity to SARS-CoV-2.J o u r n a l P r e -p r o o fKaneko et al report that severe SARS-CoV-2 infections blunt the germinal centre response, which is likely to dampen the generation of long-lived antibody responses.", [["CD8 T cell", "ANATOMY", 89, 99], ["germinal centre", "ANATOMY", 329, 344], ["SARS", "DISEASE", 297, 301], ["infections", "DISEASE", 308, 318], ["CD8 T cell", "CELL", 89, 99], ["SARS-CoV-2", "ORGANISM", 297, 307], ["germinal centre", "MULTI-TISSUE_STRUCTURE", 329, 344], ["CD8", "PROTEIN", 89, 92], ["vaccines", "TREATMENT", 38, 46], ["fIn this issue", "PROBLEM", 139, 153], ["SARS-CoV", "TEST", 224, 232], ["severe SARS", "PROBLEM", 290, 301], ["CoV", "PROBLEM", 302, 305], ["2 infections", "PROBLEM", 306, 318], ["severe", "OBSERVATION_MODIFIER", 290, 296], ["SARS", "OBSERVATION", 297, 301], ["germinal centre", "OBSERVATION", 329, 344], ["is likely", "UNCERTAINTY", 361, 370]]], ["They set out to establish the root cause of the reported short-lived humoral response to SARS-Cov-2, which was also characteristic of related coronaviruses causing severe infection in humans such as SARS and MERS.", [["root", "ANATOMY", 30, 34], ["SARS", "DISEASE", 89, 93], ["coronaviruses", "DISEASE", 142, 155], ["infection", "DISEASE", 171, 180], ["SARS", "DISEASE", 199, 203], ["Cov-2", "CELL", 94, 99], ["coronaviruses", "ORGANISM", 142, 155], ["humans", "ORGANISM", 184, 190], ["humans", "SPECIES", 184, 190], ["humans", "SPECIES", 184, 190], ["SARS", "PROBLEM", 89, 93], ["Cov", "TEST", 94, 97], ["related coronaviruses", "PROBLEM", 134, 155], ["severe infection in humans", "PROBLEM", 164, 190], ["SARS", "PROBLEM", 199, 203], ["coronaviruses", "OBSERVATION", 142, 155], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["infection", "OBSERVATION", 171, 180]]], ["For SARS infections this was thought to be caused by a lack of germinal center (GC) responses (Gu et al., 2005) .", [["germinal center", "ANATOMY", 63, 78], ["GC", "ANATOMY", 80, 82], ["SARS infections", "DISEASE", 4, 19], ["germinal center", "MULTI-TISSUE_STRUCTURE", 63, 78], ["SARS infections", "PROBLEM", 4, 19], ["infections", "OBSERVATION", 9, 19]]], ["Thus, the findings by Kaneko and colleagues suggest that TNF-\u03b1 blockade in severe COVID-19 infection may not only prevent excessive inflammation, but also enable development of long-lived, GC-derived, antibody responses.J o u r n a l P r e -p r o o fAltogether, their data suggest that a lack of germinal centre responses may account for the variable and often low and short-lived antibody responses observed in COVID-19 patients.", [["germinal centre", "ANATOMY", 296, 311], ["COVID-19", "CHEMICAL", 82, 90], ["infection", "DISEASE", 91, 100], ["inflammation", "DISEASE", 132, 144], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["COVID-19", "ORGANISM", 82, 90], ["GC", "CELL", 189, 191], ["patients", "ORGANISM", 421, 429], ["TNF", "PROTEIN", 57, 60], ["patients", "SPECIES", 421, 429], ["TNF-\u03b1 blockade", "TREATMENT", 57, 71], ["severe COVID-19 infection", "PROBLEM", 75, 100], ["excessive inflammation", "PROBLEM", 122, 144], ["the variable and often low and short-lived antibody responses", "PROBLEM", 338, 399], ["infection", "OBSERVATION", 91, 100], ["inflammation", "OBSERVATION", 132, 144]]], ["Nonetheless, given J o u r n a l P r e -p r o o f that all their analyses were conducted using tissue obtained from fatal COVID-19 cases, whether GCs are also abrogated in the average milder COVID-19 infections remains unknown.", [["tissue", "ANATOMY", 95, 101], ["infections", "DISEASE", 200, 210], ["tissue", "TISSUE", 95, 101], ["GCs", "CELL", 146, 149], ["fatal COVID", "TEST", 116, 127], ["GCs", "TEST", 146, 149], ["COVID", "TEST", 191, 196], ["infections", "PROBLEM", 200, 210]]], ["It is possible that the short-lived B cell antibody responses are the result of thymus-independent (TI) B cell activation.Although the authors interpret the presence of AID + B cells as a sign of robust T:B cell interactions,TI responses can also be isotype switched, are short-lived, and can be induced by highly repetitive epitopes coating viral capsids, or by activation of Toll-like receptors binding to viral nucleic acids.Although the authors interpret the presence of AID + B cells as a sign of robust T:B cell interactions,In their complementary study, Sekine and colleagues conduct an extensive characterisation of T cell immunity in patients suffering from COVID-19 of various degrees of disease severity and at various stages post infection.", [["B cell", "ANATOMY", 36, 42], ["thymus", "ANATOMY", 80, 86], ["B cell", "ANATOMY", 104, 110], ["AID + B cells", "ANATOMY", 169, 182], ["B cell", "ANATOMY", 205, 211], ["AID + B cells", "ANATOMY", 475, 488], ["T:B cell", "ANATOMY", 509, 517], ["T cell", "ANATOMY", 624, 630], ["nucleic acids", "CHEMICAL", 414, 427], ["infection", "DISEASE", 742, 751], ["B cell", "CELL", 36, 42], ["thymus", "ORGAN", 80, 86], ["B cell", "CELL", 104, 110], ["AID", "GENE_OR_GENE_PRODUCT", 169, 172], ["B cells", "CELL", 175, 182], ["T", "CELL", 203, 204], ["B cell", "CELL", 205, 211], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 377, 396], ["AID", "GENE_OR_GENE_PRODUCT", 475, 478], ["B cells", "CELL", 481, 488], ["T", "CELL", 509, 510], ["B cell", "CELL", 511, 517], ["T cell", "CELL", 624, 630], ["patients", "ORGANISM", 643, 651], ["B cell antibody", "PROTEIN", 36, 51], ["AID", "PROTEIN", 169, 172], ["B cells", "CELL_TYPE", 175, 182], ["Toll-like receptors", "PROTEIN", 377, 396], ["AID", "PROTEIN", 475, 478], ["B cells", "CELL_TYPE", 481, 488], ["patients", "SPECIES", 643, 651], ["the short-lived B cell antibody responses", "PROBLEM", 20, 61], ["B cells", "PROBLEM", 175, 182], ["B cell interactions", "PROBLEM", 205, 224], ["repetitive epitopes coating viral capsids", "PROBLEM", 314, 355], ["viral nucleic acids", "TREATMENT", 408, 427], ["B cells", "PROBLEM", 481, 488], ["B cell interactions", "PROBLEM", 511, 530], ["T cell immunity", "PROBLEM", 624, 639], ["COVID", "TEST", 667, 672], ["disease severity", "PROBLEM", 698, 714], ["infection", "PROBLEM", 742, 751], ["cell antibody", "OBSERVATION", 38, 51], ["thymus", "ANATOMY", 80, 86], ["viral capsids", "OBSERVATION", 342, 355], ["B cell interactions", "OBSERVATION", 511, 530], ["extensive", "OBSERVATION_MODIFIER", 594, 603], ["T cell immunity", "OBSERVATION", 624, 639], ["various degrees", "OBSERVATION_MODIFIER", 679, 694], ["disease", "OBSERVATION", 698, 705], ["various stages", "OBSERVATION_MODIFIER", 722, 736], ["infection", "OBSERVATION", 742, 751]]], ["They find SARS-CoV-2-specific memory T cells in most convalescent individuals, including asymptomatic cases and those with undetectable antibody responses.Although the authors interpret the presence of AID + B cells as a sign of robust T:B cell interactions,In individuals with acute infection, T cells displayed an activated phenotype, whereas convalescent patients harboured SARS-CoV-2-specific CD8 T cells with a phenotype reminiscent to early differentiated memory T cells.", [["memory T cells", "ANATOMY", 30, 44], ["AID + B cells", "ANATOMY", 202, 215], ["T:B cell", "ANATOMY", 236, 244], ["T cells", "ANATOMY", 295, 302], ["CD8 T cells", "ANATOMY", 397, 408], ["memory T cells", "ANATOMY", 462, 476], ["acute infection", "DISEASE", 278, 293], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["memory T cells", "CELL", 30, 44], ["convalescent", "ORGANISM", 53, 65], ["individuals", "ORGANISM", 66, 77], ["AID", "GENE_OR_GENE_PRODUCT", 202, 205], ["B cells", "CELL", 208, 215], ["T", "CELL", 236, 237], ["B cell", "CELL", 238, 244], ["T cells", "CELL", 295, 302], ["patients", "ORGANISM", 358, 366], ["SARS-CoV-2", "ORGANISM", 377, 387], ["CD8 T cells", "CELL", 397, 408], ["memory T cells", "CELL", 462, 476], ["memory T cells", "CELL_TYPE", 30, 44], ["AID", "PROTEIN", 202, 205], ["B cells", "CELL_TYPE", 208, 215], ["T cells", "CELL_TYPE", 295, 302], ["CD8 T cells", "CELL_TYPE", 397, 408], ["early differentiated memory T cells", "CELL_TYPE", 441, 476], ["patients", "SPECIES", 358, 366], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["asymptomatic cases", "PROBLEM", 89, 107], ["B cells", "PROBLEM", 208, 215], ["B cell interactions", "PROBLEM", 238, 257], ["acute infection", "PROBLEM", 278, 293], ["T cells", "PROBLEM", 295, 302], ["an activated phenotype", "PROBLEM", 313, 335], ["harboured SARS", "TEST", 367, 381], ["CoV", "TEST", 382, 385], ["a phenotype reminiscent", "PROBLEM", 414, 437], ["B cell", "OBSERVATION", 238, 244], ["acute", "OBSERVATION_MODIFIER", 278, 283], ["infection", "OBSERVATION", 284, 293], ["early differentiated", "OBSERVATION_MODIFIER", 441, 461], ["memory T cells", "OBSERVATION", 462, 476]]], ["Expression of TCF-1 by these cells suggests that they may possess a stem-cell like phenotype that endows them the ability to differentiate into multiple effector T cell subsets upon re-infection.", [["cells", "ANATOMY", 29, 34], ["stem-cell", "ANATOMY", 68, 77], ["T cell", "ANATOMY", 162, 168], ["TCF-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["cells", "CELL", 29, 34], ["stem-cell", "CELL", 68, 77], ["T cell subsets", "CELL", 162, 176], ["TCF-1", "PROTEIN", 14, 19], ["effector T cell subsets", "CELL_TYPE", 153, 176], ["a stem-cell like phenotype", "PROBLEM", 66, 92], ["re-infection", "PROBLEM", 182, 194], ["effector T cell subsets", "OBSERVATION", 153, 176]]], ["Thus, a second SARS-CoV-2 encounter could potentially mount effective GC responses should these memory T cells give rise to T FH cells.Although the authors interpret the presence of AID + B cells as a sign of robust T:B cell interactions,Interestingly, SARS-CoV-2-specific memory T cells were detected in exposed seronegative healthy individuals (relatives of confirmed cases), indicative of asymptomatic infection.", [["memory T cells", "ANATOMY", 96, 110], ["T FH cells", "ANATOMY", 124, 134], ["AID + B cells", "ANATOMY", 182, 195], ["T:B cell", "ANATOMY", 216, 224], ["memory T cells", "ANATOMY", 273, 287], ["infection", "DISEASE", 405, 414], ["GC", "CELL", 70, 72], ["memory T cells", "CELL", 96, 110], ["T FH cells", "CELL", 124, 134], ["AID", "GENE_OR_GENE_PRODUCT", 182, 185], ["B cells", "CELL", 188, 195], ["T", "CELL", 216, 217], ["B cell", "CELL", 218, 224], ["SARS-CoV-2", "ORGANISM", 253, 263], ["memory T cells", "CELL", 273, 287], ["memory T cells", "CELL_TYPE", 96, 110], ["T FH cells", "CELL_TYPE", 124, 134], ["AID", "PROTEIN", 182, 185], ["B cells", "CELL_TYPE", 188, 195], ["memory T cells", "CELL_TYPE", 273, 287], ["B cells", "PROBLEM", 188, 195], ["B cell interactions", "PROBLEM", 218, 237], ["SARS", "TEST", 253, 257], ["CoV", "TEST", 258, 261], ["asymptomatic infection", "PROBLEM", 392, 414], ["indicative of", "UNCERTAINTY", 378, 391], ["asymptomatic", "OBSERVATION_MODIFIER", 392, 404], ["infection", "OBSERVATION", 405, 414]]], ["Remarkably, ~93% of \"exposed asymptomatic\" individuals mounted detectable T cell responses to SARS-CoV-2 despite only 60% of cases being seropositive.", [["T cell", "ANATOMY", 74, 80], ["SARS", "DISEASE", 94, 98], ["T cell", "CELL", 74, 80], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV", "SPECIES", 94, 102], ["SARS", "TEST", 94, 98], ["CoV", "TEST", 99, 102], ["seropositive", "PROBLEM", 137, 149]]], ["This suggests that asymptomatic infections may be more common than current data suggests, and that immunosurveillance through antibody testing alone may underestimate infection prevalence or population immunity.", [["infections", "DISEASE", 32, 42], ["infection", "DISEASE", 167, 176], ["asymptomatic infections", "PROBLEM", 19, 42], ["immunosurveillance through antibody testing", "TEST", 99, 142], ["infection prevalence", "PROBLEM", 167, 187], ["asymptomatic", "OBSERVATION_MODIFIER", 19, 31], ["infections", "OBSERVATION", 32, 42]]], ["The presence of SARS-CoV-2 specific T cells in the majority of convalescent patients is a promising sign that infection may give rise to immunity, but whether these T cells afford protection from reinfection remains to be tested.Although the authors interpret the presence of AID + B cells as a sign of robust T:B cell interactions,A smaller but consistent fraction of samples collected in mid 2019 (i.e. \"unexposed individuals\") also revealed SARS-CoV2-reactive memory T cells, which was not entirely unexpected.", [["T cells", "ANATOMY", 36, 43], ["T cells", "ANATOMY", 165, 172], ["AID + B cells", "ANATOMY", 276, 289], ["T:B cell", "ANATOMY", 310, 318], ["samples", "ANATOMY", 369, 376], ["memory T cells", "ANATOMY", 463, 477], ["SARS", "DISEASE", 16, 20], ["infection", "DISEASE", 110, 119], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["T cells", "CELL", 36, 43], ["convalescent", "ORGANISM", 63, 75], ["patients", "ORGANISM", 76, 84], ["T cells", "CELL", 165, 172], ["AID", "GENE_OR_GENE_PRODUCT", 276, 279], ["B cells", "CELL", 282, 289], ["T:B cell", "CELL", 310, 318], ["samples", "CANCER", 369, 376], ["CoV2", "GENE_OR_GENE_PRODUCT", 449, 453], ["memory T cells", "CELL", 463, 477], ["T cells", "CELL_TYPE", 36, 43], ["T cells", "CELL_TYPE", 165, 172], ["AID", "PROTEIN", 276, 279], ["B cells", "CELL_TYPE", 282, 289], ["SARS-CoV2-reactive memory T cells", "CELL_LINE", 444, 477], ["patients", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["infection", "PROBLEM", 110, 119], ["these T cells", "PROBLEM", 159, 172], ["reinfection", "PROBLEM", 196, 207], ["B cells", "PROBLEM", 282, 289], ["B cell interactions", "PROBLEM", 312, 331], ["SARS", "PROBLEM", 444, 448], ["CoV2", "TEST", 449, 453], ["reactive memory T cells", "PROBLEM", 454, 477], ["SARS", "OBSERVATION", 16, 20], ["infection", "OBSERVATION", 110, 119], ["B cell", "OBSERVATION", 312, 318], ["smaller", "OBSERVATION_MODIFIER", 334, 341], ["fraction", "OBSERVATION_MODIFIER", 357, 365], ["reactive memory T cells", "OBSERVATION", 454, 477], ["not entirely unexpected", "UNCERTAINTY", 489, 512]]], ["There are currently 4 known strains of coronaviruses that circulate seasonally throughout the population (Moriyama et al., 2020) , and extensive T cell cross reactivity across these strains of viruses has been documented (Mateus et al., 2020) .", [["T cell", "ANATOMY", 145, 151], ["coronaviruses", "ORGANISM", 39, 52], ["T cell", "CELL", 145, 151], ["coronaviruses", "PROBLEM", 39, 52], ["extensive T cell cross reactivity", "PROBLEM", 135, 168], ["these strains of viruses", "PROBLEM", 176, 200], ["coronaviruses", "OBSERVATION", 39, 52], ["seasonally", "OBSERVATION_MODIFIER", 68, 78], ["extensive", "OBSERVATION_MODIFIER", 135, 144], ["viruses", "OBSERVATION", 193, 200]]], ["Unexposed individuals that harbour cross-reactive T cells may be protected from severe disease, but whether the presence of these cells may negatively influence the generation of protective immunity remains to be tested.J o u r n a l P r e -p r o o fOn the basis of these results, it is tempting to speculate that although optimal protective immunity induced by COVID-19 infection may rely on the production of both memory T cells and GC-derived long-lived plasma cells, either response alone may confer some protection against severe disease.J o u r n a l P r e -p r o o fThere is abundant evidence of redundancy and diversity in the immune system that ensures a level of protection against infection in situations in which a branch of immunity is compromised.", [["T cells", "ANATOMY", 50, 57], ["cells", "ANATOMY", 130, 135], ["memory T cells", "ANATOMY", 416, 430], ["plasma cells", "ANATOMY", 457, 469], ["COVID-19", "CHEMICAL", 362, 370], ["infection", "DISEASE", 371, 380], ["infection", "DISEASE", 692, 701], ["T cells", "CELL", 50, 57], ["cells", "CELL", 130, 135], ["COVID-19", "ORGANISM", 362, 370], ["memory T cells", "CELL", 416, 430], ["GC", "CELL", 435, 437], ["plasma cells", "CELL", 457, 469], ["cross-reactive T cells", "CELL_TYPE", 35, 57], ["memory T cells", "CELL_TYPE", 416, 430], ["GC-derived long-lived plasma cells", "CELL_TYPE", 435, 469], ["harbour cross-reactive T cells", "PROBLEM", 27, 57], ["severe disease", "PROBLEM", 80, 94], ["these cells", "PROBLEM", 124, 135], ["protective immunity", "TREATMENT", 179, 198], ["COVID-19 infection", "PROBLEM", 362, 380], ["GC", "TEST", 435, 437], ["severe disease", "PROBLEM", 528, 542], ["fThere", "PROBLEM", 572, 578], ["redundancy", "PROBLEM", 603, 613], ["diversity in the immune system", "PROBLEM", 618, 648], ["infection in situations", "PROBLEM", 692, 715], ["cross-reactive T cells", "OBSERVATION", 35, 57], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["disease", "OBSERVATION", 87, 94], ["abundant evidence of", "UNCERTAINTY", 582, 602], ["redundancy", "OBSERVATION", 603, 613], ["infection", "OBSERVATION", 692, 701], ["branch", "OBSERVATION_MODIFIER", 727, 733]]], ["Finding potent memory CD8 + and CD4 + T cell responses elicited during asymptomatic infections even in the absence of detectable antibody responses increases our hopes of protective immunity post-SARS CoV-2 infection.", [["memory CD8 + and CD4 + T cell", "ANATOMY", 15, 44], ["infections", "DISEASE", 84, 94], ["infection", "DISEASE", 207, 216], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["CoV-2", "ORGANISM", 201, 206], ["CD8", "PROTEIN", 22, 25], ["CD4", "PROTEIN", 32, 35], ["CoV-", "SPECIES", 201, 205], ["SARS CoV-2", "SPECIES", 196, 206], ["memory CD8", "TEST", 15, 25], ["CD4", "TEST", 32, 35], ["T cell responses", "PROBLEM", 38, 54], ["asymptomatic infections", "PROBLEM", 71, 94], ["detectable antibody responses", "PROBLEM", 118, 147], ["protective immunity", "TREATMENT", 171, 190], ["SARS CoV", "PROBLEM", 196, 204], ["2 infection", "PROBLEM", 205, 216], ["infections", "OBSERVATION", 84, 94], ["infection", "OBSERVATION", 207, 216]]], ["However, robust memory CD8 + T cell responses may be difficult to recapitulate with vaccination, which will likely be more reliant on the induction of potent high affinity neutralising antibodies.Figure 1.", [["memory CD8 + T cell", "ANATOMY", 16, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "PROTEIN", 23, 26], ["neutralising antibodies", "PROTEIN", 172, 195], ["vaccination", "TREATMENT", 84, 95], ["potent high affinity neutralising antibodies", "PROBLEM", 151, 195]]], ["Seropositivity to SARS-CoV-2 may underestimate COVID-19 prevalence or immunity.Quantification of the percentage of individuals with detectable T cell responses, serum antibodies or germinal centers across SARS-CoV-2 exposed (either asymptomatic or those with mild or severe COVID-19 symptoms) or two cohorts of seemingly healthy unexposed individuals (blood samples collected either before or during the COVID-19 pandemic).", [["T cell", "ANATOMY", 143, 149], ["serum", "ANATOMY", 161, 166], ["germinal centers", "ANATOMY", 181, 197], ["blood samples", "ANATOMY", 352, 365], ["SARS", "DISEASE", 18, 22], ["SARS-CoV-2", "ORGANISM", 18, 28], ["COVID-19", "GENE_OR_GENE_PRODUCT", 47, 55], ["T cell", "CELL", 143, 149], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["SARS-CoV-2", "ORGANISM", 205, 215], ["blood samples", "ORGANISM_SUBSTANCE", 352, 365], ["serum antibodies", "PROTEIN", 161, 177], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 205, 213], ["Seropositivity", "TEST", 0, 14], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["COVID", "TEST", 47, 52], ["detectable T cell responses", "PROBLEM", 132, 159], ["serum antibodies", "TEST", 161, 177], ["germinal centers across SARS", "PROBLEM", 181, 209], ["CoV", "TEST", 210, 213], ["mild or severe COVID-19 symptoms", "PROBLEM", 259, 291], ["seemingly healthy unexposed individuals", "PROBLEM", 311, 350], ["blood samples", "TEST", 352, 365], ["the COVID", "TEST", 400, 409], ["percentage", "OBSERVATION_MODIFIER", 101, 111], ["cell", "OBSERVATION", 145, 149], ["severe", "OBSERVATION_MODIFIER", 267, 273]]], ["Serum antibodies and T cell responses are found in most patients with either severe or mild .", [["Serum", "ANATOMY", 0, 5], ["T cell", "ANATOMY", 21, 27], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["T cell", "CELL", 21, 27], ["patients", "ORGANISM", 56, 64], ["Serum antibodies", "PROTEIN", 0, 16], ["patients", "SPECIES", 56, 64], ["Serum antibodies", "TEST", 0, 16], ["T cell responses", "TEST", 21, 37], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["mild", "OBSERVATION_MODIFIER", 87, 91]]], ["GC responses are absent in severe cases of COVID-19, but whether they are detectable in mild or asymptomatic individuals remains unknown.", [["COVID-19", "CHEMICAL", 43, 51], ["GC responses", "TEST", 0, 12], ["COVID", "TEST", 43, 48], ["mild or asymptomatic individuals", "PROBLEM", 88, 120], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["mild", "OBSERVATION_MODIFIER", 88, 92]]], ["Most asymptomatic COVID-19 cases showed strong T cell responses even if only ~ 60% of these individuals were seropositive for SARS-CoV-2.", [["T cell", "ANATOMY", 47, 53], ["SARS", "DISEASE", 126, 130], ["T cell", "CELL", 47, 53], ["individuals", "ORGANISM", 92, 103], ["SARS-CoV-2", "ORGANISM", 126, 136], ["SARS-CoV", "SPECIES", 126, 134], ["Most asymptomatic COVID", "TEST", 0, 23], ["strong T cell responses", "PROBLEM", 40, 63], ["these individuals", "TEST", 86, 103], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134]]]], "PMC7151818": []}